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ABSTRACT
The mammary gland is a unique and specialized epidermal organ; mammary
organogenesis begins in the embryo but is not fully complete until puberty. As such,
formation of the mammary gland depends on temporally and spatially regulated
developmental steps that require coordination of multiple biological and cell signaling
processes; many of which have parallels with cancer development. Research describing
the events that occur between birth and puberty is lacking and little is known about
human breast development of youth. Since mammary gland development requires a
coordinated balance between cell growth, proliferation, and apoptosis, it is critical to
understand which signaling pathways are utilized to relay developmental signals, and
how these pathways and their targets interact and cooperate with age. Additionally,
interactions between integrin molecules and their laminin ligands, especially Laminin-5
(Ln-5; also known as Laminin-332), regulate multiple facets of both embryonic
development and tumor growth, invasion, and metastasis. α6β4 integrin serves as a
marker to detect distant metastases in the early stages of specific malignancies and β4
integrin overexpression has been found in basal-like breast cancers, correlating with
aggressiveness to institute a prognostic β4 signature that increases with tumor grade. The
mechanism α6β4 integrin utilizes to modulate oncogenic signaling through association
with Ln-5 molecules in the ECM is the basis for the recombinant protein (rG3, the third
of five G domains of Ln-5) produced for the work reported in this dissertation. Here, it is
shown there are specific transcriptional differences and a unique interaction of a gene set
over time that contributes to postnatal mammary gland development, and this model
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clearly shares similarities and signaling pathways with oncogenic development.
Especially important are pathways of the adaptive and innate immunities, ECM
remodeling and integrin interactions, and extrinsic and intrinsic TP53-mediated
apoptosis, greater understanding of which could lead to early detection of potential
tumorigenic growth and identification of potential treatment avenues. Presented is a
comprehensive model of early mammary development along with several panels of
biomarkers that possess a role in normal mammary development, are involved in
aggressive cancers, and are affected by apoptosis induced by rG3 treatment. rG3 has
proven to be a valuable tool to study apoptotic pathways and the crosstalk among those
pathways.
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CHAPTER ONE: MAMMARY DEVELOPMENT

Overview
The mammary gland is a unique and specialized epidermal organ in that mammary
organogenesis begins in the embryo but is not fully complete until puberty and pregnancy. As
such, formation of the mammary gland depends on temporally and spatially regulated
developmental efforts that require coordination of multiple biological and cell signaling
processes; many of which have parallels with cancer development 1. Three main stages of
mammary organogenesis exist: embryonic, pubertal, and reproductive 2. Of importance,
research describing the events that occur between birth and puberty is lacking. Similarly,
little is known about human breast development 3. Much of the research regarding genetic
interactions and mammary organogenesis cell signaling has been performed in the mouse
model, but initial data from humans indicates the same pathways are utilized in both models
4

. Since mammary gland development requires a coordinated balance between cell growth,

proliferation, and apoptosis 5, the current challenges in the field are to determine how
mammary cell identity is decided, which signaling pathways are utilized to relay
developmental signals, and how these pathways and their targets interact and cooperate
throughout time 4. This research aims to generate a model from transcriptomic data of
postnatal mammary gland development over time in the swine system to provide insight into
postnatal activity and cellular signaling mechanisms utilized for mammary growth.
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Significance
Research in the field of mammary organogenesis is significant largely due to the
suspected links between development and invasive caner and highly conflicting views of
researchers on the presence of developmental activity between birth and puberty. It is the
perspective of many that after birth, the mammary gland exists as a rudimentary organ that
remains quiescent and dormant until puberty, when development is truly completed 6–9.
However, reports also suggest that there is growth occurring from birth to puberty, ranging
from allometric growth of the gland 10 to significant proliferation, branching, and expansion
11–14

. If epithelial cell proliferation in the mammary gland can persist for weeks after birth,

detection and characterization of stromal influences on epithelial patterning in this phase of
development are integral 2,10. Also, there are conflicting views of post-natal/pre-pubertal
mammary gland development that need to be resolved. Despite advances in the clinical
treatment of breast cancer, the disease is still prevalent due to incomplete understanding of
mechanisms involved in normal mammary development and physiology 15. In humans
especially, the formation of the breast in the embryo and early postnatal development
contains some events akin to early breast carcinogenesis 16. Identifying and characterizing
the signaling pathways responsible for mammary development and patterning over time, and
their downstream effects, can advance our understanding of developmental biology and could
have momentous implications for breast cancer treatment 17.

Embryonic mammary gland development
Although the mammary gland is not functional at birth and the majority of
organogenesis occurs postnatally under hormonal control, development begins as a ventral
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skin derivative in the embryo independently of hormones and is very well characterized 4,10.
Embryonic mammary gland development requires precise communication between different
cell types, specifically those of the epidermis, epithelium, and mesenchyme, and is regulated
both temporally and spatially by numerous signaling pathways, which will be discussed 18–21.
There are three distinct developmental steps during mammary gland organogenesis in the
embryo, each requiring activation of specific genes and signaling pathways: the formation of
bilateral milk lines, formation of placodes along the milk lines, and lastly, formation of
mammary buds in the mesenchyme 4. The initial step, formation of the bilateral milk lines,
generates an embryonic region that will be committed to mammary cell fate 22. The gland
will eventually form in locations along two lines that run from the axilla to the groin of the
animal, known as the bilateral milk lines. These lines begin to develop around embryonic day
10-11 of gestation in mice 22. At this point, Wnt/ß-catenin signaling activity localizes along
these lines, and then quickly just to the positions of future mammary buds, making Wnt
signaling pathway members molecular markers of the milk lines 23,24. The mammary line is
marked by the presence of Wnt10b and the Wnt signaling reporter T-cell factor optimal
promoter (TOP) ß-galactosidase (GAL) 23. Formation of the mammary line and expression of
Wnt10b is the earliest detectable ectodermal event in mammary gland organogenesis in the
mouse model 24 and within these lines, the previously single-layered ectodermal cells of the
embryo become morphologically columnar and multilayered, forming a definitive ridge that
is more mature than the primitive epidermis and rises above and below this layer 22,24.
During the second stage of embryonic mammary organogenesis, mammary milk line
cells migrate to the locations of future mammary buds along the lines 4,18,25. When the
mammary cells have arrived at these specific locations, five pairs of small lens-shaped
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placodes begin to form around E11.5 in mice; placodes are multilayered ectodermal
structures that will eventually become epithelial bulbs and are also under the control of
WNT/ß-catenin signaling and the transcriptional mediator Lymphoid Enhancer Binding
Factor 1 (LEF1) 24,26,27. In humans, the mammary lines form during the first trimester and
contain only one pair of placodes 3. Several other signaling mechanisms promote placode
formation, growth, and positional direction along the milk line, including Parathyroid
hormone-related protein (PTHrP), fibroblast growth factor 10 (FGF10), Polo-like kinase 2
(Plk2), and bone morphogenetic protein 4 (BMP4) 28–32. During the third step, around E13.5
in the mouse, the placodes begin to increase in size and cells within each placode invade the
underlying dermal tissue to form mammary buds 1,10,22–24. These buds are bulb-shaped
structures containing mammary epithelial cells that are connected to the embryonic epidermis
by a stalk. Neighboring cells begin to condense, concentrically surrounding the buds and
becoming more densely packed and slightly more organized than other epidermal tissue,
forming what is known as the initial mammary mesenchyme 28,29. The mammary
mesenchyme aids in continued early development by maintaining epithelial cell identity,
secreting growth factors and other key proliferative signals, and supporting ductal invasion
2,20

. By E16, the mammary epithelial cells have proliferated and elongated the mammary bud

to form a small sprout that is primed to invade the fat precursor (an immature collection of
pre-adipocytes at this stage) 2,22. The mammary bud is now a rudimentary mammary ductal
tree that will contain multi-laminate club-shaped terminal end buds (TEBs) at their distal
ends responsible for leading proliferation out through the adipose and stroma, further
branching to generate the primary ductal tree 33. TEBs are supported by dense stroma
containing fibroblasts, macrophages, mast cells, and eosinophils 34–36 as they are forming.
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Basophils, T cells, and B cells are not detected 37. In contrast to mice, the pre-pubertal
mammary glands of humans and swine contain a greater degree of ductal branching and
terminal ductal units (TDUs) are present instead of TEBs. The TDUs reside in a collagenous
stroma and have a higher degree of inter and intra-lobular heterogeneity than TEBs 38. By
E18 in mice and 21 weeks in humans, the TEBs or TDUs, respectively, divide rapidly to
generate a rudimentary ductal tree with lumen that begins to embed in the immature fat pad
39,40

. At the conclusion of embryonic development, the framework has been established for

pubertal expansion. Existing is a rudimentary bi-layered ductal tree with an inner luminal
layer of epithelial cells facing the central cavity and an outer layer of basal (mainly
myoepithelial, termed from high concentrations of actin microfilaments and α smooth muscle
actin present) cells that are adhered to the basement membrane (BM) predominantly through
integrin-mediated interactions 3,41–43. It is widely accepted that during embryonic, and
postnatal, mammary gland development, crosstalk and interactions between stromal,
epithelial, luminal, and myoepithelial cells are critical for normal development and expansion
of the gland 44. This signaling relies heavily upon the extracellular matrix (ECM), ECM
receptors, and ECM degrading enzymes such as matrix metalloproteinases (MMPs),
cytokines, and growth factors 45. At birth, it is believed that growth halts until puberty but
conflicting work has been published on this matter. Shortly after birth, adipocytes densely
packed in the fat pad begin to mature and become capable of supporting further epithelial
morphogenesis 46,47. Increased recognition has been given to the significance of the stroma
and ECM in both development and disease in the past decade 48 which will be discussed
subsequently.
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Postnatal mammary development
Postnatal mammary growth in the mouse can be classified into five periods: neonatal
(1-3 weeks of age), juvenile (3-4 weeks of age), pre-pubertal (4-5 weeks of age), pubertal (57 weeks of age), and mature virgin (7-9 weeks of age) 49. In these phases, mammary
epithelial ducts activate invasive cell signaling to penetrate the surrounding mesenchyme
populated by fibroblasts and adipocytes 9,10. This activity is known as branching
morphogenesis, which is a fundamental process in development utilized to increase epithelial
surface area in organs such as the lung, kidney, salivary gland, and mammary gland.
Branching morphogenesis consists of iterative steps of epithelial bud formation, extension,
branching and remodeling; the process has been thoroughly reviewed 50.

Human breast development
A considerably smaller amount of information regarding human breast development
exists, but the bulk of knowledge can found in the review by Howard and Gusterson 3.
Comprehensive studies of mammary gland development in humans have not been executed,
in comparison with rodent models, due to constraints on tissue availability and ethical
concerns, so the best that can be reported is parallels and obvious differences in
developmental stages between humans and rodents 51. Similar comparisons can identify gaps
that need to be addressed in a more appropriate model animal 3. Importantly, in humans, the
infant mammary gland completes involution once separated from maternal hormones and
these changes are similar to events that can be found in breasts of post-menopausal women 3.
Collection of mammary tissue from humans, and relevant animal models, across ages during
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all developmental stages would be a valuable tool to understand developmental variations
and disease implications 3.

Signaling pathways and the ECM
A multitude of common cell signaling pathways and molecular factors integral in
mammary development across species have been detected and thoroughly reviewed,
including: Human epidermal growth factor receptor 2 (ErbB-2), fibroblast growth factor
(FGF), Wingless-related integration site (Wnt), hedgehog, GATA3, Hepatocyte growth factor
like protein (HGFL), nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB),
Phosphatidylinositol-4,5-bisphosphate 3-kinase/ Protein kinase B (PI3K/AKT), Janus
kinase/Signal Transducer and Activator of Transcription (JAK-STAT), T-box transcription
factor (TBX), epidermal growth factor receptor (EGFR or ErbB-1), Β-Interferon Gene
Positive-Regulatory Domain I (Blimp-1) and insulin-like growth factor (IGF) 5,52–71.
Importantly, the ECM, immune system, and cytoskeleton and constituted molecular factors
have been implicated to influence both embryonic and postnatal mammary organogenesis.
The ECM and stroma, including growth factors, cytokines and proteinases within these
niches, have long been known for morphogenesis 72 and are essential for development of a
functional mammary gland 7,73 where these also play important roles in breast cancer
development (reviewed by 74–78). The branching morphogenesis of the mammary gland is
controlled partially by the basement membrane (BM), interacting epithelial and mesenchymal
cell populations, and cell-cell/cell-matrix adhesions, but this crosstalk is not comprehensively
understood 79. It is accepted that post-natal stroma (previously embryonic mesenchyme)
influences cell fate and differentiation throughout mammalian adulthood 80,81. After birth,

7

mammary epithelial cells are tightly connected to both each other and surrounding stroma,
relying on tight adhesion to transmit biochemical signals, allow cell migration, and function
normally 7,41,82. Interestingly, epithelial cell movement utilizes many of the same molecules
that modulate activity of the actomyosin network, including Ras-related C3 botulinum toxin
substrate (Rac), rho-associated, coiled-coil-containing protein kinase (ROCK) and myosin
light chain kinase, implying that actomyosin contractility possesses a critical role in
mammary gland morphogenesis 83.

Immune involvement in mammary development
Another seemingly unrelated organ system that compasses a major portion of prenatal
and postnatal mammary development is the immune system 11,84–88. The well-known
cytokines interleukin-4 (IL-4) and IL-13 have been shown to support differentiation and
maturation of luminal epithelial cells 89, and macrophages, in addition to their roles in
pathogen clearing and wound healing, are important regulators of branching morphogenesis
during embryonic and post-natal development of the mammary gland 36,90,91. Other innate
immune cells have been found in pre-pubertal mammary tissue, likely influencing
development prior to puberty 11. Macrophages are abundant cells in nipple aspirates from
reproductive age women 92 and taken together with previous reports of this cell type
localizing with mammary epithelial cells 36, it can be inferred that immune cells play roles
throughout all stages of mammary development. Macrophages can be visualized lining the
mammary ducts where they secrete growth factors, chemokines, and cytokines to support
epithelial cell proliferation 91. Previous work has shown that the cytokines IL-4 and IL-13 are
critical for promoting the differentiation and maturation of luminal epithelial cells 89;
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reciprocally, data from genetically modified mouse models show that Colony stimulating
factor 1 (CSF1,) Transforming growth factor ß1 (TGFB1) and C-C Motif Chemokine Ligand
2 (CCL2), all secreted by mammary epithelial cells, regulate macrophages during mammary
development 34,93–97. This relationship creates a positive developmental loop, wherein
mammary epithelial cells signal to macrophage populations to secrete factors that provide
support and promotion of further epithelial development 93. In humans, high amounts of
CSF1 protein and mRNA were found in normal and lactating breast epithelium 98–100. In
response to IL-4/IL-13 stimulation, macrophages can produce members of the MMP family
in vitro 101,102. In the context of mammary gland development, MMPs function in ECM
remodeling to allow ductal branching into the fat pad 14,103–107. Importantly, MMP3 is an
extracellular regulator of the Wnt signaling pathway and an effector of epithelial stem cell
function 108, and MMP11 has a paracrine function during development that can be exploited
to promote tumor progression, providing another link between development, immune
molecules, and malignancy 109. MMP14 and MMP15 also regulate adipocyte fate
determination in the developing mammary gland 14. In addition to their roles during normal
mammary organogenesis, macrophages are often present in the breast tumor
microenvironment, where they correlate with reduced overall survival 110–113. The importance
of immune cells in mammary gland development is well known 34,35, but more research is
needed to elucidate the molecular signaling that guides them within the gland, and largely
unexplored are the roles of chemokines and the adaptive immune system 86,114. Accordingly,
understanding the function of immune molecules in normal development and their concert
with other signaling mechanisms can provide insight into these roles during cancer
development 91.
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Cytokeratins, integrin molecules, and laminin molecules in mammary development
Several other molecules that are commonly implicated in early mammary
development are cytokeratins, integrin molecules, and laminins. Cytokeratins can be found in
most epithelial cells where they function as intermediate filament proteins. In the mouse
mammary gland, K5 and K14 are markers of basal/myoepithelial cells and K8 and K18 are
luminal cell markers 115,116 and K5 and K14 are co-expressed during the first few postnatal
weeks of development 117. The role of integrin molecules in mammary development has been
thoroughly reviewed by Ramovs et al118. As previously mentioned, remodeling of cell–cell
and cell–ECM interactions is critical in both normal mammary development and oncogenic
development; integrin molecules and laminins are both significant components of the ECM.
Integrin molecules function to sense and integrate signals between the ECM and
cytoskeleton, influencing intracellular signaling and cell proliferation, migration, and
differentiation 119. Integrin molecules can also respond to intracellular signals (inside-out
signaling) and mediate cell adhesion and transmission of contractile forces for migration
119,120

. More than 150 proteins have been detected to interact with integrin molecules at sights

of adhesion, known as adhesomes 121–123. Interacting proteins at the adhesome include
cytoskeletal components, enzymes, and adaptor proteins that control downstream signaling
cascades and regulate proliferation, differentiation, and migration of cells 124. Cells must
utilize integrin-mediated adhesion to progress through the G1/S cell cycle checkpoint 125
through signaling using mitogen-activated protein kinases/extracellular signal-regulated
kinase (MAPK/ERK), PI3K/Akt, and the small GTPase Rac pathways 124. Two of the most
critical integrin molecules for mammary branching morphogenesis are integrin molecules β1
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and β4 126,127. Both β1 and β4 are involved throughout mammary morphogenesis 128, but it is
important to note that β1 can form integrin heterodimers with α1, α2, α3, α5 and α6 chains,
whereas β4 can only associate with α6 119,129, appointing β4 as an indicator of α6 presence. β1
integrin, while associated with laminin molecules, has been shown to transmit signals to
mammary epithelial cells during pregnancy and lactation 130. β4 is more controversial;
although its contribution to epithelial biology has been investigated for over two decades, its
role in mammary gland biology is unclear and confusing 131. β4 is expressed mainly on the
basal surface of epithelial ducts and like β1, is an adhesion receptor for laminins 132. This
association allows formation and mediation of stable hemidesmosomes (HDs) on the basal
cell surface that link the cellular cytoskeleton with the BM 133. β4 and its exclusive partner α6
are organized primarily in basal/myoepithelial cells or basal luminal cells, appearing to prefer
the basal plasma membrane surface where they provide an anchor to the BM 131,134. The
upregulation of integrin expression by several growth hormones and growth factors in the
bovine model proved that integrin α6β4 was critical for mammary development 134, but
studies in mice suggest α6β4 integrin is actually not essential for proper branching
morphogenesis in vivo 135. In immortalized mammary epithelial cell lines such as MCF10A,
α6β4 integrin is critical in the formation of HDs and branching morphogenesis is disrupted
without their presence 136. Additionally, studies using three-dimensional cultures seem to
prove α6β4 is necessary for mammary gland development and function 137. Li et al
hypothesize that β4 contributes to mammary gland development by sustaining Parathyroid
hormone-related protein (PTHrP) expression and enabling PTHrP signaling, but the
mechanism and function of α6β4 integrin in mammary organogenesis is still poorly
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understood compared to other molecules 131. α6β4 integrin involvement in cancer will be
discussed in Chapter 2.

Laminin molecules in mammary development
Through basally located integrin molecules and laminins, direct attachment of
mammary epithelial cells to the ECM can occur 138,139. Laminin-binding integrin molecules
commonly are found in focal adhesions (FAs) and HDs, which are two adhesion complexes
that form mechanical links between the ECM and the actomyosin cytoskeleton 140. Laminins
are large heterotrimeric ECM glycoproteins and major components of the BM 141. Four
integrin molecules recognize laminins as their extracellular ligands: α3β1, α6β1, α7β1 and
α6β4 (reviewed in 142). Laminin-5 can precisely interact with integrin α6β4 in
hemidesmosomes to support stromal adhesion 133. The first study to implicate Laminin
molecules in mammary morphogenesis was completed by Barcellos-Hoff et al using Matrigel
73

. Since then, a study with MCF-10A cells in vitro confirmed Laminin-5 and α6β4 integrin

are needed for hemidesmosome assembly and branching morphogenesis 136. Using the
murine model, it was confirmed that both laminin and integrin molecules are required to
support migration and cellular traction through the stromal, therefore critical in normal
mammary gland development 143. Although evidence is strong for a supportive role of
integrin molecules and laminins in mammary development, much remains to be discovered
regarding the localization of these complexes and how they truly interact 118.
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The swine model of mammary development
Currently lacking in the field of mammary biology is continuous developmental data
collected from the same live animal over time, which would allow a deeper understanding of
developmental processes involved in the period between birth and puberty. Previous attempts
commonly used necropsy samples from different animals at different ages 144 which does not
completely control for variability between animals. Additionally, much previous research
utilizes a mouse or rat model because despite many anatomical and physical differences with
humans, these small mammals can be manipulated easily 2. Due to tissue availability
constraints, comprehensive studies of human breast development do not exist. The best that
could be accomplished is to draw parallels between the human and the mouse mammary
gland 3 and studying the infant breast has been difficult and inconclusive 145. Difficulty in
maintaining cultures of primary human cells and continuous human mammary epithelial cells
also prove controversial, as exemplified by the MCF-10A human mammary epithelial line
which will be discussed 146. Moreover, in vitro and ex vivo model systems have not been able
to truly represent mammary gland architecture or stromal cell interactions; reviewed by 79.
Anatomically and physiologically, the swine model is more closely related to that of the
human. Sullivan et al conducted a comprehensive review of the swine model for wound
healing and concluded it is an excellent tool for the evaluation of therapeutic agents destined
for use in human wounds 147. Miller & Ulrey concluded the swine model was appropriate to
study human nutrition 148 while Meurens et al concluded that domestic pigs are related
enough to humans in terms of anatomy, genetics and physiology that they represent a perfect
model to study various microbial infectious diseases, vaccine development, and contribute
significant knowledge to improve human health 149. The use of swine biomedical models has
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been well-reviewed by Lunney in 2007; some highlights of the swine model’s suitability for
human disease include its similarity in size and physiology, organ development, disease
progression, allowance of deliberately timed studies and imaging of vessels and organs using
clinical technology, and collection of repeated samples 150. It is valuable to have the ability to
study multiple pigs from the same litter as well as access to numerous swine cell lines
developed from a broad range of tissues 150. Especially useful for genomic and transcriptomic
studies is the existence of the swine genome sequence that shows high homology with
humans, resulting in the development of advanced genetic and proteomic tools 150. Lastly, the
immune system of humans differs considerably from that of the mouse; the swine model may
address the limitation of the mouse model to study the immune system in a living animal.
With the assessment of key immune regulators and markers in swine, it is now viewed as a
better model of human innate immunity and disease than rodents 151.

Novel techniques to study mammary development
Nearly all previous studies of postnatal mammary gland development have used
microarrays 152. Recently, next-generation sequencing (NGS) technology has emerged as a
revolutionary tool in genomics due to its high throughput, reasonable cost, and genome-wide
investigation capabilities 153,154. One application of NGS, and a major improvement over
microarrays, is RNA sequencing (RNA-Seq), which uses NGS technology to sequence, map,
and quantify mRNA transcripts 155,156. It can be used to directly survey RNA content of
mammalian cells and has been used effectively for human samples 157. Technical reviews of
RNA-Seq conclude that this technology is an effective way to study the transcriptome of a
cell or animal 153,154,158–160. Successful use of RNA-Seq to analyze transcriptomes of the sheep
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mammary gland 161, the lactating bovine mammary gland 162, MDA-MB-231 mammary
carcinoma cells 163, B-cell lymphoma biopsies compared with normal biopsies in dogs 164 and
whole mouse 165 have been published. In 2014, Zhao et al predicted that the RNA-Seq
platform will become the predominant tool for transcriptome analysis after demonstrating the
benefits over microarrays by performing a T-cell transcriptome comparison using both
methods 166. They concluded RNA-Seq was superior in detecting low abundance transcripts,
able to better differentiate biologically critical isoforms, allowed for the detection of more
differentially expressed genes, and avoided many of the technical issues present in
microarrays 166. Mantione et al, also in 2014, compared RNA-Seq and microarrays for whole
genome profiling and concluded RNA-Seq has a bright future in bioinformatics 167. There are
numerous software packages available to use with the technology 168,169 and it has been
fruitful for both coexpression analysis 170 and miRNA expression analysis during mammary
gland development 171.
Despite the complexity of RNA-sequencing for gene expression, studies often only
use a small number of biological replicates due to tissue availability, invasiveness, or cost
limitations. This poses a statistical problem that can be mitigated with the use of specialized
statistical techniques, particularly multivariate statistics to assess dependency of inherent
variabilities on each other, to extract the most value out of the data 172. These techniques are
currently commonly used in microbial and community ecology; multivariate techniques for
exploratory analysis 173 and application of multivariate statistics in microbial ecology 174 have
been expertly reviewed. Benefits compared to traditional statistical methods are seen from
utilization in community ecology 175,176, microbial ecology 177, gut microbiology 178,179, and
endometriosis 180.
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Chapter 1 Hypothesis: There are specific transcriptional differences and unique interaction
of gene set over time that play critical roles in postnatal mammary gland development
Based on our current knowledge of mammary gland development in the post-natal
period up to puberty, the hypothesis for this study is that there are specific transcriptional
differences and unique interactions of gene sets over time that contribute to postnatal
mammary gland development, which have not been fully documented. Since we have high
throughput data from mammary development over time in a post-natal swine model analyzed
by RNA-Seq, it is both novel and appropriate to use multivariate statistical techniques to
identify trends although not currently commonly used in developmental biology. Here, we
use a clinically relevant swine model to repeatedly sample mammary tissue throughout early
post-natal development in the same animal using minimally invasive technology. In this
manuscript, we will provide novel information about the postnatal but pre-pubertal gene
expression in swine, insight into the unique developmental trends over time characterized by
gene sets, novel pathways utilized and support of currently known pathways in embryonic
and pubertal development, and for the first time (to our knowledge) show the transcriptome
of mammary development over time in the same animal.

CHAPTER TWO: BREAST CANCER
Overview
Breast cancer is a heterogeneous disease and is currently classified into subtypes
based on similar molecular features 181. There currently exist five molecular breast cancer
subtypes: luminal A, luminal B, normal breast-like, HER2, and basal-like 182–186. Of the five
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subtypes, basal-like breast cancer (also sometimes known as triple negative breast cancer
(TNBC)) is the deadliest form of breast cancer 181,187. TNBC lacks the hormone receptors
(HRs) present on the cell surface of other cancer varieties (estrogen (ER), progesterone (PR),
and human epidermal growth factor 2 (HER2)) 188. In the U.S., TNBC represents 12% of all
breast cancers and is more prevalent in pre-menopausal women, African-American women,
and women with the breast cancer 1 (BRCA1) gene mutation 181,187,189. For the purpose of this
dissertation, the definition of TNBC will be a group of malignant tumor cells that lack the
expression of ER, PR and HER2.
In contrast with TNBC, approximately 70% of breast cancers do possess ER and PR
on their cellular surface 190. Termed luminal cancers, they can additionally be classified based
on HER2 status to represent the luminal A and B subtypes 185. ER positive breast cancers
represent the majority of HR positive cases and the estrogen cell surface receptor has long
been a major target for therapy with relatively good prognosis 191. HER2 overexpression
occurs in about 15–20% of luminal cases and also holds a favorable projection 192. In
contrast to the well characterized HR positive subtypes of breast cancer, there remains a rare
case with a variable phenotype termed Inflammatory Breast Cancer (IBC) 193. This is an
extremely aggressive form titled by the extremely swollen condition of IBC patients 194. This
swollen presentation, due to cancerous cells obstructing lymph vessels underneath the skin,
resembles inflammation 195,196. IBC occurs in approximately 1-5% of breast cancers in the
U.S 194. Interestingly, although IBC is a heterogeneous disease with the ability to express all
(or none) of the HRs, the tumors are frequently HR negative, resemble TNBC, and are very
difficult to treat 197,198.
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Basal-like vs TNBC
Basal-like breast cancer is a subtype with defining features that has some overlap
with characteristics of TNBC. Some adopt the two terms interchangeably and claim basallike breast cancer is composed of almost entirely TNBC tumors 187,199–203. However, other
researchers believe this usage is misleading and that TNBC and basal-like tumors do have
significant differences 182,204–210. Expression of basal markers such as CK5, CK6, CK14,
CK17, and EGFR are associated with a higher histological and morphological grade,
presence of BRCA1 mutation, and poor prognosis when compared to TNBC tumors without
basal phenotype 209,211,212. If basal-like tumors were classified based on IHC expression of
basal markers, 10-30% of HR positive tumors would be termed basal-like, leading to this
discrepancy 213,214; TNBC tumors that do express basal markers are a subgroup with an
especially poor outcome 209,211. These disparities, combined with the fact that both types are
distinct classes with high overlap 204, expose the need for a more defined set of biomarkers
for each class.

TNBC complications
Despite its grave short-term prognosis and a 300% higher recurrence rate than other
types of breast cancer, there are presently no FDA-approved targeted therapies for TNBC 215–
217

. An improved clinical outcome is possible for patients suffering from other breast cancers

through the use of targeted therapies toward defective cellular signaling pathways assuming
the cells express common surface receptors; this is demonstrated by the success of
trastuzumab, pertuzumab, and lapatinib in HER2-overexpressing breast cancer 218–221. TNBC
patients have a dismal prognosis from the sheer lack of available targeted therapies, and
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sadly, most cases eventually develop therapeutic resistance and capitulate to the cancer 222. In
addition to the absence of targeted therapies, TNBC lacks a definitive panel of biomarkers for
phenotypic correlation 220. If a panel existed, it could aid in one of the most critical
intervention steps in cancer development: early disease detection. Without any predictive
factors, mammography remains the most powerful advanced detection approach, but often
presents over diagnoses as the method cannot distinguish between threatening and nonthreatening cancers. Because of the shortcoming in detection, approximately 5%-30% of
women are misdiagnosed and undergo unnecessary and costly surgeries, procedures, and
undue agony 223. TNBC is a diverse and complicated set of diseases, each consisting of
extended intratumoral heterogeneity and a distinct molecular subtype, resulting in
unpredictable responses to chemotherapy 224. Inherent heterogeneity has severe consequences
related to treatment resistance even when targeted therapeutics are administered 225. Targeted
therapy for TNBC has been inadequate due to the lack of specific targets and partial
understanding of the pathways involved 226,227.

Signaling pathways in TNBC
One of the most important and well known mutations of TNBC and basal-like breast
cancer is that of the BRCA1 (BReast CAncer 1) and BRCA2 (BReast CAncer 2) genes and
associated pathways 228–230. Tumors from BRCA1 mutation carriers show dysfunctional cell
cycle progression 231–234 and express low levels of Cyclin-dependent kinase inhibitor 1B
(p27), high levels of S-Phase Kinase Associated Protein 2 (Skp2), cyclin E, and caspase-3 in
comparison with sporadic tumors and tumors with BRCA2 mutations 232,234. Other genes
found mutated with or without BRCA1 and BRCA2 mutations are ATM serine/threonine
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kinase (ATM) and tumor protein 53 (TP53); these have a potential role in TNBC metastasis
through interaction with BRCA1, BRCA2, and additional proteins that will be discussed
subsequently 183,235–238. An inherited TP53 mutation causes a condition known as FraumeniLi syndrome, which has been proven to predispose women to breast cancer at an early age
235,238

.
A second pathway critical in cell cycle maintenance and cellular proliferation (and a

possible contributor to oncogenic development) is the Phosphatidylinositol 3kinase/mammalian target of rapamycin (PI3K/mTOR) pathway 239–241. PI3K/mTOR is a
common focus of clinical research; it is one of the most frequently altered pathways in
human breast tumors and controls central aspects of cancer, which include cell proliferation,
survival, metabolism, and genomic stability 242. It has also become a desirable target for
therapy 243,244. Mutations are commonly found in the PIK3CA gene in TNBC 245 with
dysfunction in supporting genes of this pathway including AKT3, Phosphatase and tensin
homolog (PTEN), and Tuberous Sclerosis 1 (TSC1) 245,246. Functional PI3K molecules
transduce upstream signals from receptor tyrosine kinases (RTKs) and G protein-coupled
receptors (GPCRs) by phosphorylating the 3′-hydroxyl group of the inositol ring of
phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) to generate phosphatidylinositol-3,4,5trisphosphate (PIP3) 247,248. PIP3 then can recruit cytosolic proteins to the plasma membrane
to promote activation or co-localization with other proteins 249–251. AKT, a protein with
multiple roles in metabolism, growth, and cancer, is able to bind PIP3 252,253 and activate a
wide range of target proteins. The 3′ phosphatase PTEN is a lipid phosphatase that converts
PIP3 back to PIP2, blocks and regulates PI3K signaling 254, and has been characterized as a
major tumor suppressor in humans 255,256. The PI3K-AKT pathway regulates cell cycle
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progression at the G1/S transition through inhibition of degradation of cyclin D1 and Myc,
two proteins that drive S phase entry 257,258. Specifically, FOXO transcription factors inhibit
cyclin D1 expression and promote the cell cycle regulators p27kip1 and p130Rb2 259. When
phosphorylated by AKT, FOXO supports cyclin D1 expression and inhibits expression of cell
cycle inhibitors. Human tumors often show overexpression of cyclin D1 or Myc and
reduction in expression of p27kip1, which allows cancerous cells to proliferate 260,261. p53 is a
critical tumor suppressor protein involved in cell cycle regulation and apoptosis; in normal
cells p53 is negatively regulated by the p53-binding protein Mouse double minute 2 homolog
(MDM2), which blocks the apoptotic properties of p53 and targets it for ubiquitination 262,263.
p53 selectively regulates cell cycle arrest, DNA repair, and apoptosis to protect genomic
stability and prevent tumor formation 264. Instinctively, p53 is often mutated in metastatic
tumors; somatic p53 mutations occur in greater than 50% of tumors and almost every cancer
type 235,265,266. PI3K-AKT is critical in the survival, growth, and proliferation of normally
functioning cells; inhibitors of this pathway would require the tumor to be more sensitive
than normal tissue which complicates therapeutic development 267.
Additionally, several critical AKT-independent PI3K signaling pathways exist,
including the PDK1-mTORC2-SGK axis, Rac signaling, and the TEC family kinases 268. It is
important to note that the Rac proteins (RAC1, 2, and 3) are a subfamily of the Rho GTPase
family that function to remodel the actin cytoskeleton 269 to promote invasion and metastasis
270

. Additional pathways potentially exhibiting causal involvement in TNBC are the

RAS/RAF/MEK pathway, including amplifications or mutations in Fibroblast Growth Factor
Receptor 1 (FGFR1), Insulin-Like Growth Factor 1 Receptor (IGF1R), B-Raf ProtoOncogene, Serine/Threonine Kinase (BRAF), KRAS Proto-Oncogene, GTPase (KRAS),

21

HRas Proto-Oncogene, GTPase (HRAS), and Dual Specificity Phosphatase 4 (DUSP4) 245,246.
Furthermore, cell cycle checkpoints, including amplifications or deletions of RB
Transcriptional Corepressor 1(RB1), Cyclin Dependent Kinase 6 (CDK6), Cyclin D1
(CCND1), and Cyclin D2 (CCND2) can lead to tumorigenesis when dysfunctional 239,246,271–
276

. Other pathways commonly studied are the Janus kinase/signal transducers and activators

of transcription (JAK/STAT) pathway (amplification in JAK2), and the Notch pathway
(including amplification or mutation in WNT and β catenin) 61,276–283.

Integrin molecules in cancer
As discussed in Chapter 1, the interactions between integrin molecules and their
laminin ligands, especially laminin-5, regulate multiple facets of embryonic development.
However, they also effect cell proliferation, tumor growth and the capability of human breast
tumors to metastasize 284–290. During progression from tumor growth to metastasis, specific
integrin signals enable cancer cells to detach from neighboring cells, re-orientate their
polarity during migration, and survive and proliferate in foreign areas, similar to their
function in normal mammary development 291. In mature normal tissue, laminin-5 is
primarily involved in adhesive function; however, in cancer, it has a more complex role in
cell migration and tumor invasion 292. The most common integrin molecules that function as
laminin receptors on cancer cells are α2β1, α3β1, α6β1, and α6β4 293. Integrin heterodimers
comprised of the α6 subunit can pair with either the β1 or β4 subunit, while integrin β4
subunit can only pair with the α6 subunit, making β4 an indicator of the presence of α6β4 291.
Increased expression of integrin α6 has been observed in invasive ductal carcinomas 294, skin
squamous cell carcinomas 295,296, oral squamous cell carcinomas 297, ovarian carcinoma 298,
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prostate tumors 299, bladder cancer 300, pancreatic cancer 301 and colorectal cancer 302.
Furthermore, a range of studies implicate α6β4 integrin as a contributor to oncogenic
development in breast cancer 137,303–305. In advanced breast carcinomas, α6β4 integrin
localizes to the leading edge of invasive cells, cooperating with ErbB2/3 and associating with
F-actin to promote metastasis, which leads to deregulation of adhesion, liberation from
hemidesmosomes, loss of cell polarity, and hyper-proliferation 306. In contrast with
development, α6β4 is not limited to the basal layer of epithelial cells in cancer and in tumors
it can be found in multiple cell layers of the tissue 285,289. Many normal cellular signaling and
ECM pathways containing integrin receptors are deregulated in cancer to allow cellular
migration, as evidenced by differential integrin expression among normal breast, simple
hyperplasia, atypical hyperplasia, ductal carcinoma in situ (DCIS) and invasive tumors 307.
α6β4 integrin is thought to remodel the ECM through interaction with the PI3K and RhoA
cell signaling pathways previously discussed and induction of traction forces generated by
the actomyosin cytoskeleton 308,309. Additionally, α6β4 can induce the production of MMP1
and MMP2 310,311, which as discussed in Chapter 1, drive normal mammary development in
conjunction with macrophages. α6β4 supports PI3K activation through different receptor
tyrosine kinases (RTKs) which is necessary for cell survival 312. PI3K signaling induced by
integrin molecules can also activate the transcription factors STAT3 and c-Jun 313. Moreover,
α6β4 serves as a marker to detect distant metastases in the early stages of specific
malignancies 289,314 and β4 overexpression was found in basal-like breast cancers, correlating
with aggressiveness to institute a prognostic β4 signature 288 that increases with tumor grade
289,315

. Integrin β1 and β4 signaling also leads to resistance to treatments including

radiotherapy, chemotherapy, hormone therapy and targeted therapies 137. Notably, α6β4
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integrin may modulate oncogenic signaling through association with Laminin molecules in
the ECM.

Wnt in cancer
The Wnt gene family consists of 19 Wnt genes encoding closely related proteins and
are the most critical family of signaling molecules in embryonic and postnatal development
316

. As described in Chapter 1, formation of the mammary line and expression of Wnt10b is

the earliest detectable ectodermal event in mammary gland organogenesis in the mouse
model 24 and the Wnt family continues to support placode development and TEB expansion
throughout mammary organogenesis 24,26,27. In fact, expression of Wnt2, Wnt4, Wnt5a,
Wnt5b, Wnt6, Wnt7b, and Wnt10b regulate growth and differentiation in the developing
mammary gland; in other tissues, Wnt proteins influence analogous processes including cell
fate determination, cell growth, apoptosis, maturation, and differentiation 317. In human breast
tumors, overexpression of WNT2, WNT4, WNT5A, WNT7B, WNT10B, and WNT13 has
been detected 318–322. Specifically, WNT2 is normally expressed in mammary stroma while in
breast carcinomas is present in both the epithelium and the stroma 320. Defining the functional
significance of Wnt overexpression in breast cancer is difficult due to additional oncogenic
mutations found in downstream signaling components in the pathway 280. Recently, data
suggest that Wnt signaling can promote stem cell self-renewal 283,323–326.
Cell surface receptors for the Wnt proteins are composed of a transmembrane domain
plus one low density lipoprotein receptor related protein, either LRP5 or LRP6 316,327–329. A
critical downstream signaling component, β catenin, aids in cell adhesion and transcriptional
regulation. It is cytosolically degraded in the absence of Wnt signaling and in the presence of
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Wnt is translocated to the nucleus to form a complex with LEF-1 family members, allowing
regulation of target genes such as c-Myc and cyclin D1 317,326,327. This is classified as the
canonical Wnt signaling pathway 54,316,327. It is important to note that many Wnt and β catenin
target genes are tumor suppressors or oncogenes; in colon cancer, 85% of tumors have a
mutation in the APC protein, a negative Wnt regulator that normally destabilizes β catenin
327

. Elevated β catenin activity has been shown in many breast cancer cell lines and in the

nucleus and cytosol of close to 60% of human breast cancer tissue samples, correlating with
poor prognosis 330. In addition, elevated levels have also been found in tumor lysates
confirmed by Western Blotting 331. Transgenic mouse models containing stabilized
expression of β catenin in their mammary gland result in tumor formation 332,333. Importantly,
many researchers suspect Wnt signaling in breast cancer may be influenced by other
members of the Wnt pathway that have not yet been comprehensively studied 334. Several
studies have reported altered expression of regulators of the Wnt pathway in breast cancer at
the RNA and protein level 335,336.

Of significance is the crosstalk between Wnt and the

PI3K signaling pathways in breast cancer; mutations in or inactivation of PTEN occurs in a
significant portion of breast cancers 337. When PTEN is silent, it acts as a PI3K suppressor
and leads to the hyperactivation of AKT and nuclear accumulation of β catenin 338. Upon
binding growth factors such as Insulin, IGF1, and FGF1, the PI3K/AKT pathway may
contribute to the stimulation of β catenin signaling 339. An important downstream signaling
molecule in the PI3K pathway, p53, may rely on β catenin degradation to function 317. The
p53 gene is mutated in 20-40% of human breast cancers and can trigger β catenin
degradation; this may be a method utilized by the cell to prevent excessive β catenin levels
340

. Loss of TP53 function in cancer would then result in overexpression and stability of β
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catenin and increased expression of transcriptional targets- potentially oncogenes 317. Finally,
kinases of the NF-κB signaling pathway (IκB kinases IKKα and IKKβ) can regulate βcatenin transcription and activity, further supporting the large network of signaling pathways
converging with the Wnt pathway 341. Data currently indicate activation of the Wnt signaling
pathway is frequently one of the most critical signaling abnormalities in breast cancer
276,283,318,327,334,342,343
344

and may be a source of novel therapeutic targets for treatment of TNBC

.

Macrophages in cancer
As reviewed in Chapter 1, MMPs secreted by macrophages function in ECM
remodeling to allow ductal branching into the mammary fat pad 14,103–107. One MPP, MMP3,
serves as an extracellular regulator of the Wnt signaling pathway and effector of epithelial
stem cell function 108, offering a link between the Wnt pathway and the immune system that
can impact adult epithelial cell function 108. Similar to normal mammary organogenesis, the
stroma and ECM play a vital role in tumorigenesis 345. There are conflicting opinions on
whether macrophages present in the tumor stroma environment are involved in tumor
rejection or promotion of tumor growth and invasion 346, but a detailed review by Lin et al 347
provides significant evidence that macrophages support tumorigenesis in a comparable
manner to their function in normal mammary organogenesis. CSF-1, a regulator of
macrophage recruitment, is frequently overexpressed in human breast cancer tissues and
correlates with poor prognosis 348,349. Furthermore, several clinical studies provide strong
evidence in a causal role for CSF-1 in breast cancer progression and metastasis 347. The
current hypothesis implies CSF-1 produced by tumors, in conjunction with other cytokines
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(especially TGFB1 and CCL2), recruits macrophages to the tumor microenvironment and
simultaneously inhibits development of immune cells that may present tumor antigens to Tcells. This strategy provides an attractive site of therapeutic intervention 347. The role of
TGFB1 in breast cancer is not fully understood; data show that it can both suppress tumor
development and promote tumor invasion 350 and possess a pro-tumorigenic effect at later
stages of cancer progression where it modulates EMT 351,352. CCL2, secreted by mammary
epithelial cells during development, recruits macrophages and can be found in high levels in
tumor tissue and surrounding stromal cells 353, where its expression is highly correlated with
macrophage infiltration 354–357. It is evident that mammary epithelial cell interactions with
macrophages, mediated by a range of cytokines, can significantly affect the risk of breast
cancer by supporting tumor development 347. Future studies should investigate the specific
signaling pathways utilized in mammary gland development that involve cytokines,
macrophages, and if dysfunctional, promote tumor growth and metastasis.

Mammary stem cells
Given that normal stem cells, mammary stem cells (MaSCs), and cancer stem cells all
share the ability to self-renew, differentiate, initiate anti-apoptotic pathways, increase
membrane transporter activity, and migrate, understanding mammary stem cell profiles and
their role in normal development aids in identifying the mechanisms involved in
carcinogenesis. These properties make mammary stem cells ideal candidates for the initial
events that drive tumor growth and metastasis 358. Adult mammary stem cells are older, and
they have had more exposure to damage, leaving them susceptible to accumulate cancerous
mutations. It is believed that the deregulation of self-renewal is a key event in cancer
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progression, and many of the dysfunctional pathways seen in breast cancer are just
reactivated developmental pathways 57,76,281,286,359–362. It is hypothesized that MaSCs could be
the original cancer-initiating cell for at least some classes of breast cancer 81,325,358,363,364. Liu
et al characterized breast cancer stem cells as a subpopulation of mammary stem cells
containing the cell surface marker phenotype of ESA+/CD44+/CD25-/low and found that if
these cells were isolated and purified from primary human breast cancers, only 100 were
required to form tumors in NOD/SCID mice in contrast with tens of thousands of unpurified
cells 365. Each time this purified population of cells was passaged, the cells were capable of
generating both differentiated cells and a stem cell population, consistent with the original
stem cell theory365. These cancer stem cells were better able to form colonies under lowadherence conditions and also displayed increased resistance to chemical compounds 365. Liu
et al also identified multiple normal developmental pathways involved and extensive
interaction between them, including Hedgehog, Notch, and Wnt, which were discussed in
Chapter 1. The hedgehog signaling pathway mediates communication between the epithelial
cells and stroma during mammary duct development and is also involved in MaSC selfrenewal 279,365,366. The notch signaling pathway contains proteins commonly found in a
variety of stem and progenitor cells, functioning to modify cell fate and differentiation along
lineages and regulating asymmetric cell divisions 365. Many of the notch genes can function
as proto-oncogenes, which are normal genes that could become an oncogene if specific
mutations are induced 365. Wnt signaling plays a role in self-renewal of MaSCs 326. Liu et al
used mammosphere cultures to demonstrate the interaction between these different pathways
and found that activation of the notch pathway leads to subsequent activation of the hedgehog
pathway, and that deregulation of this positive feedback loop could induce cancer 326. Like
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TNBC, it is known that mammary stem cells lack ER/PR/HER2 receptors suggesting that
they may be the original cell that undergoes a mutation and leads to carcinogenesis and tumor
formation in basal breast cancers 364. Additionally, the regulatory pathways utilized by
MaSCs such as notch ligands, p63, and Wnt pathway are also known to be involved in basal
like tumors and are associated with poor prognosis 278,367–371 Breast cancers that are positive
for ER, PR, and Erb2 most likely arise in a committed progenitor cell population and are
generally easier to treat 372. Recent research has shown a linear relationship in the number of
cancer stem cells in breast tumors and the aggressiveness of the cancer and likelihood that it
will spread 361,365.

TNBC cell lines
Proper in vitro models for breast cancer are necessary for accurate and reproducible
results. In this dissertation, three cell lines are used: MDA-MB-231, MCF-10A, and primary
swine fibroblasts. MDA-MB-231 cells and primary swine fibroblasts are used for RNA-seq
due to complications with the MCF-10A cells which will be discussed. Frequently used in
breast cancer research are the human cancer cell line MDA-MB-231 and the normal human
mammary epithelial cell line MCF-10A. Both of these cell lines express some level of
integrin α6 and varied expression levels of integrin ß4 284,312,373–377. The MDA-MB-231 line is
an invasive breast cancer cell line that lacks expression of estrogen (ER) α, progesterone (PR)
and human epidermal growth factor receptor 2 (HER2), and is classified as a TNBC line 378.
In addition to showing high expression of integrin α6 and integrin ß4, the α6ß4 complex is
necessary for the tumorigenic properties of these cells 303. The MCF-10A cell line, a normal
human mammary epithelial cell model, is commonly used as a normal control, but recent
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research suggests that these cells may not represent phenotypically normal epithelial cells 146
as these cells exhibit a basal phenotype but also share features of mesenchymal cell
populations. In order to alleviate this concern, swine primary fibroblasts were used as a
normal mammary cell type in development as they do have a role in the regulation of
differentiation 379.

TNBC treatment
As mentioned, TNBC patients have a poor prognosis and therapeutic outcome in
comparison to HR positive breast cancer because of the aggressive nature and lack of
targetable cell surface receptors. Current molecular targets include EGFR, vascular
endothelial growth factor (VEGF), Poly (ADP-ribose) polymerase (PARP), PI3K, MEK, heat
shock protein 90 (HSP90), and histone deacetylases (HDAC) 216,380. TNBC has been shown
to express EGFR at a higher level in comparison to other subtypes 381. EGFR is involved in
tumor growth and survival, and inhibition of this molecule via monoclonal antibodies or
small molecule inhibitors induces cell cycle arrest, initiation of apoptosis, and inhibition of
angiogenesis, invasion, and metastasis 382–384. Tumors require a blood vessel system in order
to obtain nutrients for metastasis, growth, and invasion; one of the most important
proangiogenic factors and mediators of this activity is VEGF (Hoeben et al., 2004). VEGF
expression within tumors in TNBC is higher than non-TNBC tumors 386. Currently, VEGF
can be blocked using specific antibodies and small molecule oral tyrosine kinase inhibitors
387

. Further investigation of the cellular signaling pathways utilized by TNBC could provide

novel therapeutic targets.
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rG3- Overview
As discussed, the interactions between integrin molecules and their laminin ligands,
especially Laminin-5 (Ln-5; also known as Laminin-332), regulate multiple facets of both
embryonic development and tumor growth, invasion, and metastasis in many carcinoma
types 284–287,289,290,292,294,308,388–391. Additionally, integrin heterodimers comprised of the
integrin β4 subunit can only pair with the α6 subunit, making β4 an indicator of the presence
of α6β4 291. α6β4 integrin serves as a marker to detect distant metastases in the early stages of
specific malignancies 289,314 and β4 integrin overexpression was found in basal-like breast
cancers, correlating with aggressiveness to institute a prognostic β4 signature 288 that
increases with tumor grade 289,315. The mechanism α6β4 integrin utilizes to modulate
oncogenic signaling through association with Ln-5 molecules in the ECM is the basis for the
recombinant protein (rG3) produced in this dissertation.

Laminin-5
Ln-5 is a trimeric glycoprotein present in the ECM and basal lamina; each laminin
molecule forms a cruciform structure with three chains, α, β, and γ, linked by disulfide bonds;
five α, three β, and three γ chains have been identified 132,388. These chains combine to form
at least 15 laminin isoforms that are uniquely distributed in tissues and carefully regulated
during early development 392,393. Ln-5 can be degraded by proteases during tissue remodeling;
the γ2 subunit is proteolyzed by MMP-2 to promote cell migration 394. Within the Ln-5
subunit, distinct functional domains are able to bind with other ECM molecules and integrin
cell surface receptors 395. Importantly, the globular (G) domain at the carboxy-terminal of the
laminin α chain interacts with high affinity for the α6β4 integrin 396,397 and the complex
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promotes hemidesmosome formation 398,399 and stromal adhesion 133. The G3 domain is
essential for the unique biological activity of Ln-5 400; deletion of the G3 domain in
recombinant forms of Ln-5 leads to a drastic loss of cell adhesion and motility 401. Studies
have shown the G3 domain to contain at least two sites that regulate cell adhesion and
motility in different ways, and activities of Ln-5 are largely dependent on these sites 388.
When cleaved during proteolytic processing, the G4/G5 fragment that is released from the G3
domain also functions to support cell migration 397.
Ln-5 is associated with each of the seven defined cancer stages: mutation of normal
cells, cancer cell proliferation, infiltration/invasion, migration, metastasis, angiogenesis, and
additional cell proliferation in the metastatic lesion 402 and its expression is altered at the
transcriptional, translational, and posttranslational levels in many types of cancer 403,404.
Notably, overexpression of Ln-5 is controlled by additional molecules of the Wnt pathway; in
colorectal carcinoma, β-catenin upregulation activates the laminin γ2 subunit resulting in
enhancement of tumor development and cancer cell invasion 405,406. High levels of Ln-5 are
correlated with poor prognosis in cervical cancer, pancreatic carcinoma, hypopharyngeal
cancer, urinary bladder urothelial cancer, small-sized lung adenocarcinoma, malignant
glioma, gastric cancer, squamous cell carcinoma (SCC) of the tongue, colorectal adenoma
and hepatocellular carcinoma 407–414. The accepted consensus is that Ln-5 is overexpressed in
the leading edge of tumorigenic cells 395. Although Ln-5 is best known as an epithelial BM
component, it has also been reported in the BM of blood vessels along with α6β4 integrin on
endothelial cells 415,416 and is thought to play critical roles in angiogenesis 417.
The role of Ln-5 in tumor invasion and metastasis makes it a popular target for cancer
therapy and several synthetic peptides have been developed to inhibit Ln-5 expression or
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mitigate its biological function in tumors 418–420. To develop effective reagents that limit
ability of Ln-5 to induce cellular proliferation through association with α6β4 integrin, a better
understanding is needed of signaling cascades regulated by this adhesion 395. Therefore, we
have developed a recombinant form of the G3 domain of Ln-5 (rG3) in order to assess Ln5/α6β4 integrin signaling and the critical pathways utilized in tumorigenic cells.

rG3 production history
The G3 domain of the rat Ln-5 α3-chain was expressed in a prokaryotic system
engineered with chaperone proteins, allowing for soluble protein expression in a cold
temperature environment 421. Turner confirmed recombinant rG3 had a molecular weight
(MW) of approximately 27 kDa based on the G3 input sequence and the addition of a
histidine tag for purification and detection 421. After expression, Turner purified the
recombinant protein using chromatography and performed adhesion and proliferation assays
on three cancer cell lines (MDA-MB-231, MDA-MB-435 and MCF-7). For all cell lines, rG3
demonstrated dose-dependent adhesion and an inhibitory effect on proliferation and produced
an apoptotic phenotype with elevated caspase levels present after varied hours of rG3
treatment 421. Further studies by Turner showed altered levels of phosphorylated AKT and
reduced cell viability through pro-apoptotic signaling induced by the binding of rG3 to the α
subunit of α6β4 integrin 421. These results induced the activity of rG3 on the PI3K/AKT
pathway to be studied in depth 422. Results from those studies showed significant differences
in protein expression of PI3K/AKT pathway members in MDA-MB-231 after rG3 treatment
compared to untreated cells; higher levels of AKT and phosphorylated AKT were seen in
untreated cells, indicating the inhibitory effect the rG3 protein has on this pathway. Both
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IKKαβ and the phosphorylated IKKβ catalytic subunit were expressed at a significantly
higher level in untreated cells, as were the levels of phosphorylated nuclear NFκB.
Importantly, the greatest change in expression was seen in p53; in treated cells, it was present
at higher levels than in the untreated cells, confirming Turner’s conclusions that rG3 is able
to significantly reduce cell viability of tumorigenic cells through specific PI3K/AKT
signaling events 422.

Hypothesis: There are transcriptional similarities in normal development and TNBC that can
be affected through rG3 signaling pathways
As evidenced in Chapter 1, normal mammary development requires finely
coordinated signaling between mammary epithelial cells, stromal molecules, and the ECM in
order to produce a fully functional gland. This involves drastic tissue remodeling,
degradation of the ECM, immune system regulation, and EMT- all key processes also
implicated in TNBC. Although TNBC manifests in the mammary epithelium, surrounding
cells play important roles in tumor growth and metastasis. Many critical signaling factors are
shared between normal mammary development and cancer, especially those of the Wnt
pathway, integrin and laminin association, ECM, PI3K pathway, and macrophage functions.
Here, transcriptomic data collected over time in a post-natal swine model is analyzed by
RNA-Seq from Specific Aim 1 to compare trends with the MDA-MB-231 TNBC cell line
and primary swine fibroblasts. It is suspected that the postnatal but pre-pubertal gene
expression in swine utilizes a unique set of developmental genes over time that is shared
closely with cancer development.
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Additionally, rG3 production will be optimized and the resulting recombinant protein
will be characterized to determine suitability and purity for treatments; additional protein
complexes in the sample will be identified by mass spectrometry. Next, dose-dependency of
rG3 will be determined on MDA-MB-231 cells and a non-tumorigenic cell line and cellsignaling pathways and potential biomarkers affected by rG3 treatment in vitro will be
compared to biomarkers in Chapter 1. It is hypothesized that signaling pathways effected by
rG3 will share similarities with those present in early mammary development and tumor
development, generating a panel of significant biomarkers for further study.

CHAPTER THREE: MATERIALS AND METHODS

Animal sampling
In order to identify signals involved in early mammary development, a fine needle
biopsy sampling method was developed to collect mammary tissue of multiple species
(bovine, ovine, and porcine) across different pre-pubertal ages (U.S. patent application
number 62/256,416). A 14-gauge spring activated needle was used (Jorgenson Labs Inc.
J0528) with a dual setting specimen notch of 8 mm or 16 mm depending on animal age and
size. According to AUP 2015-064 approved 10/2015, each animal was manually restrained
for no longer than about 10 minutes. The sample site was cleaned with a triple wash of
chlorhexidine (2%; Durvet) and βdine (Purdue Products). A body weight was taken during
each sampling and recorded. Based on weight, 1-4 CCs of Lidocaine (2%) was administered
at the sample site via intradermal and subcutaneous routes and a core tissue sample was then
removed from the parenchyma of the mammary gland below the nipple using the biopsy
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needle. Mammary gland locations were alternated week to week to decrease risk of tissue
damage. The animal was evaluated for 5 minutes following the procedure to ensure any
bleeding had stopped from the biopsy sample site. If bleeding was observed, pressure was
applied. After being released from the restraint the animal returned to a normal diet and
housing with daily observation for 3-5 days for observation of any signs of infection. During
the sampling procedure, the animal was closely monitored for any signs of pain. Postsampling, tissue was handled according to downstream methods below.

Necropsy
Per AUP 2015-064 approved 10/2015, two euthanized animals were used to measure
how deep the mammary tissue expands into the body and to compare necropsied tissue
sample with live biopsy samples to confirm there is low or no variability in sampling live
animals with the needle. Intravenous euthanasia was performed according to accepted
practices under Godley-Snell Research Center veterinary supervision. After death was
confirmed, a tissue sample was removed from the parenchyma of the mammary gland either
using the biopsy needle for a small core sample or a sterile scalpel for a larger sample
representative of past sampling technology. Post-sampling, tissue was handled according to
downstream methods below.

Collection for RNA isolation
If RNA was to be extracted from the tissue, after sampling, each biopsy was placed
directly into a sterile 1.5 mL microcentrifuge tube containing 1mL of RNAlater (Thermo
Fischer Scientific) and stored at -20°C until RNA isolation.
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Collection for histology
If the sample was to be processed histologically, each biopsy was immediately placed
in a tissue cassette (VWR) with 0.67mm pore openings and fixed in 10% neutral buffered
formalin (supplier) for 18-24 hours at room temperature. Fixed tissues were then dehydrated
in ethanol, cleared in xylene, embedded in paraffin blocks, sectioned to a thickness of 6-8µ
using a rotary microtome (Leica Microsystems), mounted onto glass slides, and dried
overnight on a slide warmer at 37°C. Slides were then visualized for morphology with
hematoxylin and eosin (H&E).

Contingency analysis and developmental index
A contingency analysis was conducted for two necropsied animals to confirm that the
mammary biopsy procedure produces a tissue sample that is representative of the results
obtained by necropsy. In the contingency analysis, H&E stained tissue sections obtained by
each method were visually assigned a development index (DI) score. The development index
can be seen in Fig. 1. As illustrated in Fig. 1, cells with a maturity index of 0 are a cluster of
cells without lumen and 1 ring layer, cells with a maturity index of 1 present as a cluster of
cells without lumen and more than 1 ring layer of cells, cells with a maturity index of 2
present as loosely organized cells with lumen, cells with a maturity index of 3 present as
semi-organized cells with lumen, cells with a maturity index of 4 present as dense and
organized cells with lumen, cells with a maturity index of 5 present as dense and organized
cells with lumen and branching. Tissue was prepared histologically according to previous
section and development index scores were statistically compared between the two methods
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using JMP Pro 12 software (SAS, Cary, NC).

Sequential H&E in swine mammary tissue collected over time proves ability of method to
study time course of development

Figure 1: H&E stained formalin fixed, paraffin embedded sections of swine mammary tissue
demonstrate developmental index levels 0-5.

RNA isolation
RNA sequencing was performed with RNA isolated from the tissue using an RNeasy
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Kit (Qiagen Inc., Valencia, CA) according to manufacturer’s instructions and a TissueRuptor
(Qiagen Inc., Valencia, CA) according to manufacturer’s instructions. After disruption with
the TissueRuptor, the RNA samples were also treated with an on-column DNase (Qiagen
Inc., Valencia, CA) to remove any possible genomic DNA contamination. Isolated RNA
samples were quantified and integrity validated on a Nano Drop 1000 Spectrophotometer
(Thermo Scientific, Waltham, MA) and Bioanalyzer 2100 (Agilent Technologies) and stored
in 1.5mL microcentrifuge tubes at -20°C until library preparation.

Library preparation and RNA sequencing
Each mammary tissue sample was normalized to a standard input concentration of
total RNA and an Illumina compatible sequencing library was prepared robotically on a
Microlab STAR (Hamilton) with the TruSeq stranded total RNA library prep kit (Illumina)
following the manufacturer’s recommended procedures (Illumina). The resulting sequencing
libraries were assessed for size on a 2100 Bioanalyzer (Agilent) and sequence data collected
on 1 lane of an Illumina HiSeq2500 with a 2x125 bp PE read on high-output mode (Hollings
Cancer Center, MUSC) up to a depth of at least 22 million reads. Raw sequence reads were
assessed for run quality with the FastQC analysis package (Babraham Bioinformatics) and
then preprocessed to remove adapter and low quality bases with the Trimmomatic software
package423. Trimmed reads were aligned to the Sscrofa 10.2 genome using gsnap424.
SAMtools was used to generate sorted and indexed bam files425. Subread’s featureCounts was
used to identify paired-end reads that were concordantly assigned to known genes in the
correct order of transcription426,427. Raw read counts were normalized for each technique
using MATLAB (MathWorks) and RStudio version 1.0.136 (The R Foundation).
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From the resulting dataset, more advanced statistical analysis methods were utilized
using MATLAB and R. Preprocessing of redundant variables was completed using
correlation analysis (Caret R) with a cutoff of 0.95. Details for RNA-seq input are shown in
Table 1.

Table 1: Phenotype of mammary gland tissue biopsies submitted for RNA sequencing shows
age ranges.
Sample
labels
1
5
6
11
13
16
3
7
9
12
15
2
4
8
10
14
17

Tissue source
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary

Phenotype (age
in days)
4.0
11.0
18.0
25.0
32.0
39.0
11.0
18.0
25.0
32.0
39.0
8.0
11.0
18.0
25.0
32.0
39.0

Age in
weeks
0.6
1.6
2.6
3.6
4.6
5.6
1.6
2.6
3.6
4.6
5.6
1.1
1.6
2.6
3.6
4.6
5.6

Pig ID
1-8
1-8
1-8
1-8
1-8
1-8
1-13
1-13
1-13
1-13
1-13
1-10
1-10
1-10
1-10
1-10
1-10

Functional analysis
From the resulting transcriptomic dataset, in depth biological analysis was performed
to determine functional significance of transcriptomic trends in the data using Panther
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(Thomas Lab at the University of Southern California), Genesis428, Cytoscape429,
Reactome430,431 for pathway analysis, NCBI (U.S. National Library of Medicine), and
GeneCards (Weizmann Institute of Science).

Recombinant G3 (rG3) Protein production, isolation, and purification
In Turner's work, the G3 cDNA was cloned into a vector including an ampicillin
resistance gene to allow for selection of the plasmid and an N-terminal 6X-histidine tag was
added 432. ArcticExpress™ cells were used for expression of rG3 421. Once cells were induced
for protein expression and harvested, they were prepared for separation by SDS-PAGE to
confirm rG3 expression. Once soluble rG3 expression was confirmed, a culture was prepared
to yield a larger volume of the recombinant protein for purification and the fraction was
applied to a G50 Sephadex column for size exclusion separation. As previously
demonstrated, the molecular weight of rG3 including the histidine tag is ~27 kDa421. To
determine which fractions contained the protein, an OD reading was taken, and to confirm
the identity of the expressed soluble protein as rG3, a Western Immunoblot was performed
using an anti-polyHistidine monoclonal antibody 421.
For this dissertation, production was modified to get the purest form of rG3.
ArcticExpress™ cells were still used for expression. Transformed cells were cultured by
streaking for isolation on LB agar plates containing ampicillin (62.5µl 100mg/mL stock per
125 mL agar) and gentamicin (250 µl 10mg/mL stock per 125 mL agar) and incubating at
37°C overnight until colonies were clearly identified the next day. One isolated colony was
chosen from the plate and added to 10mL sterile LB broth with 5µl ampicillin and 20µl
gentamicin into a 125mL flask, which was incubated overnight at 37°C with shaking at 250
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RPM. The next day, 2.5mL of the overnight culture was added to 247.5 mL sterile LB broth
without antibiotics and incubated at 30°C with shaking at 250 RPM. The OD was checked
periodically until the culture reached absorbance of approximately 0.4, or the exponential
growth phase. At this point, cells were induced for protein expression with IPTG (1mM) and
incubated at 11.5°C with shaking at 250 RPM for 24 hours. The flask was transferred to a
sterile bottle and spun to pellet at 5250 RPM for 10 minutes at 4°C. The pellet was either
snap-frozen in liquid nitrogen and sent to Vanderbilt (MSRC Proteomics Laboratory,
Vanderbilt Medical University, Nashville, TN) for further purification using their equipment
or purified in house using the Ni-NTA Fast Start purification kit for His-tagged proteins
(Qiagen, Germantown, MD).
At Vanderbilt, the pellet was lysed using an Emulsiflex C3 homogenizer (Avestin)
and spun down in an ultracentrifuge. After filtering, the lysate was applied to a Roche
cOmplete nickel column (Roche Life Science) using a GE AKTAxpress purification system
(GE Healthcare Life Sciences). The system applied the lysate to the column and the column
was washed with binding buffer until a stable UV baseline was achieved. A gradient elution
of 0mM Imidazole and increasing to 500mM Imidazole was used to elute into different wells
of a 96-well deep well plate based on single, separate peaks. The wells were examined via
coomassie staining to find wells containing protein of the appropriate size. Protein was
quantified using a NanoDrop 1000 Spectrophotometer (Thermo Scientific).
Mass spectrometry analysis of the purified protein components after separation by
SDS-PAGE was performed by the MSRC Proteomics Laboratory (Vanderbilt University,
Nashville, TN). All MS/MS samples were analyzed using Sequest (Thermo Fisher Scientific,
San Jose, CA, USA; version 27, rev. 12) and X! Tandem (The GPM, thegpm.org; version
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CYCLONE (2010.12.01.1)). Sequest was set up to search the ecoli-uniprot-012309200901_rev_4292_20151111_rev database assuming the digestion enzyme trypsin. X!
Tandem was set up to search the ecoli-uniprot-012309-200901_rev_4292_20151111_rev
database (unknown version, 9378 entries) also assuming trypsin. Sequest was searched with a
fragment ion mass tolerance of 0.00 Da and a parent ion tolerance of 2.5 Da. X! Tandem was
searched with a fragment ion mass tolerance of 0.50 Da and a parent ion tolerance of 2.5 Da.
Glu->pyro-Glu of the n-terminus, ammonia-loss of the n-terminus, gln->pyro-Glu of the nterminus, oxidation of methionine and carbamidomethyl of cysteine were specified in X!
Tandem as variable modifications. Oxidation of methionine and carbamidomethyl of cysteine
were specified in Sequest as variable modifications. Scaffold (version Scaffold_4.4.8,
Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and
protein identifications. Peptide identifications were accepted if they could be
established at greater than 99.0% probability by the Peptide Prophet algorithm 433. Protein
identifications were accepted if they could be established at greater than 99.0% probability
and contained at least 2 identified peptides. Protein probabilities were assigned by the
Protein Prophet algorithm 434. Proteins that contained similar peptides and could not be
differentiated based on MS/MS analysis alone were grouped to satisfy the principles of
parsimony.
For in house purification using the Ni-NTA Fast Start purification kit for His-tagged
proteins (Qiagen, Germantown, MD) according to the manufacturer’s protocol with the
addition of a liquid nitrogen freeze-thaw cycle for cell lysis and 4°C incubation for binding.
A cleanup process to eliminate salts and smaller fragments was conducted with Pall spin
columns (10 K) according to the manufacturer’s protocol.
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Western Blotting – rG3
In preparation for protein separation by SDS-PAGE, purified rG3 and pure HSP60
(Prospec Bio, Israel) samples were added to an equal volume of Laemmli Buffer with 5% 2mercaptoethanol. Samples were mixed and loaded onto a 10-20% Ready Gel Precast Gel
(Bio-Rad Laboratories, Inc., Hercules, CA) together with a protein ladder (Precision Plus
Protein™ Kaleidoscope™ Prestained Protein Standards #1610375). The gel was run in the
Ready Gel System (Bio-RadLaboratories, Inc., Hercules, CA) with running buffer (15g Tris
Base, 72g glycine, 5g SDS per 1L) at 200 V for 30 minutes. Meanwhile, a sheet of ImmunoBlot™ PVDF Membrane and two pieces of 14 x 11 cm filter pads (Bio-Rad Laboratories)
were soaked in chilled Western transfer buffer (3.03g Tris Base, 14.4g glycine per 1L) for
least 30 minutes. Following electrophoresis, the gel was washed in cold Western transfer
buffer for 30 min. The filter pads, gel, and PVDF membrane were arranged in a layered
fashion, and protein transfer was completed at 100 V for 45 minutes using a Mini TransBlot® Cell (BioRad Laboratories). Non-specific proteins were blocked with 5% non-fat dry
milk in TBS at room temperature on a shaker, followed by three washes of 5 minutes each in
TBS with 0.5% Tween (Sigma, St. Louis, MO) (TTBS) added. An overnight primary
antibody incubation at 4°C was performed with the following antibodies (insert anti-his and
hsp ab specs) at dilutions according to manufacturer’s instructions (Cell Signaling
Technology, Inc.). Following primary antibody incubation, a 15 min wash with TTBS was
performed to remove unbound antibody. Next, a secondary anti-rabbit IgG HRP-linked
antibody (Cell Signaling Technology®, Inc. #7074) was added for 1 hr at RT. Protein
detection was obtained through the use of the HR Peroxidase Visualization Kit (Vector
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Laboratories, Burlingame, California).

Cell Culture
MDA-MB-231, MCF-10A, and primary fibroblast cells were used for biological
assays. The MDA- MB-231 cells (ATCC HBT-26) are a metastatic breast cancer cell line
obtained from a 51-year old female patient, derived from a pleural effusion removed on
October 17, 1974. MDA-MB-231 cells were maintained in Dulbecco’s Modified Eagles’
Medium (DMEM) with 4.0 mM L-glutamine and 4500 mg/L glucose (HyClone, Logan,
Utah). The culture medium was supplemented with 10% bovine growth serum, penicillin G
(100 units/ml)/streptomycin sulfate (100 µg/ml) and sodium pyruvate (0.11 µg/ml). MCF10As (ATCC CRL-10317) are a non-tumorigenic human mammary epithelial cell line.
MCF10A cells were maintained in DMEM/ high glucose supplemented with 5% horse
serum, 20 ng/mL human epidermal growth factor (Sigma Chemical Co.), 0.05 mg/mL
hydrocortisone (Sigma Chemical Co.), 100 ng/mL of cholera toxin (Calbiochem), 10 µg/mL
of insulin (Sigma Chemical Co.), and penicillin G (100 units/ml)/streptomycin sulfate (100
µg/ml). The primary fibroblasts were obtained from swine mammary tissue in our laboratory;
details are below. All cell lines were grown in 75 cm2 tissue culture flasks (Corning inc.,
Corning, NY) and maintained at 37°C and 5% CO2. To prevent overcrowding of cells, they
were routinely passaged using Cell stripper (Corning, NY) or 1X Trypsin/EDTA (HyClone,
Logan, Utah), which removed the cells from the bottom of the flask. Before cells were
transferred into a new culture flask, they were washed at least one time with fresh culture
medium and centrifuged at 400 x g for 5 min at 23°C.
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Primary cell culture and fibroblast isolation:
After collection in the field, fresh biopsy tissue was immediately placed in a 1.5 mL
microcentrifuge tube containing warm primary cell culture medium. Culture medium for
mammary epithelial cells, per 100mL of medium, consisted of: 4ug/mL insulin (40ul from
10mg/mL stock), 10ng/mL EGF (5ul from 200ug/mL stock), 10% Fetal Bovine Serum
(10mL), 1% Penicillin-Streptomycin solution (Cellgro #30-002-CI) (1mL), and Hyclone
DMEM/high glucose media (Thermo #SH300222) to volume. In the lab, immediately before
digestion, collagenase solution was prepared which consisted of (per 10mL of solution): 5%
Fetal Bovine Serum (500ul), 1mg/mL Type 1 collagenase (EMD Millipore, 234153) (10mg),
and Hyclone DMEM/high glucose media (Thermo #SH300222) to volume. All media was
sterile filtered using vacuum filtration. Biopsy samples were minced using sterile supplies
into pieces smaller than 1mm3. Tissue pieces were transferred into a sterile dish and washed
until clear of blood with sterile PBS. Clean pieces were transferred into a small autoclaved
beaker with the collagenase type 1 solution and incubated at 37°C O/N with gentle shaking to
stir. Following O/N incubation, the tissue fragments were disrupted with a sterile 1mL pipette
and spun to pellet at 820 RPM and 23°C for 5 minutes. Liquid and fat were removed with a
sterile pipette and organoids pelleted at the bottom were resuspended in fresh media and
plated in T25 flasks with 10 mL culture media. After several days of incubation at 37°C and
5% CO2 for several days, the cells were adhered and ready for differential trypsinization.
To separate mammary epithelial cells from fibroblasts, differential trypsinization was
performed on adhered cells. Media was aspirated and flasks were gently washed with warm
culture media. 2-3 mL of trypsin was added and the flasks were incubated at 37°C and 5%
CO2 for 2-3 minutes or until fibroblasts began to lift off. Fresh media was added to
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deactivate the trypsin and this layer was removed and transferred to a new culture flask with
fresh media. After 2-3 days at 37°C and 5% CO2, the fibroblasts were ready for subculture.

Subculture: rG3 treatment and cell collection for RNA isolation
Once flasks were confluent, medium was aspirated and each flask was washed with
5-7 mL of warm, sterile PBS. For human cell lines, 3-4 mL of Cell Stripper was added to
each flask with incubation at 37°C with 5% CO2 for 5 min or until most cells are detached.
For primary mammary epithelial cells, trypsin was added to form a thin layer on top of the
cells with incubation at 37°C with 5% Co2 for 25-20 minutes or until the cells were detached.
The flask was tapped lightly on the counter to loosen cells and the cell suspension was
transferred into a 15 mL tube. For human cell lines, sterile PBS was added and for primary
mammary cells, sterile media was added to get to 10-12 mL in the tube. Tubes were
centrifuged at 820 RPM for 5 min at 23°C. Supernatant was discarded and pellets were
washed again with either sterile PBS or media, vortexing to mix. Tubes were centrifuged a
second time at 820 RPM for 5 min at 23°C and pellet resuspended in 1mL fresh culture
medium. Cells were counted by adding 180µl trypan blue to 20 µl cells in media and loading
20µl of mix onto a hemacytometer. Cells were plated at 1x106 cells per well in a 6-well plate
in 1mL fresh media and let adhere overnight at 37°C and 5% CO2. After overnight adhesion,
all wells were treated with either 20µg/mL rG3 diluted in fresh media or equal amounts
media for controls. Cells were then collected immediately after addition of rG3 for time 0
followed by 3, 6, 9, 12, and 24 hours after treatment. To collect cells from well, culture
medium was removed from the well of interest and well was gently washed with sterile PBS.
400ul cell stripper (for human lines) or trypsin (for primary lines) was added to well and
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plates incubated at 37°C and 5% CO2 for 10 minutes. Cells were added to a sterile 1.5 mL
microcentrifuge tube along with 500ul PBS, spun at 12,000 rpm for 2 minutes at room
temperature. Supernatant was removed and wash repeated with 500ul PBS and another 2minute spin at 12,000 rpm. Pellet was resuspended in 100ul RNA later and stored at -20° C
for RNA isolation.

Subculture: Cell collection for Western Blotting
Once flasks were confluent, medium was aspirated and each flask was washed with
5-7 mL of warm, sterile PBS. For human cell lines, 3-4 mL of Cell Stripper was added to
each flask with incubation at 37°C with 5% CO2 for 5 min or until most cells are detached.
For primary mammary epithelial cells, trypsin was added to form a thin layer on top of the
cells with incubation at 37C with 5% Co2 for 25-20 minutes or until the cells were detached.
The flask was tapped lightly on the counter to loosen cells and the cell suspension was
transferred into a 15 mL tube. For human cell lines, sterile PBS was added and for primary
mammary cells, sterile media was added to get to 10-12 mL in the tube. Tubes were
centrifuged at 820 RPM for 5 min at 23°C. Supernatant was discarded and pellets were
washed again with either sterile PBS or media, vortexing to mix. Tubes were centrifuged a
second time at 820 RPM for 5 min at 23°C and pellet resuspended in 1mL fresh culture
medium. Cells were counted by adding 180µl trypan blue to 20 µl cells in media and loading
20µl of mix onto a hemacytometer. Cells were plated at 1x106 cells per well in a 6-well plate
in 1mL fresh media and let adhere overnight at 37°C and 5% CO2. After overnight adhesion,
all wells were treated with either 20µg/mL rG3 diluted in fresh media or equal amounts
media for controls. Cells were then collected immediately after addition of rG3 for time 0
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followed by 3, 6, 9, 12, and 24 hours after treatment. Before each collection, fresh lysis
buffer was prepared using 100 µl of cold 10X lysis buffer (Cell Signaling #9803), 890 µl
sterile water, and 10 µl of protease inhibitor cocktail (Thermo Scientific #78410) and kept on
ice. To collect cells from well, culture medium was removed from the well of interest and
well was gently washed with cold sterile PBS. 100 µl of lysis buffer was added directly on
the well and plates were incubated on ice for 5 minutes. After incubation, wells were scraped
and cell suspension collected in a 1.5 mL microcentrifuge tube. Tubes were spun at 12,000
rpm at 4°C for 15 min after which supernatant was transferred to a fresh tube and stored at 20° C until Western Blotting.

RNA isolation for cells
RNA sequencing will be performed with RNA isolated from the cells using an
RNeasy Kit (Qiagen Inc., Valencia, CA) according to manufacturer’s instructions. The RNA
samples will be treated with an on-column DNase (Qiagen Inc., Valencia, CA) to remove any
possible genomic DNA contamination. Isolated RNA samples will be quantified and integrity
validated on a Nano Drop 1000 Spectrophotometer (Thermo Scientific, Waltham, MA) and
Bioanalyzer 2100 (Agilent Technologies).

RNA seq of cells
Quality control checks, library preparation, and sequencing of RNA collected from
cells was performed by Vanderbilt University Medical Center. Total RNA quality was
assessed using the 2100 Bioanalyzer (Agilent). At least 200ng of DNase-treated total RNA
with a RNA integrity number greater than 6 was used to generate polyA (mRNA) enriched
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libraries using TruSeq Stranded mRNA sample kits with indexed adaptors (Illumina). Library
quality was assessed using the 2100 Bioanalyzer (Agilent) and libraries were quantitated
using KAPA Library Quantification Kits (KAPA Biosystems). Pooled libraries were
subjected to 75 bp paired-end sequencing according to the manufacturer’s protocol (Illumina
HiSeq3000). Bcl2fastq2 Conversion Software (Illumina) was used to generate de-multiplexed
Fastq files.

RNA-seq data analysis
To analyze differential gene expression using RNA-sequencing data, three unique
and independent methods were utilized: shift change with normalization by control, shift
change with normalization by treatment, and statistically significant differences between
treated samples and untreated samples assuming normal data distribution and calculating zscores for each individual gene. Formulas for shift change are below. For shift change with
normalization by control, ((Raw count of treated sample – raw count of control sample) /
(raw count of control sample)) was used. For shift change with normalization by treated
sample, ((Raw count of treated sample – raw count of control sample) / (raw count of treated
sample)) was used.
RNA seq shift change values between rG3 treated and untreated MDA-MB-231 cells
were used to curate pathways using PathVisio and WikiPathways 435–438; raw counts for rG3
treated and untreated MDA-MB-231 cells and primary swine fibroblasts were normalized
and prepared into heat maps in Genesis 428. Blue represents downregulation (negative shift
change) or low expression, as noted in figure legends. Red represents upregulation (positive
shift change) or high expression, as noted in figure legends. In PathVisio, gray indicates no
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shift change; in Genesis heat maps, gray indicates gene or gene ortholog not found in dataset.
For comparison of human and swine genes, swine gene orthologs were included if possible
using OrthoDB 439.

Western blotting for cells
In preparation for protein separation by SDS-PAGE, cell lysate samples were added
to an equal volume of Laemmli Buffer with 5% 2-mercaptoethanol. Samples were mixed and
loaded onto a 10-20% Ready Gel Precast Gel (Bio-Rad Laboratories, Inc., Hercules, CA)
together with a protein ladder (Precision Plus Protein™ Kaleidoscope™ Prestained Protein
Standards #1610375). The gel was run in the Ready Gel System (Bio-Rad Laboratories, Inc.,
Hercules, CA) with running buffer (15g Tris Base, 72g glycine, 5g SDS per 1L) at 200 V for
30 minutes. Meanwhile, a sheet of Immuno-Blot™ LF-PVDF Membrane and two pieces of
14 x 11 cm filter pads (Bio-Rad Laboratories) were soaked in chilled Western transfer buffer
(3.03g Tris Base, 14.4g glycine per 1L) for least 30 minutes. Following electrophoresis, the
gel was washed in cold Western transfer buffer for 30 min. The filter pads, gel, and PVDF
membrane were arranged in a layered fashion, and protein transfer was completed at 100 V
for 45 minutes using a Mini Trans-Blot® Cell (BioRad Laboratories). Non-specific proteins
were blocked with 5% non-fat dry milk in TBS at room temperature on a shaker, followed by
three washes of 5 minutes each in TBS with 0.5% Tween (Sigma, St. Louis, MO) (TTBS)
added. An overnight primary antibody incubation at 4C was performed with p53 (Cell
Signaling Technology, Inc.), beta4 integrin (Abcam, Cambridge, MA, Cambridge, MA), and
beta actin (Cell Signaling Technology, Inc.) at dilutions according to manufacturer’s
instructions (Cell Signaling Technology, Inc.). Following primary antibody incubation, a 15
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min wash with TTBS was performed to remove unbound antibody. Next, a secondary antirabbit IgG HRP-linked antibody (Cell Signaling Technology®, Inc. #7074) was added for 1
hr at RT. Protein detection was obtained through the use of the Pierce ECL Plus
Chemifluorescent kit (Thermo Fischer), visualized on the Typhoon FLA 7000 (GE
HealthSciences), and quantified using Image Studio Lite (Licor).

Viability Assay
To assay for cellular activity (viability), replicate MTT (3-[4,5-Dimethylthiozol –2yl] –2, 5-diphemyltetrazolium bromide) assays were performed with purified rG3 and
appropriate controls. Different dilutions of rG3 were made in fresh culture medium. One
hundred µl of each concentration was added in triplicate to wells of a treated Falcon 96-well
tissue culture plate (Falcon, Franklin Lakes, NJ). All cell lines were collected following the
same method described previously. Cells were plated at 1 x 104 per well (in 100 µl), and the
plate was incubated for 24 hr at 37°C in a humidified incubator (5% CO2). Cells were either
treated immediately with rG3, or allowed to adhere for 6-18 hr before treatment. Four hr
prior to the end of incubation, 20 µl of MTT (Sigma-Aldrich Co., St. Louis) was added to all
wells. At the end of the 24 hr incubation, the culture supernatant was removed from the
wells and 150 µl of dimethylsulfoxide (DMSO) were added to solubilize cells. The plate was
shaken for 15 min and absorbance values for MTT were recorded using a BioTek plate reader
at dual wavelengths of 570/640 nm. Optical Density (OD) values of dissolved MTT were
used to create a stimulation index (SI), which was calculated using the ratio of treatment OD
÷ control OD.
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Statistical Analysis
Statistical models were developed to relate responses (including stimulation index,
differential gene expression, and protein expression) to experimental factors (including rG3
dosage, treatment, and cell type). Analysis of Variance (ANOVA) was used to test
significance of the experimental factors on responses. When ANOVA indicated the responses
were significantly affected by the experimental factors, Tukey HSD and Student’s t tests
were used accordingly. All statistical tests used α = 0.05 and were performed using the
Statistical Analysis System (SAS, Research Triangle Park, NC) and/or JMP Pro 12 software
(SAS, Cary, NC).

CHAPTER FOUR: RESULTS AND DISCUSSION
Chapter 1 results and discussion
Mammary tissue sampling procedure causes minimal adverse effects
Growth curves for animals sampled are shown in Fig. 2. Numerical representation for each
sample indicates the litter and animal, respectively. For example, a numerical representation
such as “1-10” would indicate the tenth animal of the first litter with the assigned number
having no significance except as a system to ensure consistency and monitor the animals.
Weights were taken before each sampling period weekly, and animals maintained a similar
growth curve throughout sampling, gaining a similar amount of weight throughout the study.
Several studies have implicated adverse effects of repeated sampling of the mammary
gland 440,441, especially when bluntly dissecting the tissue requiring wound closure 441. It is
necessary to utilize a sampling technique that is minimally invasive, yet still tissue specific.
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The results presented in this figure demonstrate that the animals gained a similar and healthy
amount of weight over the course of sampling, and along with histological results below that
show tissue specificity, indicate minimal or no effects of the sampling procedure causing
adverse effects to health.

Swine growth rates during sampling
20
18
16

Weight (lbs)

14
1-10

12

1-13

10

1-8

8

5-10

6

5-5
5-7

4
2
0
0

5

10

15

20

25

30

Age (DAYS)

Figure 2. Swine growth rates during sampling demonstrate that the animals gained a
similar and healthy amount of weight over the course of sampling. “1-10” indicates
litter 1, animal 10. Animals were weighed before each tissue biopsy collection.
Sequential H&E in swine mammary tissue collected over time proves ability of method to
study time course of development
Figure 3 represents samples taken from the same pig at 4 days, 8 days, 11 days, 18
days and 32 days, respectively. Samples are formalin fixed, paraffin embedded, and H&E
stained to show histological differences in mammary tissue morphology over time. These
samples demonstrate normal differentiation of mammary tissue 442,443 over time with no noted
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biasing or alteration of the tissue differentiation due to repeated sampling compared to the
first sampling taken. This indicates the fine needle biopsy method is adequate to sequentially
monitor mammary growth in a single animal at the cellular level without detriment to the
animal or alteration of the morphology or differentiation.

Figure 3: Formalin fixed, paraffin embedded, H&E stained sections of swine mammary tissue at
a) 4 days, b) 8 days, c) 11 days, d) 18 days, e) 25 days, and f) 32 days of age demonstrating
histological differences in mammary tissue morphology over time. These samples show normal
differentiation of mammary tissue with no noted biasing or alteration of the tissue differentiation
due to repeated sampling compared to the first sampling taken.

Necropsy and fine needle biopsy comparison utilizing novel development index confirms
biopsy method is histologically representative of larger core sampling
The development maturity index can be seen in Fig 1. As illustrated, tissue areas with
a developmental index of 0 are a cluster of cells without lumen and 1 ring layer, areas with a
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developmental index of 1 present as a cluster of cells without lumen and more than 1 ring
layer of cells, areas with a developmental index of 2 present as loosely organized cells with
lumen, areas with a developmental index of 3 present as semi-organized cells with lumen,
areas with a developmental index of 4 present as dense and organized cells with lumen, and
areas with a developmental index of 5 present as dense and organized cells with lumen and
branching. This developmental index was used to score mammary tissue sections obtained by
both live fine needle biopsy and tissue necropsy post-euthanasia. A contingency analysis was
conducted for pigs 19-12 and 20-7, at the age of 4 weeks to confirm that the mammary
biopsy procedure produces a tissue sample that is representative of, and no different than, the
results obtained by necropsy. After tissue sections collected by both techniques were
assigned a numerical developmental index, a contingency analysis was performed. For pig
19-12, a p ³ 0.3267 indicates that any differences in the samples are likely due to chance and
therefore the null hypothesis is correct and there is no statistical difference in the responses
for the two methods. For pig 20-7, a p ³ of 0.4835 also confirms tissue sections obtained via
the fine needle biopsy technique are statistically equivalent to the tissue sections obtained by
necropsy. Once confirmed that the sampling method is appropriate, data obtained could be
confidently interpreted through RNA sequencing and H&E.
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Weighted scores over time can quantify histological trends in mammary tissue collected over
time
In an effort to quantify mammary development using histology, several weighted scoring
methods were evaluated. These took into account the developmental index score of each
tissue area as well as the total count of tissue areas and percent of tissue compared to stroma,
connective, and adipose tissue.

Figure 4: Weighted scores calculated for Pig IDs 1-10 and 1-8 over time. Weighted
Score 1: (:Index 0 * 0 + :Index 1 * 1 + :Index 2 * 2 + :Index 3 * 3 + :Index 4 * 4 +
:Index 5*5) / (:Index 0 + :Index 1 + :Index 2 + :Index 3 + :Index 4 + :Index 5). New
Weighted Score: Weighted Score * (1 + Total Count for week/total count for
sampling period). A split is seen at 18 DOA that can be used for discriminate analysis
using Weighted Score 1 and Weighted Score 2. Weighted Score 3 attempted to take
into account the percentage of mammary tissue in comparison to adipose and stroma,
but did not represent the histological results as well as the first two methods.
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Formulas used were:
1. Weighted Score: (:Index 0 * 0 + :Index 1 * 1 + :Index 2 * 2 + :Index 3 * 3 + :Index 4
* 4 + :Index 5
•

5) / (:Index 0 + :Index 1 + :Index 2 + :Index 3 + :Index 4 + :Index 5)

2. New Weighted Score: Weighted Score * (1 + Total Count for week/total count for
sampling period)

It proved difficult to quantify consistently over time, but a split is seen at 18 DOA in Fig.
4 that can be used for discriminate analysis using Weighted Score 1 and Weighted Score 2.
Weighted Score 3 attempted to take into account the percentage of mammary tissue in
comparison to adipose and stroma, but did not represent the histological results as well as the
first two methods.

Mammary biopsy technique produces tissue samples with high quality and quantity for
downstream RNA isolation and sequencing
Table 2 shows quantity, quality, and integrity values of RNA isolated from swine
mammary tissue collected via the fine needle biopsy technique.

Table 2: Quality Control for swine mammary tissue samples submitted for RNA sequencing
Sample
labels

Tissue source

1
2

Swine mammary
Swine mammary

Phenotype
Other
Quality
(age in
descriptor- (260/280)
days)
Pig ID
4.0
8.0

1-8
1-10

58

2.11
2.15

Total
mass of
RNA
(ug)
5.04
1.47

RNA
integrity
number
(RIN)
10
10

3

Swine mammary

11.0

1-13

2.12

1.34

10

4
5
6
7
8
9
10
11
12
13
14
15
16
17

Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary
Swine mammary

11.0
11.0
18.0
18.0
18.0
25.0
25.0
25.0
32.0
32.0
32.0
39.0
39.0
39.0

1-10
1-8
1-8
1-13
1-10
1-13
1-10
1-8
1-13
1-8
1-10
1-13
1-8
1-10

2.16
2.15
2.13
2.13
2.18
2.17
2.29
2.13
2.14
2.13
2.14
2.27
2.40
2.17

2.41
2.98
2.10
1.57
0.56
1.22
0.81
2.97
1.85
2.97
1.85
0.26
1.16
0.95

10
9
9.7
9.8
10
9.9
10
8.8
NA
9.1
9.5
10
10
9.9

These high quality and quantity values indicate the fine needle biopsy sampling,
method and intermediate processing procedures are adequate to generate a tissue sample
enabling accurate library preparation, RNA sequencing, and data analysis. RNA integrity and
quality is vital to reproducible RNA sequencing results, and contaminated or degraded
mRNA can have a detrimental effect on downstream analysis444–447. RIN is calculated using a
software algorithm developed by Schroeder et al; values range from 1-10 with 10 possessing
the least amount of RNA degradation and being ideal for transcriptome analysis 448. There
was an issue with sample quantity for sample 12, so an RIN could not be established, but
based on the NanoDrop values for quality and quantity, it was safe to proceed with library
preparation for all samples. Once it was confirmed through the above results that the fine
needle biopsy was an appropriate method of sampling, data could be confidently interpreted
from RNA sequencing output.
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PCA presents large patterns of variability within the gene expression data contributing to
specific ordination trends

Figure 5: PCA plot for PC2 vs PC3 of developing swine mammary
gland transcriptome. Dot color corresponds to Pig ID; size of dot
corresponds to age (days). PCA presents large patterns of variability
within gene expression data contributing to specific ordination
trends.
PCA is an exploratory technique used at the beginning of study to confirm whether
there are any trends in data. The color of the dots in Fig. 5 corresponds to pig ID, and size of
the dot represents the time at which the biopsy sample was collected (age; 4 days smallest –
39 days largest). As shown in the figure, the younger samples are on the top left corner and as
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one moves away toward the right, the sample dot sizes become larger indicating older pigs
were sampled.
PCA is commonly used as a simple visualization tool to summarize data variance and
present the dominant factors contributing to variance in a large data set 174,449,450. When
dealing with multiple variables, as are present in large scale gene expression and
transcriptomics studies such as the present, relationships between variables (here, gene
expression and age) can be quickly assessed. PCA assumes that the data set contains linear
combinations of variables and that large variances have important dynamics, such as
contribution to a trend over time; this exploratory technique is appropriate for the large
transcriptomic data set 450,451. The first PC axis, PC1, of the PCA output represents the largest
gradient of variability in the data set 174 with the PC2 axis containing the second largest,
followed by PC3 until all of the data set variability has been accounted for. Here, variables
were displayed in the first three PC dimensions and PC2 and PC3 were found to contain the
most important gradients. Fig. 5 shows significant variability due to age of the animal across
the PC2 axis and little organization by animal (Pig ID) across the PC3 axis. This suggests
animal age is the dominant gradient in the data set that effects the data distribution. It also
suggests there is a functional pattern within the variability of the RNA-sequencing data that
corresponds to time of sample collection. This supports the hypothesis that there are unique
signaling events occurring over time; PCA confirms the transcriptomic data set allows for
evaluation of mammary development throughout time without interference from variability
between animals used.
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RDA confirms that variability in pigs does exist, but does not contaminate variability over
time (age)
The color of the dots in Fig. 6 corresponds to pig ID, and size of the dot represents
the time at which the biopsy sample was collected (age; 4 days smallest – 39 days largest).

Figure 6: RDA of swine mammary transcriptome. Color of dots
corresponds to Pig ID; size of dot corresponds to pig age (size
increases with age). RDA shows orthogonal variabilities in the two
axes (canonical axis 1 representing Pig ID and canonical axis 2
representing time/age) indicating that the variabilities are
independent and very low redundancy is present in the data set.
Redundancy analysis (RDA) is a constrained ordination technique that analyzes how much
variation in one set of variables (i.e. pig ID) explains variation in a second set of variables
(i.e. time/age). 174,452–455. In multivariate statistics, RDA is the equivalent of linear regression;
it assumes a linear dependence between the response variables on the explanatory variables
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and is appropriate for use with the transcriptomic data set. RDA is widely used in community
ecology and has been reviewed in depth by Paliy et al 174; it is not currently used to assess
trends in mammary development. For the transcriptomic data set collected from different
pigs over a period of time, RDA shows orthogonal variabilities in the two axes (canonical
axis 1 representing Pig ID and canonical axis 2 representing time/age) indicating that the
variabilities are independent and very low redundancy is present in the data set. Therefore,
trends in gene expression can be attributed mainly to age with little contamination from
variability in Pig ID, providing higher confidence in the dataset.

CLA confirms trends are present in the transcriptomic data set correlating to time
The panels in Fig. 7 show k-means clustering for genes present in the RNA
sequencing data set. Two panels are for downward trend (downregulated expression over
time; clusters 19 and 13), one panel for upward trend (upregulated expression over time;
cluster 16), and two panels are shown that have a periodic or sinusoidal trend and one with no
trend or change across time (clusters 2 and 10). The objective of a cluster analysis (CLA) is
to separate variables into groups based on the similarity of their scores, generating functional
clusters; the variables contained in each cluster are more similar to each other than variables
in other groups (minimizing within-group distances and maximizing between-group
distances) 174. Like PCA, DCA, CCA, and RDA, CLA is an exploratory technique to confirm
trends in a data set and is becoming a popular choice for use in high-throughput microarray
gene expression data, suggesting that it also could be a valuable tool in transcriptomic data
sets from RNA-seq. CLA assumes data independence; the RDA results in Fig. 6 suggest CLA
is appropriate for use. K-means clustering was utilized in Genesis 428 to group all variables
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defined by RNA-seq counts into 20 individual clusters (k=20) based on the different
variability patterns over time in the dataset.

Figure 7: K-means cluster analysis in Genesis. Two panels are for downward trend
(downregulated expression over time; clusters 19 and 13), one panel for upward trend
(upregulated expression over time; cluster 16), and two panels are shown that have a
periodic or sinusoidal trend and one with no trend or change across time (clusters 2 and
10).
In the literature, K-means clustering has been used to: define groups of genera that
are modified by the faecal microbiota transplantation (FMT) in patients with Clostridium
difficile-associated disease 179, reveal molecular cascades underlying adult neurogenesis 456,
dissect the multicellular ecosystem of metastatic melanoma 457, identify novel gene
expression signatures of heart failure 458, tie macrophage polarization to growth rates of
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intracellular bacteria 459, and reveal cell type-specific transcriptional signatures at the
maternal-fetal interface 460. However, most of these studies use single-cell RNA-seq, and kmeans clustering not yet been used to analyze developmental gene expression data in the
mammary gland. K-means clustering of the RNA-seq data set created clusters of genes
containing distinct patterns over time, which can be further dissected into biologically
significant functions and pathways.
Clusters containing genes with distinct patterns over time are dispersed into various
functional biological categories. Reactome pathway analysis is shown in Table 3 for clusters
with downward trend (downregulated expression over time; clusters 19 and 13), upward
trend (upregulated expression over time; cluster 16), and periodic or sinusoidal trend and one
with no trend or change across time (clusters 2 and 10). K-means clustering of our RNA-seq
data set in Genesis generated twenty clusters of genes containing distinct patterns over time,
which were then further analyzed for functional significance and pathways using Reactome.
All clusters revealed signaling pathways expected to be present in early mammary
development, including immune system, metabolism, signal transduction, cell cycle
regulation, gene transcription, and protein translation, as shown in Table 3. Interestingly,
gene expression contributing to the upward trend in cluster 16 utilized signal transduction
pathways in conjunction with those of the immune system, innate immune system, cytokine
signaling, interleukin signaling, and the adaptive immune system. Clusters 13 and 19,
displaying downward trends over time, contained genes that utilized mainly metabolic, gene
expression, transcription and translation, and cell cycle pathways. Clusters 2 and 10,
displaying periodic trends over time, contained genes that utilized a mix of pathways.
Clusters containing distinct patterns of gene expression over time indicate that the
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transcriptomic data can be partitioned based on specific developmental trends present, many
of which contain immune system components, which will be further elucidated with more
advanced methods.

Table 3: CLA indicates genes cluster into functional groups with similar trends over time
Pathway
Rank
1
2
3
4

Cluster 2
(periodic)
Metabolism of
proteins
Metabolism
Signal
Transduction
Cell Cycle,
Mitotic

Cluster 10
(periodic)
Metabolism

Cluster 13
(downward)
Metabolism

Cluster 16
(upward)
Signal
Transduction
Immune
System
Metabolism

Signal
Transduction
Immune
System
Metabolism of
proteins

Signal
Transduction
Cell Cycle
Gene
expression
(Transcription)

Innate Immune
System
Cytokine
Signaling in
Immune
system
Developmental
Biology

Cluster 19
(downward)
Metabolism
Metabolism of
proteins
Immune
System
Posttranslational
protein
modification
Metabolism of
lipids

5

Cell Cycle

Innate Immune
System

Metabolism of
proteins

6

Posttranslational
protein
modification
Cellular
responses to
external
stimuli
Metabolism of
RNA

Posttranslational
protein
modification
Generic
Transcription
Pathway

RNA
Polymerase II
Transcription
Cell Cycle,
Mitotic

Signaling by
Interleukins

Disease

RNA
Polymerase II
Transcription
Gene
expression
(Transcription)
Adaptive
Immune
System
Cytokine
Signaling in
Immune
system
Developmental
Biology

Generic
Transcription
Pathway
Immune
System

Axon guidance

Signalling by
NGF

Gene
expression
(Transcription)
RNA
Polymerase II
Transcription
Organelle
biogenesis and
maintenance
Cell Cycle,
Mitotic

Hemostasis

Cell Cycle

7

8
9
10
11

12

Gene
expression
(Transcription)
Cellular
responses to
stress
Immune
System
Mitochondrial
translation
initiation

Transcriptional
Regulation by
TP53
Cell Cycle
Checkpoints
Metabolism of
RNA
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Adaptive
Immune
System
Metabolism of
proteins

Metabolism of
RNA

13

Mitochondrial
translation
elongation
Mitochondrial
translation
termination

Transport of
small
molecules
Metabolism of
lipids

15

Mitochondrial
translation

Signaling by
Interleukins

16

Respiratory
electron
transport, ATP
synthesis by
chemiosmotic
coupling, and
heat
production by
uncoupling
proteins.
The citric acid
(TCA) cycle
and respiratory
electron
transport
Translation

14

17

18
19

Developmental
Biology

20

Generic
Transcription
Pathway

Metabolism of
lipids

Signaling by
GPCR

HIV Infection

Posttranslational
protein
modification
M Phase

Gene
expression
(Transcription)

Infectious
disease

Membrane
Trafficking

Adherens
junctions
interactions

RHO GTPase
Effectors

Vesiclemediated
transport

Transcriptional
Regulation by
TP53
Cytokine
Signaling in
Immune
system

Collagen
degradation

Signaling by
Rho GTPases

Signaling by
Rho GTPases

Generic
Transcription
Pathway

Cell-cell
junction
organization
Respiratory
electron
transport, ATP
synthesis by
chemiosmotic
coupling, and
heat
production by
uncoupling
proteins.
Degradation of
the
extracellular
matrix

DNA Repair

Signal
Transduction

Cellular
responses to
stress

Generic
Transcription
Pathway
RNA
Polymerase II
Transcription

Cellular
responses to
external
stimuli

Fc epsilon
receptor
(FCERI)
signaling

Translation
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HIV Life
Cycle

Discriminant function analysis of mammary development over time indicates temporal
regulation during 4-18 days (phase one) vs. 25-39 (phase two)
Based on histological trends seen in Fig. 4, the RNA-seq dataset was partitioned into
two groups representing early postnatal prepubertal (4 days after birth through 18 days after
birth, hereafter referred to as phase one) and late postnatal prepubertal development (25 days
after birth through 39 days after birth, hereafter referred to as phase two). Discriminant
function analysis using three different widely accepted methods showed significant biological
differences in the two groups, summarized in Table 4.
The objective of discriminant function analysis (DFA) is to find linear combinations
of observed variables that maximize the grouping of objects into separate classes; DFA
assumes multivariate normal distribution and homogeneity of variance and covariance 461.
Here, three DFA methods were used to isolate two significantly different groups of
transcriptomic variables based on a split in time. Early development and late development
were chosen and defined as 4-18 days and 25-39 days, respectively (19-24 days fell in
between two sampling weeks). In DFA, the numeric weights (discriminant coefficients) can
be used to define the relative importance of each predictor variable 174 (in our case, gene) to
the observed discrimination between two classes of objects (early phase one vs. late phase
two). DFA is appropriate for extremely large data sets and has been successfully employed
to: predict clinical outcomes from microarray data 462, study reprogramming of cancer
metabolism 463, identify lipodomic biomarkers for NAFLD 464, compare hepatocellular
carcinoma miRNA expression profiles 465, discriminate gene expression profiles of plants to
melatonin 466, and assess sex differences in the human skeletal muscle transcriptome 467.
However, this method has not been used to study early mammary gland development.
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Therefore, three individual DFA methods were utilized to characterize the two phases seen
initially in histological analysis: partial least-squares (PLS), support vector machine (SVM),
and random forest (RF). PLS assumes linear relationships within the data while SVM and RF
can be used with any distribution; the basis of these DFA techniques has been reviewed in
depth by Paliy et al 174. Here, all three methods were utilized to find the most significant
differences in gene expression during early and late phases of postnatal/pre-pubertal
development.

Table 4: Common genes identified in mammary transcriptome using three DFA methods
GENE ID
COL8A1
DTX3L
MAP3K14
SLC29A4
TBC1D8
ANP32A
ARHGAP9
ARL16
ATP8
BHLHE40
CDYL2
DENND5B
GPAT3
GRB10
HSPA4L
IF2
ITIH4
KCND2
MAP3K8
NT5DC1
PAX8
PCGF1
PCGF5
PRUNE2
RAP1GAP2
RBP5

SVM
SVM
SVM
SVM
SVM
SVM
PLS
SVM
SVM
SVM
SVM
SVM
SVM

PLS
PLS
PLS
PLS
PLS
PLS
PLS
PLS
PLS

SVM
SVM
SVM
SVM
SVM
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RF
RF
RF

PLS
PLS
PLS
PLS
PLS

SVM
SVM

RF
RF
RF
RF
RF
RF
RF

PLS
PLS
PLS
PLS
PLS
PLS

RF
RF
RF
RF
RF
RF

RF
PLS
PLS

RF

RHOBTB2
RNF217
SLC47A2
THPO
VAMP5

SVM
SVM
SVM
SVM
SVM

PLS
PLS
PLS
PLS
RF

Table 5: Reactome pathway characterization of genes identified using DFA
GENE ID

SVM

PLS

RF

Reactome Pathway

COL8A1

SVM

PLS

RF

DTX3L

SVM

PLS

RF

MAP3K14

SVM

PLS

RF

SLC29A4

SVM

PLS

RF

Assembly of collagen fibrils and other
multimeric structures
Collagen biosynthesis and modifying
enzymes
Collagen formation
Extracellular matrix organization
Adaptive Immune System
Antigen processing- Ubiquitination and
Proteasome degradation
Class I MHC mediated antigen processing
and presentation
Immune System
Adaptive Immune System
CD28 co-stimulation
CD28 dependent PI3K/Akt signaling
CLEC7A (Dectin-1) signaling
Costimulation by the CD28 family
C-type lectin receptors (CLRs)
Cytokine Signaling in Immune system
Dectin-1 mediated noncanonical NF-κB
signaling
Immune System
Innate Immune System
NIK-->noncanonical NF-κB signaling
TNF receptor superfamily (TNFSF) members
mediating non-canonical NF-κB pathway
TNFR2 non-canonical NF-κB pathway
SLC-mediated transmembrane transport
Transmembrane transport of small molecules
Transport of nucleosides and free purine and
pyrimidine bases across the plasma
membrane
Transport of vitamins, nucleosides, and
related molecules
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TBC1D8

SVM

ANP32A

PLS

ARHGAP9

SVM

ARL16

SVM

ATP8

SVM

CDYL2

SVM

DENND5B

SVM

GPAT3

Unknown

RF

Gene Expression
HuR (ELAVL1) binds and stabilizes mRNA
Regulation of mRNA stability by proteins
that bind AU-rich elements
Immune System
Innate Immune System
Rho GTPase cycle
Signal Transduction
Signaling by Rho GTPases

RF

RF

PLS

Formation of ATP by chemiosmotic coupling
Metabolism
Respiratory electron transport, ATP synthesis
by chemiosmotic coupling, and heat
production by uncoupling proteins.
The citric acid (TCA) cycle and respiratory
electron transport
BMAL1-CLOCK,NPAS2 activates circadian
gene expression
Circadian Clock

RF

PLS

PLS

SVM

RF

PLS

PLS

BHLHE40

GRB10

PLS

PLS

Membrane Trafficking
Vesicle-mediated transport
RF

Fatty acid, triacylglycerol, and ketone body
metabolism
Glycerophospholipid biosynthesis
Metabolism
Metabolism of lipids and lipoproteins
Phospholipid metabolism
Synthesis of PA
Triglyceride Biosynthesis
Axon guidance
Developmental Biology
Insulin receptor signaling cascade
IRS activation
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HSPA4L

PLS

RF

IF2

PLS

RF

ITIH4

SVM

KCND2

MAP3K8

RF

PLS

SVM

PLS

RF

RET signaling
Signal attenuation
Signal Transduction
Signaling by Insulin receptor
Signaling by SCF-KIT
Cellular response to heat stress
Cellular responses to stress
Regulation of HSF1-mediated heat shock
response
Cap-dependent Translation Initiation
Eukaryotic Translation Initiation
Gene Expression
GTP hydrolysis and joining of the 60S
ribosomal subunit
Metabolism of proteins
Translation
Hemostasis
Platelet activation, signaling and aggregation
Platelet degranulation
Response to elevated platelet cytosolic Ca2+
Cardiac conduction
Muscle contraction
Neuronal System
Phase 1 - inactivation of fast Na+ channels
Potassium Channels
Voltage gated Potassium channels
Activated TLR4 signaling
Adaptive Immune System
CD28 co-stimulation
CD28 dependent PI3K/Akt signaling
Costimulation by the CD28 family
Cytokine Signaling in Immune system
Immune System
Innate Immune System
Interleukin-1 signaling
MAP kinase activation in TLR cascade
MAP3K8 (TPL2)-dependent MAPK1/3
activation
MyD88 cascade initiated on plasma
membrane
MyD88 dependent cascade initiated on
endosome
MyD88-independent TLR3/TLR4 cascade
MyD88-Mal cascade initiated on plasma
membrane
Signaling by Interleukins
Toll Like Receptor 10 (TLR10) Cascade
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Toll Like Receptor 2 (TLR2) Cascade
Toll Like Receptor 3 (TLR3) Cascade
Toll Like Receptor 4 (TLR4) Cascade
Toll Like Receptor 5 (TLR5) Cascade
Toll Like Receptor 7/8 (TLR7/8) Cascade
Toll Like Receptor 9 (TLR9) Cascade
Toll Like Receptor TLR1-TLR2 Cascade
Toll Like Receptor TLR6-TLR2 Cascade
Toll-Like Receptors Cascades
TRAF6 mediated induction of NFkB and
MAP kinases upon TLR7/8 or 9 activation
NT5DC1

PLS

RF

PAX8

SVM

PLS

PCGF1

SVM

PLS

Developmental biology

PCGF5

SVM

PLS

Developmental biology

PRUNE2

SVM

RAP1GAP2

SVM

RBP5

RF

PLS

PLS

Immune System;Rap1 signaling; Adaptive
Immune System
RF

RHOBTB2

SVM

PLS

Signal Transduction; Signaling by Rho
GTPases;Rho GTPase cycle

RNF217

SVM

PLS

Adaptive Immune System
Antigen processing- Ubiquitination and
Proteasome degradation
Class I MHC mediated antigen processing
and presentation
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Immune System

SLC47A2

SVM

PLS

THPO

SVM

PLS

VAMP5

SVM

SLC-mediated transmembrane transport
Transmembrane transport of small molecules
Transport of glucose and other sugars, bile
salts and organic acids, metal ions and amine
compounds
Hemostasis; Platelet activation, signaling and
aggregation; Platelet Aggregation (Plug
Formation)
RF
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Figure 8: DFA of mammary development over time indicates temporal regulation
during 4-18 days of age vs 25-39 days of age: heatmap visualization performed in
Genesis of top discriminant genes. Genes in bold were identified using all three
DFA methods; others were identified using two out the three methods.
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Table 6: Gene name reference for genes identified during DFA
GENE ID

SVM PLS

RF

Gene Name, Gene Symbol, Ortholog

COL8A1

SVM

PLS

RF

Collagen α-1(VIII) chain;COL8A1;ortholog

DTX3L

SVM

PLS

RF

E3 ubiquitin-protein ligase DTX3L;DTX3L;ortholog

MAP3K14

SVM

PLS

RF

SLC29A4

SVM

PLS

RF

Mitogen-activated protein kinase kinase kinase
14;MAP3K14;ortholog
Equilibrative nucleoside transporter 4;SLC29A4;ortholog

TBC1D8

SVM

PLS

RF

TBC1 domain family member 8;TBC1D8;ortholog

ANP32A

PLS

RF

ARHGAP9

SVM

Acidic leucine-rich nuclear phosphoprotein 32 family
member A;ANP32A;ortholog
Rho GTPase-activating protein 9;ARHGAP9;ortholog

ARL16

SVM

RF

ADP-ribosylation factor-like protein 16;ARL16;ortholog

RF

ATP synthase protein 8;MT-ATP8;ortholog

RF

Class E basic helix-loop-helix protein
40;BHLHE40;ortholog
Chromodomain Y-like protein 2;CDYL2;ortholog

ATP8

PLS

BHLHE40

SVM

CDYL2

SVM

DENND5B

SVM

GPAT3
GRB10

PLS

PLS

PLS
PLS

SVM

DENN domain-containing protein 5B;DENND5B;ortholog
RF

PLS

Glycerol-3-phosphate acyltransferase 3;AGPAT9;ortholog
Growth factor receptor-bound protein 10;GRB10;ortholog

HSPA4L

PLS

RF

Heat shock 70 kDa protein 4L;HSPA4L;ortholog

IF2

PLS

RF

Eukaryotic translation initiation factor 5B;EIF5B;ortholog

RF

Inter-α-trypsin inhibitor heavy chain H4;ITIH4;ortholog

RF

ITIH4

SVM

KCND2

PAX8

SVM

PLS

Potassium voltage-gated channel subfamily D member
2;KCND2;ortholog
Mitogen-activated protein kinase kinase kinase
8;MAP3K8;ortholog
5'-nucleotidase domain-containing protein
1;NT5DC1;ortholog
Paired box protein Pax-8;PAX8;ortholog

PCGF1

SVM

PLS

Polycomb group RING finger protein 1;PCGF1;ortholog

PCGF5

SVM

PLS

Polycomb group RING finger protein 5;PCGF5;ortholog

PRUNE2

SVM

MAP3K8

PLS
SVM

NT5DC1

PLS
PLS

RF

RF

Protein prune homolog 2;PRUNE2;ortholog
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RAP1GAP2

SVM

RBP5

PLS
PLS

Rap1 GTPase-activating protein 2;RAP1GAP2;ortholog
RF

Retinol-binding protein 5;RBP5;ortholog

RHOBTB2

SVM

PLS

RNF217

SVM

PLS

SLC47A2

SVM

PLS

Rho-related BTB domain-containing protein
2;RHOBTB2;ortholog
Probable E3 ubiquitin-protein ligase
RNF217;RNF217;ortholog
Multidrug and toxin extrusion protein 2;SLC47A2;ortholog

THPO

SVM

PLS

Thrombopoietin;THPO;ortholog

VAMP5

SVM

RF

Vesicle-associated membrane protein 5;VAMP5;ortholog

Discriminate analysis of gene expression during early (Day 4 – Day 18) and later (Day 25 –
Day 29) postnatal mammary development reveals temporal regulation of important signaling
events
Discriminate analysis between the mammary transcriptome during 4-18 days of age
(DOA) (phase one) and 25-39 DOA (phase two) implicated important biological differences
that are temporally regulated during early postnatal mammary development and support the
two phases suggested by histology (see histology Fig. 3). As shown in Table 4, five known
genes were found using all three discriminate analysis methods (SVM, PLS, and RF):
COL8A1, DTX3L, MAP3K14, SLC29A4, and TBC1D8. 26 known genes were found in two
out of the three discriminate analysis methods: ANP32A, ARHGAP9, ARL16, ATP8,
BHLHE40, CDYL2, DENND5B, GPAT3, GRB10, HSPA4L, IF2, ITIH4, KCND2,
MAP3K8, NT5DC1, PAX8, PCGF1, PCGF5, PRUNE2, RAP1GAP2, RBP5, RHOBTB2,
RNF217, SLC47A2, THPO, and VAMP5. Genes found using all three or two out of the three
methods were deemed significant and will be discussed along with their upregulation or
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downregulation during phase one (and respectively, downregulation and upregulation during
the phase two).
Discriminate analysis data was assembled into a heat map using hierarchical
clustering in Genesis428. As shown in Fig. 8., genes identified using all three discriminate
methods are bolded; generation using three separate methods indicates the highest
significance of differential gene expression between the two phases. Differential expression
of all five highly significant genes was upregulated during phase two of postnatal
mammary gland development in comparison to their downregulated expression
immediately after birth in phase one. Importantly, the large majority (75%) of discriminately
expressed genes identified with all three DA methods were expressed highly during phase
two with significantly lower expression during phase one. Overall, common Reactome
pathways utilized by the top 31 known differentially expressed genes were (from most often
to least): Immune System, Adaptive Immune System, Signal Transduction, SLC-mediated
transmembrane transport, Transport of small molecules, Innate Immune System, CD28
dependent PI3K/Akt signaling, CD28 co-stimulation, Rho GTPase cycle, Costimulation by
the CD28 family, BMAL1:CLOCK,NPAS2 activates circadian gene expression, Transport of
glucose and other sugars, bile salts and organic acids, metal ions and amine compounds,
Antigen processing: Ubiquitination & Proteasome degradation, Circadian Clock, Class I
MHC mediated antigen processing & presentation, Signaling by Rho GTPases, and Cytokine
Signaling in Immune system. Greater than 50% of the pathways utilized by differentially
expressed genes were direct components of the immune system, indicating significant impact
of both innate and adaptive immune system factors in regulation of postnatal developmental
events. The immune system’s involvement in prenatal and postnatal mammary development
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has been gaining acceptance 11,84–88, and this data further confirms significant involvement,
specifically suggesting critical roles in temporal regulation during the first two months after
birth. Although the importance of immune cells in mammary gland development is well
known 34,35, the molecular signaling that guides them, the roles of chemokines, and the
importance of the adaptive immune system remain unexplored 86,114.
Pathway analysis was performed on each phase of discriminately expressed genes
separately. Pathways utilized by the smaller subset of differentially expressed genes that are
upregulated during phase one were (from most often to least): signal transduction,
metabolism of proteins, lipids, and RNA, and organelle biogenesis. CLA analysis using kmeans clustering in Fig. and Table 5 also indicated that gene expression contributing to the
downward trends over time in Clusters 13 and 19 utilized mainly metabolic, gene expression,
transcription and translation, and cell cycle pathways. In stark contrast, the larger subset of
differentially expressed genes that were upregulated during phase two utilized mainly
immune system pathways, including (from most often to least): immune system, adaptive
immune system, innate immune system, CD28 dependent PI3K/AKT signaling, CD28 costimulation, co-stimulation by the CD28 family, Class I MHC mediated antigen processing
and presentation, platelet activation, signaling, and aggregation, and cytokine signaling in
immune system. These immune system pathways were not found in differentially expressed
genes of phase one. Pathway analysis on the differentially expressed genes during early
mammary development indicates that the adaptive immune system is highly utilized
beginning in the period of 18-25 days after birth and remains active until at least 39 days
after birth, during which it contributes to developmental trends. The adaptive immune system
pathway is only preceded in use by differentially expressed genes by the generic immune
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system category, which includes both adaptive and innate components. This is especially
novel because adaptive immune roles in mammary development are currently unexplored.
CLA analysis using k-means clustering in Fig. 7 and Table 3 also indicated that gene
expression contributing to the upward trend in cluster 16 utilized signal transduction
pathways in conjunction with those of the immune system, innate immune system, cytokine
signaling, interleukin signaling, and the adaptive immune system, further supporting the
notion that the immune system’s role in early mammary development does increase over time
during the period of 4-19 days after birth. Taken together, these results do indicate significant
involvement and regulation of innate and adaptive immune system genes and components in
early postnatal, but prepubertal, mammary gland development. Genes of functional
significance will be discussed individually below.

Differentially expressed genes that are upregulated during Phase one: Day 4- Day 18 after
birth
Differentially expressed genes that are suspected, as a result of DFA analysis, to hold
important roles in mammary development will be individually discussed, beginning with the
small subset that are upregulated during phase one (from 4-18 days after birth) and
expressed at lower levels from days 25-39. As mentioned, pathway analysis initially
indicated that these genes mainly utilize signal transduction and metabolic pathways and are
not present in innate or adaptive immune system pathways. Still, several functionally
significant genes are present in phase one. HSPA4L, Heat shock 70 kDa protein 4L, encodes
a heat shock inducible chaperone protein that is highly expressed in leukemia cells 468–472.
Current evidence supports a role of HSPA4L in normal spermatogenesis 470, but little to no
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data exist explaining its function in normal mammary development. Results suggest that this
chaperone protein may play a role in very early protection of developing mammary cells
from heat stress and aids in osmotolerance. KCND2, Potassium voltage-gated channel
subfamily D member 2, encodes a voltage-gated potassium channel protein that is known to
mediate transmembrane potassium transport in excitable membranes 472. Since voltage-gated
potassium (Kv) possesses diverse functions including regulation of neurotransmitter release,
heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth
muscle contraction, and cell volume 473, it is possible that this gene is upregulated during
phase one in order to immediately regulate electrolyte transport of mammary epithelial cells
after birth. ANP32A, or Acidic leucine-rich nuclear phosphoprotein 32 family member A,
encodes a protein implicated in a number of cellular processes, including proliferation,
differentiation, caspase-dependent and caspase-independent apoptosis, suppression of
transformation (via acting as a tumor suppressor) and is aberrantly expressed in multiple
types of cancers 474–477. ANP32A is a member of the ANP32 family, that contains a large
group of proteins implicated in a wide range of functions: modulation of cell signaling,
transduction of gene expression, hormone-receptor interactions, cell adhesion, cellular
trafficking, early mammalian development, apoptosis signaling, and regulation of
cytoskeleton morphology 478,479. The high expression of ANP32A during phase one in
contrast to its downregulation in phase two suggests it supports one or more of these
functions in very early postnatal mammary gland development. The function of NT5DC1, 5'nucleotidase domain-containing protein 1, remains unknown 472 and to our knowledge no
data exist to elucidate its role in early mammary development; this data suggest a role in the
first few weeks after birth. ATP8, ATP synthase protein 8, encodes a protein that functions as
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a subunit of mitochondrial ATP synthase 480. ATP8 supports normal mitochondrial
performance 481, therefore it is possible that this differentially expressed gene supports
mitochondrial function in young mammary cells of phase one. IF2, or Eukaryotic translation
initiation factor 5B, is a general transcription factor that supports initiation of translation by
promotion of 60S ribosome subunit joining and pre-40s subunit proofreading 482–486.
Recently, Lee at al uncovered a critical role for IF2 in specific developmental stages,
including those of immature oocytes and ES cells, and during growth-factor deprivation of
mammalian cells, inducing the transition to cell-cycle arrest 483. Importantly, these
researchers demonstrate that IF2/eIF5B controls and regulates cell-cycle transition and
developmental stages 483, which is likely akin to its function in early mammary development.
Taken together, the subset of genes that are highly differentially expressed during phase one
of postnatal mammary development likely promote signaling pathways of cellular biogenesis,
metabolism, epithelial and stromal differentiation, and widespread expansion of the gland.
Interestingly, functional characterization of the small subset of DFA genes found upregulated
in phase one immediately after birth suggests that this time period of early mammary
development is one of generic growth rather than advanced differentiation. The presence of
genes aiding in early protection of developing mammary cells from heat stress,
osmotolerance, regulation of electrolyte transport of mammary epithelial cells, modulation of
cell signaling, transduction of gene expression, hormone-receptor interactions, cell adhesion,
cellular trafficking, mitochondrial function, and cell-cycle transition provide a model for
widespread growth focused on cellular activity in phase one, rather than differentiation with
support from stromal and immune factors that is seen in phase two. It may be that
immediately after birth, the mammary gland requires three to four weeks to adjust to growth
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and expansion postnatally, after which advanced differentiation and maturation of the organ
begins.

Differentially expressed genes that are upregulated during Phase two: Days 25-39 after birth
Next, the major subset of differentially expressed genes (those that are downregulated
phase one and upregulated during later phase two) will be discussed, beginning with the five
significant genes identified using all three DA methods. COL81A encodes type VIII
collagen, a matrix protein widely expressed during tissue remodeling, wound repair, and cell
migration; little is known about its functional mechanism, especially in mammary
development 472,487–496. As discussed previously, postnatal mammary epithelial cells are
tightly connected to both each other and surrounding stroma, relying on this both collagen
and this stable adhesion to transmit biochemical signals, promote cell migration, and function
normally 7,41,82. Cell migration is a carefully coordinated process during which attachment to
matrices and subsequent release for translocation are regulated by MMPs, forming a physical
path through the ECM 497. This process is also commonly mediated by integrin and laminin
molecules: Ln-5 can be degraded by proteases (including MMP-2 and MMP-9) during tissue
remodeling to promote cell migration 394. When cleaved during proteolytic processing, the
G4/G5 fragment of Ln-5 that is released from the G3 domain also functions to support cell
migration 397. Hou et al investigated smooth muscle cell (SMC) migration via type VIII
collagen and concluded its effects are mediated by α2β1 and α1β1 integrin receptors as well
as MMP-2 and MMP-9 expression. This demonstrates a critical role for type VIII collagen in
cellular invasion and migration 488. As reviewed in Chapter 1, MMPs secreted by
macrophages function in ECM remodeling to allow ductal branching into the mammary fat
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pad 14,103–107, so it is not surprising that MMPS coordinate with type VIII collagen in this
suggested model. During tumorigenesis, reduction of COL8A1 expression leads to decreased
invasion of hepatocarcinoma cells 498, indicating that type VIII collagen has a functional role
in both cancer development and the migration and adhesion required for normal
development. However, little data exist to elucidate the role of type VIII collagen in early
postnatal mammary development or TNBC. This data show that COL81A is significantly
upregulated during phase two of early postnatal mammary development, and taken together
with the accepted role in general tissue remodeling, wound repair, cell migration, and integrin
molecule interaction, it is hypothesized that type VIII collagen has a functional role in early
postnatal mammary development and epithelial cell signaling in conjunction with MMPS and
other immune system components.
The Deltex (DTX)-3-like E3 ubiquitin ligase (DTX3L), also known as B-lymphoma
and BAL-associated protein (BBAP), is overexpressed in many high-risk, chemo-resistant,
diffuse large B cell lymphoma (HR-DLBCL) subtypes 499, is associated with both IFNgamma and STAT1 signaling 499–502, and functions as a binding partner to ADPribosyltransferase-9 (ARTD9) (also known as B-aggressive lymphoma protein (BAL1))
499,502

. These genes have also been found overexpressed in myeloma, Ewing tumors, head and

neck cancers, and cervical cancer 502–507. Functionally, DTX3L responds to cellular exposure
of DNA damaging agents and its inhibition is thought to increase the efficacy of DNAtargeting chemotherapeutic agents, but the mechanism utilized in the response is unclear 508.
In melanoma cells, DTX3L has been shown to mediate proliferation, invasion, and metastasis
through FAK/PI3K/AKT signaling 509, suggesting a similar role for this gene during tissue
remodeling in the early mammary gland during phase two while upregulated because studies
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investigating its function in mammary development do not exist.
The MAP3K14 gene, also known as NF-κB-inducing kinase (NIK), encodes a
serine/threonine protein-kinase that promotes activity of the noncanonical NF-κB pathway to
regulate cell proliferation and survival both normally and in tumorigenesis 510,511. NF-κB is a
well-characterized transcription factor family that influences cellular immune responses,
survival, proliferation, angiogenesis, and metastasis 512. NIK regulation occurs at the posttranslational level through the translocon associated protein complex (TRAF), a cellular
inhibitor of apoptosis 513, promoting differentiation, development, embryogenesis, and tumor
cell invasion through phosphorylation of either IKK α and IKK β subunits 514–519.
Additionally, Osman et al showed that both NIK and AKT are necessary for activation of
NF-κB, suggesting involvement of NIK in the PI3K/AKT pathway 520. Importantly, NIK is
overexpressed in basal breast cancer cell lines, leading to constitutive activation and
uncontrolled tumor proliferation 521–523. NIK overexpression also increases the activity of
breast cancer stem cells in vitro through the ERK pathway and is correlated with ALDH
overexpression in a tissue microarray of in vivo breast cancer samples, implicating NIK in
regulation of the breast cancer stem cell phenotype 524. Since NIK is essential for the
canonical NF-κB pathway activation normally, inhibition of NIK could be a better
therapeutic strategy in cancer. It is clear that NIK is involved in regulation of breast cancer
stem cells, tumor invasion, and basal cell expansion, but the mechanism remaining poorly
understood 524. This data identifies NIK as a highly significantly differentially expressed gene
that is upregulated during phase two of early postnatal mammary development, suggesting
NIK functions to promote differentiation and proliferation of mammary epithelial cells
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during this period in the immature gland and also may regulate growth of the mammary
gland through apoptotic cell signaling pathways.
TBC1D8, TBC1 domain family member 8, which may act as a GTPase-activating
protein for Rab family protein(s)472 and SLC29A4, Equilibrative nucleoside transporter 4,
which functions as a polyspecific organic cation transporter472, have lesser characterized
functions in development and to our knowledge data does not exist to elucidate their
function. Since these two genes are highly upregulated during phase two of postnatal
mammary development, our data suggest a role for them in this area.
Taken together, the presence of COL81A, DTX3L, MAP3K14 in the top subset of
genes upregulated during phase two suggest contribution of the ECM, immune system, and
tissue remodeling to differentiation and proliferation of mammary epithelial cells during this
period in the immature gland. Importantly, in contrast with the generic cell growth model
provided by discriminately expressed phase one genes, phase two appears to contain more
advanced regulatory and differentiation activities along with the presence of stromal
influence. Many of the phase two genes have functions in tissue remodeling, wound repair,
and cell migration while relying on stable adhesions. It is known that cell migration is a
carefully coordinated process, and this data suggests growth due to migration and
differentiation begins in phase two rather than phase one, in part due to regulation by immune
system components such as MMPS. Importantly, DFA analysis suggests that during phase
two, proliferation, invasion, and maturation may begin to rely more heavily on
FAK/PI3K/AKT signaling.
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In addition to genes identified using all three discriminant analysis methods, several
functionally important genes were generated by two of the three methods, which will be
discussed individually, including: ARHGAP9, BHLHE40, GRB10, ITIH4, MAP3K8, PAX8,
PCGF1, PCGF5, PRUNE2, RNF217, THPO. All of these genes were upregulated during
phase two of early postnatal mammary development.
ARHGAP9 encodes Rho GTPase-activating protein 9, a G-protein modulator that is a
member of the Rho-GAP family of GTPase activating proteins that has been implicated in
regulating adhesion of hematopoietic cells to the extracellular matrix 525 and interacting with
Erk2 and p38α to sequester the MAP kinases in their inactive states 526, which is a novel
mechanism of cross-talk between Rho GTPase and MAP kinase signaling. Given that matrix
adhesion is a critical activity for cell migration and mammary development, it is
hypothesized that this gene has a similar adhesion function in phase two of early postnatal
mammary development.
BHLHE40 encodes Class E basic helix-loop-helix protein 40, which is a
transcriptional repressor believed to be involved in control of circadian rhythm (through
negative regulation of clock and clock-controlled genes), cell differentiation, proliferation,
and apoptosis 527–533. Also commonly known as Differentiated embryo-chondrocyte
expressed gene 1 (DEC1), this gene has been shown to assist BHLHE41 in the suppression of
EMT effectors and tumor cell invasion in vitro 529 and its loss may promote tumor
progression in through upregulation of cyclin D1 534. Conflictingly, data suggest its presence
also promotes the invasiveness of breast cancer through downregulation of claudin-1 531.
Overexpression of this gene has been reported to contribute to the cellular differentiation,
proliferation, and apoptosis of various cancers 527–538 although the mechanism is poorly
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understood. This data suggests a significant role for BHLHE40 during phase two, which
could consist of either promotion of cellular differentiation and proliferation (positive role) or
cell cycle regulation (negative/regulatory role). Given that cell cycle regulation was a
hallmark of phase one genes, it is possible BHLHE41 in phase two contributes to
differentiation of mammary epithelial cells, a focus of this larger subset of DFA results.
GRB10, Growth factor receptor-bound protein 10, is a common adapter protein
which modulates interaction of several surface receptor kinases by interfering with
downstream signaling pathways and receptor degradation 472. GRB10 is widely accepted to
influence cell proliferation, apoptosis, and metabolism in varied cell types 539–541. It can bind
to, and suppress signals from, activated RTKs including the insulin (INSR) 542 and insulinlike growth factor (IGF1R) receptors 543 via delay and reduction of AKT1 phosphorylation.
GRB10 has a widespread functional impact in both development and cancers- it has been
shown to bind to the intracellular portion of Low-density lipoprotein receptor-related protein
6 (LRP6) and negatively influence Wnt signaling, as a negative regulator of the pathway 544.
Loss of GRB10 can also induce hyperproliferation and tumor development 545 and its
presence has also been found to negatively correlate with lactation performance 546,
illustrating its wide range of function. Interestingly, the phenotype resulting from GRB10
dysfunction is dependent on the parental origin of the mutation, a phenomenon known as
genomic imprinting 547. Genomic imprinting, reviewed in depth 548, can influence
developmental programming that links growth in early stages of life to overall health at
adulthood. Expression of GRB10 is gained from the maternal chromosome in most tissues
and presents a complex and tissue-specific expression pattern 547. Data has identified
imprinted GRB10 as a mediator of nutrient supply and demand in the postnatal period and a
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negative regulator of growth-related pathways and insulin signaling in development 547;
reduction in GRB10 expression results in widespread postnatal overgrowth and insulin
sensitivity 549–552. This data suggests that GRB10 is upregulated during phase two in order to
perform similar negative regulatory roles in early postnatal mammary development.
ITIH4, Inter-α-trypsin inhibitor heavy chain H4, is a type II acute phase protein that
is involved in the inflammatory trauma response 472,553. Predominantly expressed in liver
tissue, mRNA expression levels of this protein have been seen upregulated in response to
administration of IL-6 553, but data regarding the involvement of this protein in mammary
development does not exist. This data indicates upregulation of ITIH4 during phase two,
where it could be involved in the developing epithelial cells and the immune system in
response to cytokines present in the postnatal mammary gland.
MAP3K8, mitogen-activated protein kinase kinase kinase 8, is a potent oncogene that
encodes a member of the serine/threonine protein kinase family 472. Widely expressed in
skeletal muscle and the immune system 554, MAP3K8 is a tumor suppressor that can activate
the ERK, JNK, and p38 MAPK pathways 555, support IL-12 production and Th cell
differentiation 556, and possesses a critical role in promotion of cancer-associated
inflammation in the TME when induced by IL-22 557. IL-22 signaling can promote
aggressiveness in human breast cancer through the induction of MAP3K8, leading to
epithelial transformation; knockdown of MAP3K8 decreases tumorigenicity in MCF-7 cells
557

. It is well-known that the MAP3K8 pathway components can have both tumorigenic or

apoptotic functions that are dependent on the stimuli and the other stromal cells involved 558;
its involvement in normal mammary development can either be hypothesized as regulatory or
promotional or both, depending on the time period. Our data show that this gene is
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upregulated during phase two and downregulated during phase one, leading us to believe that
it could have a regulatory role in postnatal mammary development- possibly controlling
growth after initial widespread metabolic and biogenesis events during phase one growth.
PAX8, Paired box protein 8, encodes a transcription factor that is known to control
cellular fate and embryonic development of the central nervous system, eye, kidney, thyroid
gland, and mesonephric gut organs 559–565 and has a critical role in maintaining the normal
function of certain cells, especially epithelial cells, of these organs after birth 566,567. Ozcan et
al showed through an immunohistochemical study that PAX 8 expression occurs in a tissue
and organ specific manner in both non-neoplastic adult tissue and transformation and
metastasis 568. During phase two of postnatal mammary gland development, this transcription
factor is likely upregulated to support and control normal epithelial cell differentiation and
organ development.
Two polycomb group RING finger proteins are upregulated during phase two.
PCGF1, Polycomb group RING finger protein 1, encodes a protein component of the
polycomb group (PcG) multiprotein BCOR complex, which functions to maintain several
genes in a transcriptionally repressed state and regulate developmental genes 472. PCGF5,
Polycomb group RING finger protein 5, is also a component of a PcG complex (PRC1-like)
required to maintain the transcriptionally repressed state of HOX (homeobox) genes
throughout development 569. Target genes repressed by PCGF1 include BCL6 and CDKN1A.
CDKN1A functions as a regulator of cell cycle progression at G1 phase and its expression is
also controlled by p53 in order for cell cycle arrest to occur if needed 570–572. PCGF1, as part
of a PcG complex, can promote cell cycle progression and can enhance proliferation by
repressing various cell cycle regulators 572–579. Importantly, PcG proteins have been
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implicated in both cancer development and maintenance of embryonic and adult stem cells; it
is possible that PCGF1 and PCGF5 play a role in stem cell pluripotency 570. Recent data show
that PCGF5 is expressed preferentially in hematopoietic stem cells (HSCs) and multipotent
progenitors (MPPs) compared with differentiated cells 580. Dupret et al showed through a
zebrafish model that PCGF1 is critical in early development; zebrafish without normal
PCGF1 gene function had significantly lower early developmental growth rates and later,
signs of premature aging 581 . PCGF1 and PCGF5 are likely functioning in early postnatal
mammary development in a similar fashion as described above in order to regulate and
promote growth of the mammary gland, specifically during phase two.
PRUNE2, Protein prune homolog 2, encodes a protein of the B-cell CLL/lymphoma
2 and adenovirus E1B 19 kDa interacting family 472, where it functions in apoptotic processes
as tumor suppressor 582–584. However, little data exist for a role in mammary development.
Similarly, RNF217, E3 ubiquitin-protein ligase RNF217, encodes a protein that interacts with
a known anti-apoptotic protein, HAX-1, via its C-terminal RING finger motif, suggesting a
role in apoptosis signaling. Our data suggest that presence of both PRUNE2 and RNF217
upregulation phase two supports their regulatory roles in growth and proliferation of the
mammary gland, but further study is needed since literature is lacking for these genes.
THPO encodes the protein Thrombopoietin, the major cytokine that regulates platelet
production, controls differentiation and proliferation of megakaryocyte progenitor cells, and
maintainins normal thrombopoiesis levels 585,586. This indispensable cytokine has been shown
to activate the JAK/STAT 587 and PI3K 588 pathway as well as activate in an inside-out
manner integrin α2bβ3 589. Matsumura et al proved that THPO induced differentiation of a
human megakaryoblastic leukemia cell line through transcriptional activation of p21 by
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STAT5 590. THPO is vital for the regulation and maintenance of HSC quiescence and data
suggests it supports stem cell renewal after bone marrow transplantation 591,592. The
upregulation during Days 25-39 in the early postnatal mammary gland shown by our data
suggest that THPO supports platelet production and differentiation in the developing
mammary microenvironment.
Taken together, discriminate analysis data show temporal regulation of important
signaling events during two phases of early postnatal, prepubertal mammary development.
Differential expression of all five highly significant genes (revealed using all three methods)
was upregulated during phase two of postnatal mammary gland development in
comparison to their downregulated expression immediately after birth in phase one. Greater
than 50% of the pathways utilized by differentially expressed genes were direct components
of the immune system, indicating significant impact of both innate and adaptive immune
system factors in regulation of postnatal developmental events. The immune system’s
involvement in prenatal and postnatal mammary development has been gaining acceptance
11,84–88

, and our data further confirms significant involvement, specifically suggesting critical

roles in temporal regulation during the first two months after birth.
Pathway analysis was performed on each phase of discriminately expressed genes
indicated mainly metabolic, gene expression, transcription and translation, and cell cycle
pathways utilized in phase one while the larger subset of differentially expressed genes that
were upregulated during phase two utilized mainly immune system pathways that were not
found in differentially expressed genes of phase one. Our pathway analysis on the
differentially expressed genes during early mammary development indicates that the adaptive
immune system is highly utilized beginning in the period of 18-25 days after birth and

92

remains active until at least 39 days after birth, during which it contributes to developmental
trends. Additionally, our data and the assessment of key immune regulators and markers in
swine by other researchers suggests this is a much better model of human innate immunity
and disease than rodents 151. Accordingly, understanding the function of immune molecules
in normal development and their concert with other signaling mechanisms can provide
insight into these roles during cancer development 91.
DFA, in addition to providing novel insight regarding temporally regulated events of
early postnatal mammary development, suggested that phase one and phase two can be
defined as widespread biogenesis and refined differentiation, respectively. The presence of
genes with advanced regulatory and immune function, as well as many with tumorigenic
roles, in phase two is a unique finding; although growth is seen immediately after birth,
maturation and differentiation seems to take three to four weeks to truly begin.

There are specific trends + interactions between sets of genes that have developmental and
biological significance over time (PRC)
PRC analysis generated a list of genes that contribute functionally, both positively
and negatively, over time (4-39 DOA) to our model of early postnatal mammary gland
development. PRC identifies specific genes contributing functionally, and possibly
interacting with each other, toward development over time, as shown in Fig. 9. Positive PRC
gene transcripts increase in abundance with the curve over time; the top 20 are shown on the
effect axis in green text. Conversely, the top 20 genes that are contributing negatively toward
development over time, or decreasing in abundance with the curve, are shown in red text.
Reactome pathway analysis plus manual pathway curation if necessary is indicated by the
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colored box to the right of each Gene ID. In Tables 7 and 8, PRC weights are shown along
with each Gene ID and family for the top 50 negative and positive genes. A greater PRC
weight indicates greater contribution to the curve trend.

Figure 9: PRC identifies specific genes contributing functionally toward development
over time (days of age); Positive PRC gene transcripts increase in abundance with the
curve over time (top 20 are shown on the effect axis in green text). The top 20 genes that
are contributing negatively toward development over time, or decreasing in abundance
with the curve, are shown in red text. Reactome pathway analysis plus manual pathway
curation if necessary is indicated by the colored box to the right of each Gene ID.

In an RNA-seq data set that contains a large number of response variables (genes),
interpretation of RDA and CCA plots is complicated because interaction effects exist among
explanatory variables 593. Initially developed by van den Brink & ter Braak 594, PRC can be
used to study the effect of age (as a function of time) on gene expression in the early prepubertal/postnatal mammary gland. PRC is based on RDA with the same assumptions and is
frequently used in ecological studies as resulting biological and chemical data sets from
analysis of environmental trends are large and difficult to evaluate 593–599. PRC curves
visually show changes over time in a format that is easy to read and are usually used with an
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internal reference (overall mean, reference age, or reference year) 594,596,600. Time-dependent
effects can be clearly isolated in PRC 174, making it a valuable tool to extract developmental
trends from the large transcriptomic data set. This advanced technique has not yet been
applied to data in the field of developmental or mammary biology. Shown in Fig. 9, the PRC
plot of the transcriptomic data set illustrates a clear trend over the period of 4-39 DOA,
indicating time-dependent effects are present. PRC identifies the set of positive genes
contributing functionally toward development over time, increasing in abundance with the
curve or contributing negatively toward development over time. Each gene has a unique
weight, shown in Tables 6-7, that indicates its contribution to the curve, and therefore, its
contribution to postnatal mammary development.
Tables 7 and 8 are a summary of the top 50 positively and negatively contributing
genes to the PRC curve. It is hypothesized that the genes decreasing in abundance with the
PRC curve are very early genes contributing to the phenotype at birth or prior; these could
also be similar to phase one genes (upregulated during 4-18 DOA) discussed in the
discriminant analysis section. Reactome pathway analysis indicated that the top pathways
utilized by the top 50 genes negatively contributing to the developmental trend are: Cell
Cycle, Mitotic, Cell Cycle, Metabolism, Metabolism of proteins, Signal Transduction, RHO
GTPase Effectors, Signaling by Rho GTPases, Gene expression (Transcription), and Generic
Transcription Pathway. A review of the literature and characterization using Panther 601–605
and GeneCards 472 indicates that the main biological functions of the negatively contributing
genes are organelle biosynthesis, transcription and gene expression, cell cycle control, RNA
binding and processing, DNA elongation and amplification, CDK interactions, and molecular
chaperoning. In agreement with phase one DA genes, which mainly utilized signal
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transduction and metabolic pathways, negative PRC genes are not present innate or adaptive
immune system pathways.
Conversely, it is hypothesized that the positive PRC genes, those that increase in
abundance with the PRC curve, are developmental genes, possibly similar to phase two DA
genes discussed previously. These positive PRC genes theoretically function synergistically
to significantly contribute to early postnatal mammary development over time. Reactome
pathway analysis indicated that the top pathways utilized by the top 50 genes positively
contributing to the developmental trend are: Immune System, Metabolism of proteins, Signal
Transduction, Adaptive Immune System, Cytokine Signaling in Immune system, Posttranslational protein modification, Axon guidance, Hemostasis, Developmental Biology,
Interleukin-4 and 13 signaling, Signaling by Interleukins, and Innate immune system. A
review of the literature and characterization using Panther tools 601–605 and GeneCards 472
indicated that the main biological functions of the positively contributing PRC genes are:
comprehensive immune system function, stem cell signaling, antigen presentation, protection
from stress, inflammation, apoptosis and transcriptional repression, Integrin signaling,
utilization of NFkB, Wnt, MAPK, and AKT pathways, cell migration and adhesion, epithelial
and mesenchymal cell polarity and morphology, focal adhesion formation, adherens junction
formation, and ECM cell spreading. Interestingly, a review of the literature indicated that
65% of the positive PRC genes can function as oncogenes or proto-oncogenes in comparison
with only 22% of the negative PRC genes. As shown in Fig. 9, the top 20 positive and
negative PRC genes have the potential to utilize more than one Reactome pathway (indicated
by colored boxes). As briefly mentioned, our analysis showed the top 20 negative genes that
decrease in abundance with the curve are not reported to utilize any immune system or
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developmental biology pathways in contrast with high utilization by the positive genes (as
characterized by Reactome). Conversely, the top 20 positive genes that increase in abundance
with the curve utilize very few cell cycle and gene expression pathways in comparison by
high utilization by the negative genes. Taken together, PRC and pathway analysis suggests
that development and maturation of the mammary gland during the first 39 days after birth
heavily relies on the immune system, immune components, integrin molecules, and the ECM,
utilizing genes known to function in development and previously uncharacterized, novel
genes that are also likely to function as oncogenes or proto-oncogenes.
Since the data illustrated that a majority of the top 50 positive PRC genes are
functionally significant, linked with cell signaling pathways of biological interest, and have
been implicated in various types of cancers, a select subset and implications for functional
roles in early mammary development will be discussed herein. These are: SLA-DOA,
PINK1, DOCK4, L1CAM, FRMD4A, STARD8, VLDLR, SOX13, LIMS2, UBXN1,
DDIT3, HGF, DMAP1, and TRAF3. TRAF3 and HGF were not able to be shown due to
figure size limitations. These genes are a chosen subset of the most significant functional
genes in early mammary development uncovered through PRC analysis with critical,
widespread, and/or novel roles in the process. A full characterization for the top 50 positive
and top 50 negative PRC genes can be found in Appendix A and B.
First, a large portion of genes contributing to development over time were linked with
the innate and/or adaptive immune system. SLA-DOA, also known as HLA class II
histocompatibility antigen do α chain (HLA-DOA), modulates HLA class II restricted
antigen presentation pathways in B-cells and is both an MHC Class II molecule chaperone
and an adaptive immune system constituent

472,606,607
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. As reviewed in Chapter 1, the role of

the adaptive immune system in early mammary development remains unexplored with an
unknown what function, if any, in mammary organogenesis. An adaptive immune system
protein with the highest positive PRC weight indicates significant involvement of this
pathway in mammary development and also supports our previous findings of adaptive
immune system involvement in development using disparate statistical methods including
discriminant analysis (Fig. 8; Tables 5-6) and k-means clustering (Fig. 7). It has been
previously established that MHC Class II molecules are frequently expressed in colorectal
and breast carcinoma tumors with expression suspected to occur in response to hormones
and/or cytokines 608, but correlation with disease prognosis is unknown 609 and little is
recognized regarding roles of HLA-DOA in tumor response 607. Although HLA-DOA is
upregulated in B-Cell Lymphoma (BCL) 610,611, the mechanism is not elucidated and to our
knowledge, no data exist supporting a role for this molecule in postnatal mammary gland
development. Currently, it is believed that the role of immune cells in developmental
processes is restricted to the innate immune system with the exception of lactation 88. This
novel data suggests that both the innate and adaptive immune system have significant roles in
developmental trends during the first two months of postnatal organogenesis. Additional
immune system components are present in the top 25 positive PRC genes and will be
subsequently discussed.
TRAF3 encodes a protein member of the TNF receptor associated factor (TRAF)
family, an assembly of six proteins that mediate cellular signals through association with
members of the TNF receptor (TNFR) superfamily 472. TRAF3 is the most obscure of the six
and participates in a variety of signaling pathways in a range of cell types: it demonstrates
critical roles in both B and T lymphocyte development, including B cell homeostasis,
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development, and survival, isotype switching from IgM to IgG, B-cell malignancies, cytokine
production, CD40 signal transduction, TLR activation, T cell function, thymocyte
development, antiviral responses, Treg cell development, and NFkB/JNK activation

612

. Its

position in the top 25 positive PRC genes suggests one or more of these critical roles exists in
early postnatal mammary development. TRAF3 may also be responsible for oncogenic
consequences of several molecules, including the Epstein-Barr virus encoded latent infection
membrane protein-1 (LMP1) 613. Importantly, TRAF3 has been found to promote
ubiquitination and proteasomal degradation of MAP3K14 614, one of the important phase two
genes found using all three DA methods (Fig. 8), suggesting functional cooperation between
developmental genes discovered in our transcriptomic dataset using more than one
multivariate technique. Mouse models demonstrated that TRAF3 is critical for development
of the marginal zone (MZ) B cell subset as well as general B-cell homeostasis and survival
through mediation of the NF-κB2 pathway 615–617. In addition to NF-κB2 activation, TRAF3
is thought to act as a pro-apoptotic factor and/or restrain additional pro-survival pathways
612,615–620

. Mutations inducing loss of function are seen in TRAF genes of multiple myeloma

and some types of B cell lymphoma, indicating it plays a negative regulatory role in B
lymphocytes, commonly as a tumor suppressor 619,621–624. TRAF3 also regulates activity
downstream of B cell receptors; it has been seen to negatively regulate CD40 and LMP1
613,625

, bind to members of the TNFR subfamily including BAFFR, BLyS, TALL-1, TAC1,

and APRIL (reviewed in 45,626–629), and associate with CD120b/TNFR2 630. In TLRs, TRAF3
has been shown to positively mediate antiviral TLR signals and IFN production in myeloid
cell responses 631–633 while also functioning as a negative regulator of B cell TLR responses,
including TLRs 3, 4, 7, and 9 634. More recently, TRAF3 has been shown to be required for
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multiple stages of T cell development, production of IgG1, T- cell function in vivo, Treg
development, invariant natural killer T (iNKT) cell signaling 635, and TCR/CD28 mediated
signaling 618; it could be involved in these developmental events of the adaptive immune
system in our model. TRAF expression by B and T lymphocytes and its function in these
immune cell types indicates the versatility, criticality, and significance of this gene in cellular
development, homeostasis, immune function, and apoptosis. It is suspected that TRAF3 may
impact some or all of these processes during early postnatal mammary development,
contributing to its role as a top 25 positive PRC gene. Importantly, its dual role as a negative
regulator of TLR responses and positive regulator of myeloid responses places this gene in
both innate and adaptive immune system categories, suggesting contributory activity of both
systems during the first two months of postnatal mammary development.
HGF, hepatocyte growth factor, encodes a protein that binds to the hepatocyte growth
factor receptor (HGFR) to regulate a wide range of processes, including cell growth, motility
and morphogenesis in numerous cell and tissue types; additionally, it has roles in
angiogenesis, tumorigenesis, tissue regeneration, and MET (HGFR) activation 472. As
reviewed in Chapter one, the mammary gland is a dynamic tissue in which differentiation and
apoptosis occur cyclically during early development, puberty, pregnancy, and lactation and
most mammary branching and development occurs postnatally 22. Mammary epithelial cell
migration, growth, and proliferation depends heavily on stromal and ECM signals that
support mammary gland morphogenesis 4. HGF, produced by mesenchymal cells/mammary
fibroblasts 636, provides these specific signals that mainly influence cells of epithelial origin,
acting as a paracrine mediator of epithelial interactions 636,637. HGF potentially functions as a
paracrine mediator of mammary epithelial cell signaling and interaction in our early postnatal
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mammary development model since the gene and its cellular receptor are carefully
temporally regulated during mammary development to support ductal branching,
invasiveness, and epithelial cell motility 638. The receptor, a unique transmembrane tyrosine
kinase, is expressed in surrounding mesenchyme during development; importantly, it is also a
product of the c-met proto-oncogene expressed in epithelial cells, providing a mechanism for
EMT processes during development 639. In mature tissue types, c-met functions in wound
healing and tissue regeneration 640–642; c -met and HGF are expressed in mesenchymal stem
cells, suggesting involvement in hematopoiesis 643. The presence of HGF, and theoretically
its receptor, suggests involvement of EMT processes during postnatal mammary gland
development. It is widely accepted that this naturally occurring cytokine plays a significant
role in murine 644–646 and chick embryogenesis 647–649 collaborating with the multifunctional
cytokine, TGF-β 1-3, to promote ductal morphogenesis. Interestingly, HGF is mitogenic for
luminal cells but not myoepithelial cells and morphogenic to myoepithelial cells but not
luminal cells 636,644,650. This suggests c-met/HGF signaling can control the function of luminal
progenitors and modulate their fate during mammary development 651 and provides another
possible role for the molecule in our model. Pursuant to our research focus, it has been shown
in vitro that ductal morphogenesis induced by HGF is dependent on functional β1 integrin
molecules 143. The involvement of integrin molecules in normal mammary development and
TNBC have been reviewed in Chapters 1 and 2. Especially interesting is the finding that β4
integrin can be activated through phosphorylation by the c-met receptor for HGF, which
subsequently recruits the tyrosine phosphatase Shp2 and Src in order to signal through the
Ras–ERK cascade 652,653. HGF/c-met represent a novel signaling pathway that connects β4
integrin to ERK activation in the mammary gland 653 and the presence of HGF in the top 25
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positive PRC genes confirms our suspicion of significant β4 integrin involvement and EMT
in early postnatal mammary development. From Chapter one, it is recalled that breast cancer,
metastasis, invasion, and progression require epithelial cells to enhance their normal growth
and survival capability. Frequently, deregulated HGF/c-met signaling is observed in cancer
with c-met, β4, and Src all commonly overexpressed (and coexpressed) 413,654,655.
Constitutively active Src can upregulate HGF in breast carcinoma cells, promoting
tumorigenesis 656. Also in breast cancer, c-met and PIK3CA mutations are frequentdysregulation of c-met and PI3K significantly increased cell proliferation and invasion in
vitro and in vivo, suggesting that response to MET-targeted therapy is dependent on an
aberrant MET-HGF/PI3K axis 657. HGF/c-met signaling has recently been associated recently
with specifically basal type breast cancers/TNBC, with mutations occuring in progenitor cells
in the luminal mammary epithelium 658,659. C-met overexpression has been associated with
BRCA1 mutated tumors in a mouse model where BRCA1 and p53 were deleted in the
mammary epithelium 660; taken together, these above findings suggest functional cooperation
between HGF/c-met, β4, and Src in order to advance cell survival and metastasis which raises
the question of similar cooperation in early mammary development. Most of this information
on HGF signal transduction has been derived in vitro, however, and has not been extrapolated
to, or confirmed in the mammary gland in vivo 639 (and if it is, murine models are used).
Swine models have not been frequently used to investigate functions of any of these genes in
early postnatal development, adding further novelty to the approach.
SOX13, SRY-related HMG-box 13, encodes a member of the sox family of
transcription factors, which are well-established regulators of developmental cell fate
decisions that have roles in tissue homeostasis and regeneration and are also dysregulated in
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cancers 661–663. The role of SOX13, however, is mostly undefined 661 and this gene is one of
the lesser characterized positive PRC genes in our dataset. However, it has been identified as
a gammadelta T-cell specific gene in the immune system- promoting development of this
type of T-cell while opposing αβ differentiation, potentially through inhibition of signaling
by Wnt/T cell factor (TCF) pathway

664

.

In addition to immune involvement, protection of cells from DNA damage or
dysfunction is critical in development and genes of this nature present in the top 25 positive
PRC set. PINK1, PTEN induced putative kinase 1, also known as PARK6, is a highlyconserved Parkinson’s disease-susceptibility gene whose product protects cells from
mitochondrial dysfunction induced by stress and eradicates damaged mitochondria through
mitophagy 665–668. PINK1 is induced by the tumor suppressor PTEN 669, a significant
component of the PI3K/AKT pathway subject to mutations 255 PI3K/AKT and one of the
most frequently mutated genes in breast cancer 337,670. In parallel with the discovery that
PINK1 is induced by PTEN, increased expression of this gene was exposed in metastatic
murine cancer cell lines 671 and loss of function mutations were discovered in several forms
of Parkinson’s disease 672. Extensive Parkinson’s research has shown that signaling through
PINK1 controls several other processes along with normal function in mitochondrial
homeostasis and dynamics 673,674, including PI3K/AKT signaling, chemoresistance, and
regulation of apoptosis in cancer cells 675. The gene has been reported to promote contrasting
oncogenic and tumor suppressor properties 665,669,673,676–682, largely through activation of the
PI3K/AKT/mTORC signaling pathways 675,680,681. As mentioned in Chapter 1, AKT signaling
activates FOXO transcription factors that subsequently inhibit cyclin D1 expression and
promote the cell cycle regulators p27kip1 and p130Rb2 259. When phosphorylated by AKT,
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FOXO is inactive and supports cyclin D1 expression while inhibiting expression of cell cycle
inhibitors. One specific FOXO, FOXO3a, is the only transcription factor to date shown to
regulate PINK1 during nutrient deprivation or chemotherapeutic stress, promoting cell
survival 683. FOXO3a can also promote production of MMPs in support of tumorigenesis and
invasiveness 684; signaling during early mammary development also heavily relies on MMPs
for expansion of the gland, suggesting in our model, PINK and FOXOs could collaborate to
regulate gland expansion through MMP production. It is hypothesized that PINK1 may be
activated by FOXO3a under nutrient deprivation as a form of short-term protection so that
when stress if lifted, the system is ready to resume PI3K/AKT signaling 675. Additionally,
PINK1 loss increases the susceptibility of cells to DNA damage 685, and in parallel with the
major functional links of this gene and PI3K/AKT signaling needed for growth and survival,
it can be hypothesized that PINK1 protects actively proliferating cells during early mammary
development. PINK1, mitochondrial homeostasis, and cancer has been reviewed in depth by
O’Flanagan et al 675, who showed that PINK1 is critical for cell cycle progression, G2/M and
G0/G1 checkpoints, cell division, growth, and stress resistance in cancer 686. Importantly,
PINK1 presents a tissue specific location in epithelial tissues 687, suggesting it probably
functions to protect and regulate mammary epithelial cells in the postnatal mammary gland.
This data confirms PINK1 highly contributes as a positive PRC gene to mammary growth in
the first two months after birth and suggests PINK1 is localized in mammary epithelial cells
where it plays similar roles in stress resistance reported in the literature.
Another protective gene that positively contributes to developmental trends in the
model is DDIT3. DDIT3, DNA damage induced transcript 3, encodes a regulator of the
cellular stress response and is induced upon DNA damage, ER stress, hypoxia, and
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starvation, triggering either apoptosis or cell cycle arrest 472,688–708. DDIT3 is also involved in
differentiation and specialization of varied tissue and cell types 709–713 and is versatile; it can
be expressed either in the cytoplasm or nucleus with distinct functions 688,714. Nuclear DDIT3
controls cellular growth and can induce G1 cell cycle arrest if needed 715 while cytoplasmic
DDIT3 mainly inhibits migration 716. Pursuant to our developmental model, DDIT3 is
expressed during early embryogenesis 717 and functions as a protective Wnt repressor,
inhibiting Wnt/T-cell factor (TCF) signaling 718. It also plays a role in accumulation and
immune system regulation of tumor suppressor cells derived from myeloid cells 719. DDIT3
expression can block T cell responses 719, suggesting involvement in tumor-induced tolerance
and resistance to immunotherapy. Our data suggest it has a significant, although complicated
and unelucidated, role in early postnatal mammary development.
Positive PRC genes also fall into another prominent functional group with interesting
roles in cell adhesion, adherens junctions, and cellular migration. In Chapter one, it is
described how through basally located integrin molecules and laminins, direct attachment of
mammary epithelial cells to the ECM can occur 138,139. Laminin-binding integrin molecules
commonly are found in focal adhesions (FAs) and HDs, which are two adhesion complexes
that form mechanical links between the ECM and the actomyosin cytoskeleton 140. Linking
the ECM and the cytoskeleton is critical in regulation of a variety of processes, including
proliferation and differentiation, and multiple supporting genes are found in the top 25
positive PRC dataset. With a significant weight, DOCK4, Dedicator of cytokinesis protein 4
is detected in our early mammary development model. This gene encodes a membraneassociated, cytoplasmic protein that activates Rap GTPase in order to regulate formation of
adherens junctions between cells and also functions in cell migration 720–724. In MDA-MB-
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231 TNBC cells, DOCK4 interacts with SH3 and SYLF domain containing protein 1
(SH3YL1) to promote cancer cell migration 720. L1CAM, neural cell adhesion molecule L1,
also encodes a cell adhesion protein with both a functional role in cell migration and nervous
system development through axonin binding 472,725 and a metastatic role in the progression of
human tumors 726. L1CAM can bind homophilically to itself or heterophilically to other cell
adhesion molecules or integrin molecules 727, leading to two disparate functions: static, acting
as an adhesion molecule between cells (normally in neural settings), and motile, promoting
cell migration 728,729. The functional switch occurs when the L1CAM ectodomain is cleaved
and free to bind integrin molecules 730. This subsequently promotes cell migration 731,732,
resistance to apoptosis 733–735, and angiogenesis 736. Recently, studies have shown that
L1CAM cleaved by MMPs can heterophilically bind to integrin molecules 737–740 and activate
signaling pathways including PI3K, Rac-1, and ERK 730,741–744. Taken together, several recent
studies suggest that L1CAM/integrin signaling can converge with growth factor signaling
pathways, activate conventional ERK/PI3K signaling, and promote growth and development
728,729

. LICAM’s presence as a top 25 positive PRC gene demonstrates potential for a similar

function in postnatal mammary development. L1CAM is also important in human cancers,
appearing overexpressed in ovarian and endometrial carcinoma (EC), pancreatic ductal
adenocarcinoma (PDAC), melanoma, and glioblastoma where it is associated with poor
prognosis through a highly motile and invasive phenotype (reviewed 745). As an oncogene,
L1CAM expression can induce constitutive activation of NFκB activation through IL-1β
746,747

. Interestingly, it can also indicate and promote EMT transition at the primary tumor

site; mesenchymal tumor cell phenotypes exude high levels of vimentin, SLUG and L1CAM
733,748

. L1CAM expression in human breast cancer cell lines results in disruption adherens
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junctions, increased β-catenin transcription, and high motility at the leading edge of cell
monolayers 748–750 while L1CAM knockdown significantly decreases cell motility 748,
suggesting this gene is an EMT trigger in epithelial cells. In Chapter one, it was presented
how the ECM and stroma, including growth factors, cytokines and proteinases within these
niches, have long been known for morphogenesis 72. Not only are ECM-cell interactions,
adherens junction regulation, EMT, and cell migration essential for development of a
functional mammary gland 7,73, these also play important roles in breast cancer development
(reviewed by 74–78. Current research indicates branching morphogenesis of the mammary
gland is controlled by interacting epithelial and mesenchymal cell populations, and cellcell/cell-matrix adhesions, but that this crosstalk is not comprehensively understood 79. Our
presentation and characterization of positively influencing PRC genes in development, such
as L1CAM, suggest previously unrealized potential roles for these molecules in postnatal
mammary development. Taken together, the studies discussed above illustrate a relationship
between immune cell activation, the ECM, TME, integrin molecules, cell migration, and
L1CAM. If LICAM can induce IL-1B secretion by immune cells, it could promote
tumorigenicity and/or inflammation. A review of the literature combined with this novel
transcriptomic data confirming that L1CAM is one of the highest weighted genes impacting
the PRC curve suggests this gene is functioning in early postnatal mammary development in
conjunction with integrin molecules and laminins to promote mammary organogenesis.
FRMD4A, FERM domain-containing 4A (FRMD4A), is a human epidermal stem
cell marker 751 encoding a protein that regulates epithelial cell polarity 752. FRMD4A belongs
to the Four-point-one, Ezrin, Radixin, Moesin (FERM) superfamily, whose members all
contain a FERM domain 753–755. FERM domains have been shown to possess functional roles
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in cytoskeleton organization and structure, tissue development, maintenance of cell
morphology, cell signaling, and tumor cell migration 754,756–760. Specifically, FRMD4A has
been shown to control cytoskeleton protein expression and mediate the assembly of adherens
junctions between mammary epithelial cells, essential to tissue morphogenesis, through the
activation of a central player in actin cytoskeleton dynamics: ADP ribosylation factor 6
(Arf6) 752. FRMD4A has also been found upregulated in squamous cell carcinoma (SCC)
cells, especially head and neck squamous cell carcinoma (HNSCC) 751, and rectal cancer 761,
while FRMD4A silencing in vitro stimulates caspase activity and expression of terminal
differentiation markers 762. This data shows significant impact on mammary development
through FRMD4A signaling, suggesting this gene potentially supports organization of the
cytoskeleton and maintenance of mammary tissue morphology.
STARD8, START domain protein 8, also known as deleted in liver cancer 3 (DLC3), encodes a member of the Rho GTPase protein family 763. This protein is widely expressed
in normal tissues but downregulated or absent in various cancers including breast cancer 764,
suggesting it functions as a tumor suppressor. Importantly, STARD8 protein localizes to
adherens junctions and is essential for E-cadherin function and maintaining epithelial cell–
cell contacts; deletion leads to leads to mislocalization of E-cadherin and disruption of
adherens junctions and catenin molecules, impaired cell aggregation, and increased migration
763,765,766

. STARD8/DCL3 is best characterized as a novel negative regulator of Rho signaling

that can promote carcinogenesis by compromising epithelial cell integrity 763. Taken together
with the data showing STARD8 positively contributes to early postnatal mammary
development, it may function through potential maintenance/protection of mammary
epithelial cell integrity.
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LIMS2, LIM Zinc Finger Domain Containing 2, also more commonly known as
PINCH2 (Particularly Interesting New Cys-His Protein 2) 767, is an important focal adhesion
and/or nuclear protein which interacts with ILK (integrin-linked kinase) to mediate
extracellular matrix adhesions 767. Importantly, LIMS2 can link integrin molecules to the
actin cytoskeleton, activate Rac signaling, and create connections to cell surface RTKs and
growth factor receptors, and promote mammary epithelial cell differentiation and migration
768–771

. Zhang et al characterized LIMS2/PINCH-2 in depth and novelly demonstrated that:

PINCH-2 is co-expressed with PINCH-1 (another member of the PINCH family) in a variety
of human cells; PINCH-2 localizes to both cell-ECM contact sites and the nucleus; PINCH-2
forms a complex with ILK in mammalian cells; the PINCH-2 LIM1 domain, which mediates
the association with ILK, is required for the localization of PINCH-2 to cell-ECM contact
sites; overexpression of PINCH-2 inhibits the PINCH-1-ILK interaction and reduces cell
spreading and migration 767. Taken together with the PRC analysis and denotation of this
gene as highly positive, a potential role is suggested for PINCH-2/LIMS2 in postnatal
mammary epithelial cell differentiation, migration, and adhesion.
Lesser characterized genes that are still significant in development are UBXN1 and
SOX13. UBXN1, UBX domain-containing protein 1, is a ubiquitin-binding protein that
recognizes autoubiquinated BRCA1 772. As covered in Chapter 1, one of the most important
and well known mutations of TNBC and basal-like breast cancer is that of the
BRCA1/BRCA2 genes and associated pathways 228–230. E3 ligase activity of the BRCA1
complex is dramatically reduced in the presence of UBXN1, suggesting that UBXN1
regulates the enzymatic function of BRCA1 772. UBXN1 is also a negative regulator of NFkB
activity 773, but most of the mechanism of its function remains to be elucidated. Our data
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suggest it highly contributes to normal mammary development, possibly as a tumor
suppressor or regulatory element. Only just characterized in 2013, the novel F-box and
WD40 containing protein, FBXW4, is part of a ubiquitin ligase complex with SKP1–cullin
1–F-box protein (SCF), highly expressed in mammary gland involution, and may function as
a novel tumor suppressor that regulates developmental processes and maintains normal cell
growth 774. F-Box proteins (FBPs) are responsible for ubiquitination of proteins with varied
cellular function and can also regulate the expression and activity of oncogenes and tumor
suppressor genes 775. However, very little is known regarding the function of FBXW4 in
general 774, especially in mammary development; a better understanding is needed for how
this gene may regulate critical cell signaling pathways. This data suggests it highly
contributes to normal mammary development, possibly as a tumor suppressor or regulatory
element.
Taken together, PRC analysis (Tables 7-9; Fig. 9) indicated that development and
maturation of the mammary gland during the first 39 days after birth heavily relies on the
immune system, immune components, integrin molecules, and the ECM, utilizing genes
known to function in development and previously uncharacterized, novel genes that are also
likely to function as oncogenes or proto-oncogenes. This novel data also confirms the trends
seen in phase one vs. phase two genes from DFA; positive PRC genes have similar functions
to phase two DFA genes and represent more refined, advanced growth and differentiation
rather than a spurt of initial unregulated growth immediately after birth. Additionally, many
positive PRC genes have reported links with adherens junctions, cellular migration, the ECM,
and apoptosis, indicating the contribution of stromal and extracellular factors in
differentiation that were not seen in phase one DFA. As seen in Table 8, the hypothesis has
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been confirmed that phase two and positive PRC genes represent refined development and
differentiation, while phase one and negative PRC genes function for generic biosynthesis
and growth.

Table 7: PRC positive weights
Ranking
1

PRC Weight
0.51559019

Gene ID
SLA-DOA

2

0.515449036

PINK1

3

0.495199325

EFCC1

4

0.489631223

SNAPIN

5

0.461953857

DOCK4

6

0.454108222

ZNF613

7

0.443115828

GALNT15

8

0.422306462

L1CAM

9

0.416458647

FRMD4A

10

0.412167164

STARD8

11

0.410868587

ZNF174

12

0.404149309

PDE2A

13

0.393960511

VLDLR

14

0.391076702

MPND

15

0.381996691

SOX13

16

0.381912433

LIMS2

Family/Subfamily
HLA CLASS II HISTOCOMPATIBILITY
ANTIGEN, DO Α CHAIN (PTHR19944:SF67)
SERINE/THREONINE-PROTEIN KINASE
PINK1, MITOCHONDRIAL
(PTHR22972:SF11)
EF-HAND AND COILED-COIL DOMAINCONTAINING PROTEIN 1-RELATED
(PTHR11595:SF36)
SNARE-ASSOCIATED PROTEIN SNAPIN
(PTHR31305:SF3)
DEDICATOR OF CYTOKINESIS PROTEIN 4
(PTHR23317:SF89)
ZINC FINGER PROTEIN 613
(PTHR24404:SF49)
POLYPEPTIDE NACETYLGALACTOSAMINYLTRANSFERA
SE 15 (PTHR11675:SF77)
NEURAL CELL ADHESION MOLECULE L1
(PTHR10489:SF812)
FERM DOMAIN-CONTAINING PROTEIN
4A (PTHR23281:SF29)
STAR-RELATED LIPID TRANSFER
PROTEIN 8 (PTHR12659:SF11)
ZINC FINGER PROTEIN 174
(PTHR10032:SF270)
3',5'-CYCLIC PHOSPHODIESTERASE PDE2-RELATED (PTHR11347:SF164)
VERY LOW-DENSITY LIPOPROTEIN
RECEPTOR (PTHR10529:SF318)
MPN DOMAIN-CONTAINING PROTEIN
(PTHR12802:SF80)
TRANSCRIPTION FACTOR SOX-13
(PTHR10270:SF273)
LIM AND SENESCENT CELL ANTIGENLIKE-CONTAINING DOMAIN PROTEIN 2
(PTHR24210:SF13)
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17

0.381038717

UBXN1

18

0.380960327

DDIT3

19

0.380488353

TRIM3

20

0.379222784

FBXW4

21

0.379074354

HGF

22

0.378892532

DMAP1

23

0.377950717

TRAF3

24

0.367656669

25

0.363138248

LOC1065063
16
LHX6

26

0.356873254

RGS18

27

0.356526442

CTIF

28

0.356237482

29

0.354164393

LOC1007391
21
C1QTNF9

30
31
32

0.352729291
0.352600564
0.350038204

GNLY
PPFIA1
RNF31

33
34

0.349655753
0.349297781

FLI1
A4GALT

35

0.347687199

CCDC28A

36

0.347099383

GPANK1

37

0.346498169

CCDC130

38

0.341624683

CEP95

39
40

0.341619986
0.341569075

CTSF
LOC1065050

UBX DOMAIN-CONTAINING PROTEIN 1
(PTHR13020:SF47)
DNA DAMAGE-INDUCIBLE TRANSCRIPT
3 PROTEIN (PTHR16833:SF1)
TRIPARTITE MOTIF-CONTAINING
PROTEIN 3 (PTHR24103:SF458)
F-BOX/WD REPEAT-CONTAINING
PROTEIN 4 (PTHR14381:SF2)
HEPATOCYTE GROWTH FACTOR
(PTHR24256:SF291)
DNA METHYLTRANSFERASE 1ASSOCIATED PROTEIN 1
(PTHR12855:SF11)
TNF RECEPTOR-ASSOCIATED FACTOR 3
(PTHR10131:SF96)

LIM/HOMEOBOX PROTEIN LHX6
(PTHR24208:SF148)
REGULATOR OF G-PROTEIN SIGNALING
18 (PTHR10845:SF226)
CBP80/20-DEPENDENT TRANSLATION
INITIATION FACTOR (PTHR23254:SF18)

COMPLEMENT C1Q AND TUMOR
NECROSIS FACTOR-RELATED PROTEIN
9A-RELATED (PTHR24023:SF654)
GRANULYSIN (PTHR15541:SF3)
LIPRIN-Α-1 (PTHR12587:SF27)
E3 UBIQUITIN-PROTEIN LIGASE RNF31
(PTHR16004:SF6)
LACTOSYLCERAMIDE 4-ΑGALACTOSYLTRANSFERASE
(PTHR12042:SF27)
COILED-COIL DOMAIN-CONTAINING
PROTEIN 28A (PTHR13400:SF5)
G PATCH DOMAIN AND ANKYRIN
REPEAT-CONTAINING PROTEIN 1
(PTHR20923:SF2)
COILED-COIL DOMAIN-CONTAINING
PROTEIN 130 (PTHR12111:SF5)
CENTROSOMAL PROTEIN OF 95 KDA
(PTHR22545:SF1)
CATHEPSIN F (PTHR12411:SF425)
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41
42

0.337943464
0.337929917

43
HMCN2
MID2

43

0.336405962

ABLIM3

44

0.334111451

CUX1

45

0.333882104

TCTP

46

0.333209584

KCNB1

47

0.332306307

PTPRM

48

0.331268784

CUX1

49

0.33121179

50

0.329721287

PBLD

51

0.328474016

FADS3

ANKRD24

HEMICENTIN-2 (PTHR10489:SF755)
E3 UBIQUITIN-PROTEIN LIGASE MID2RELATED (PTHR24103:SF450)
ACTIN-BINDING LIM PROTEIN 3
(PTHR24213:SF24)
HOMEOBOX PROTEIN CUT-LIKE 1
(PTHR14043:SF18)
TRANSLATIONALLY-CONTROLLED
TUMOR PROTEIN (PTHR11991:SF7)
POTASSIUM VOLTAGE-GATED CHANNEL
SUBFAMILY B MEMBER 1
(PTHR11537:SF177)
RECEPTOR-TYPE TYROSINE-PROTEIN
PHOSPHATASE MU (PTHR19134:SF391)
HOMEOBOX PROTEIN CUT-LIKE 1
(PTHR14043:SF18)
ANKYRIN REPEAT DOMAIN-CONTAINING
PROTEIN 24 (PTHR24173:SF53)
PHENAZINE BIOSYNTHESIS-LIKE
DOMAIN-CONTAINING PROTEIN
(PTHR13774:SF23)
FATTY ACID DESATURASE 3
(PTHR19353:SF39)

Table 8: PRC negative weights
Ranking
1

PRC Weight
-0.755312569

Gene ID
CENPU

2
3

-0.687764094
-0.678439898

TIMM8A
CCNE2

4
5

-0.650314355
-0.646226192

NPM3
MYBL2

6

-0.642932862

RNFT1

7

-0.630912134

TTC27

8

-0.629593806

GAR1

9

-0.628766562

DONSON

10

-0.626469029

RFC4

Family/Subfamily
CENTROMERE PROTEIN U
(PTHR32222:SF2)
G1/S-SPECIFIC CYCLIN-E2
(PTHR10177:SF330)
NUCLEOPLASMIN-3 (PTHR22747:SF24)
MYB-RELATED PROTEIN B
(PTHR10641:SF744)
RING FINGER AND TRANSMEMBRANE
DOMAIN-CONTAINING PROTEIN 1
(PTHR15860:SF10)
TETRATRICOPEPTIDE REPEAT PROTEIN
27 (PTHR16193:SF1)
H/ACA RIBONUCLEOPROTEIN
COMPLEX SUBUNIT 1 (PTHR23237:SF9)
PROTEIN DOWNSTREAM NEIGHBOR OF
SON (PTHR12972:SF1)
REPLICATION FACTOR C SUBUNIT 4
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11

-0.61727193

CCNE1

12
13
14

-0.612904564
-0.609914388
-0.608331544

NEDD1
CIT
WDR12

15

-0.606545954

DESI1

16

-0.601177154

NUDCD2

17
18

-0.598877627
-0.595805113

FAM64A
GALE

19

-0.593420751

ABT1

20

-0.59256649

21

-0.592304891

CDKN2C

22
23

-0.586226873
-0.583969995

LOC102167061
PRELID3B

24
25

-0.581429846
-0.578118522

CTPS1
DOHH

26

-0.576783145

ERCC6L

27

-0.572198441

CENPK

28
29

-0.571350974
-0.56764138

DUSP11
ALG8

30

-0.56630587

MTHFD2

31

-0.565106896

WDR74

32

-0.562372872

RABGGTB

33

-0.560353639

MPHOSPH6

34

-0.559254552

RNFT1

KCNE5

(PTHR11669:SF30)
G1/S-SPECIFIC CYCLIN-E1
(PTHR10177:SF288)
PROTEIN NEDD1 (PTHR22847:SF508)
RIBOSOME BIOGENESIS PROTEIN
WDR12 (PTHR19855:SF13)
DESUMOYLATING ISOPEPTIDASE 1
(PTHR12378:SF23)
NUDC DOMAIN-CONTAINING PROTEIN
2 (PTHR12356:SF22)
PROTEIN FAM64A (PTHR35819:SF2)
UDP-GLUCOSE 4-EPIMERASE
(PTHR43725:SF5)
ACTIVATOR OF BASAL
TRANSCRIPTION 1 (PTHR12311:SF8)
POTASSIUM VOLTAGE-GATED
CHANNEL SUBFAMILY E REGULATORY
Β SUBUNIT 5 (PTHR15282:SF14)
CYCLIN-DEPENDENT KINASE 4
INHIBITOR C (PTHR24148:SF54)
PROTEIN SLOWMO HOMOLOG 2
(PTHR11158:SF37)
CTP SYNTHASE 1 (PTHR11550:SF16)
DEOXYHYPUSINE HYDROXYLASE
(PTHR12697:SF23)
DNA EXCISION REPAIR PROTEIN ERCC6-LIKE (PTHR10799:SF911)
CENTROMERE PROTEIN K
(PTHR14401:SF7)
DOLICHYL PYROPHOSPHATE
GLC1MAN9GLCNAC2 Α-1,3GLUCOSYLTRANSFERASE-RELATED
(PTHR12413:SF3)
BIFUNCTIONAL
METHYLENETETRAHYDROFOLATE
DEHYDROGENASE/CYCLOHYDROLASE,
MITOCHONDRIAL (PTHR10025:SF48)
WD REPEAT-CONTAINING PROTEIN 74
(PTHR16038:SF5)
GERANYLGERANYL TRANSFERASE
TYPE-2 SUBUNIT Β (PTHR11774:SF13)
M-PHASE PHOSPHOPROTEIN 6
(PTHR13582:SF1)
RING FINGER AND TRANSMEMBRANE
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35

-0.557948831

RRP8

36

-0.551866159

PRELID3B

37

-0.549404483

BUB1

38

-0.548547924

CYP26B1

39
40

-0.546993466
-0.545884312

BCHE
MPLKIP

41
42

-0.545783381
-0.545548898

LOC106509864
INCENP

43

-0.54113617

44

-0.540628807

NQO1

45

-0.537488756

CSRNP1

46

-0.536682609

ANP32A

47

-0.536194601

UBE2T

48

-0.535012107

ADAMTS4

49

-0.533396073

AMD1

50

-0.531299615

C2H11orf31

MINPP1

DOMAIN-CONTAINING PROTEIN 1
(PTHR15860:SF10)
RIBOSOMAL RNA-PROCESSING
PROTEIN 8 (PTHR12787:SF1)
PROTEIN SLOWMO HOMOLOG 2
(PTHR11158:SF37)
MITOTIC CHECKPOINT
SERINE/THREONINE-PROTEIN KINASE
BUB1 (PTHR14030:SF10)
CYTOCHROME P450 26B1
(PTHR24286:SF101)
CHOLINESTERASE (PTHR11559:SF337)
M-PHASE-SPECIFIC PLK1-INTERACTING
PROTEIN (PTHR22446:SF4)
INNER CENTROMERE PROTEIN
(PTHR13142:SF2)
MULTIPLE INOSITOL POLYPHOSPHATE
PHOSPHATASE 1 (PTHR20963:SF31)
NAD(P)H DEHYDROGENASE [QUINONE]
1 (PTHR10204:SF49)
CYSTEINE/SERINE-RICH NUCLEAR
PROTEIN 1 (PTHR13580:SF16)
ACIDIC LEUCINE-RICH NUCLEAR
PHOSPHOPROTEIN 32 FAMILY MEMBER
A-RELATED (PTHR11375:SF9)
UBIQUITIN-CONJUGATING ENZYME E2
T (PTHR24067:SF205)
A DISINTEGRIN AND
METALLOPROTEINASE WITH
THROMBOSPONDIN MOTIFS 4
(PTHR13723:SF205)
S-ADENOSYLMETHIONINE
DECARBOXYLASE PROENZYME
(PTHR11570:SF8)

Table 9: Summary of PRC trends

Trend
Top 50

Negative weight (red)
Decrease with curve
abundance
CENPU
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Positive weight (green)
Increase with curve
abundance
SLA-DOA

genes by
weight

TIMM8A
CCNE2
NPM3
MYBL2
RNFT1
TTC27
GAR1
DONSON
RFC4
CCNE1
NEDD1
CIT
WDR12
DESI1
NUDCD2
FAM64A
GALE
ABT1
KCNE5
CDKN2C
LOC102167061
PRELID3B
CTPS1
DOHH
ERCC6L
CENPK
DUSP11
ALG8
MTHFD2
WDR74
RABGGTB
MPHOSPH6
RNFT1
RRP8
PRELID3B
BUB1
CYP26B1

PINK1
EFCC1
SNAPIN
DOCK4
ZNF613
GALNT15
L1CAM
FRMD4A
STARD8
ZNF174
PDE2A
VLDLR
MPND
SOX13
LIMS2
UBXN1
DDIT3
TRIM3
FBXW4
HGF
DMAP1
TRAF3
LOC106506316
LHX6
RGS18
CTIF
LOC100739121
C1QTNF9
GNLY
PPFIA1
RNF31
FLI1
A4GALT
CCDC28A
GPANK1
CCDC130
CEP95
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BCHE
MPLKIP
LOC106509864
INCENP
MINPP1
NQO1
CSRNP1
ANP32A
UBE2T
ADAMTS4
AMD1
C2H11orf31
CDCA4
Hypothesis These are phase one
genes (very early
genes)
Top
Cell Cycle, Mitotic
pathways Cell Cycle
in
Metabolism
Reactome
Metabolism of proteins
Signal Transduction
RHO GTPase Effectors
Signaling by Rho
GTPases
Gene expression
(Transcription)
Generic Transcription
Pathway

Biological
functions
manually
curated
from
literature

Organelle biosynthesis
Transcription and gene
expression
Cell control: cycle,
division, survival
RNA binding and
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CTSF
LOC106505043
HMCN2
MID2
ABLIM3
CUX1
TCTP
KCNB1
PTPRM
CUX1
ANKRD24
PBLD
FADS3
These are phase two genes;
developmental genes
Immune System
Metabolism of proteins
Signal Transduction
Adaptive Immune System
Cytokine Signaling in
Immune system
Post-translational protein
modification
Axon guidance
Hemostasis
Developmental Biology
Interleukin-4 and 13
signaling
Signaling by Interleukins
Innate immune system
Immune function
Stem cell signaling
Antigen presentation, stress
protection, inflammation
Apoptosis and transcriptional

processing
DNA elongation and
amplification
CDK interactions

Oncogene
function

22% are potential
oncogenes

repression
Organelle biogenesis, cell
fate regulation
Integrin signaling- NFkB,
Wnt, MAPK, AKT pathways
Migration/adhesion/epithelial
and mesenchymal cell
polarity and morphology
Focal adhesions, adherens
junctions, and ECM
Cell spreading
65% are potential
oncogenes

Top
oncogenes

CCNE2

PINK1

MYBL2
RFC4
CCNE1
CDKN2C
BUB1
NQO1
ANP32A
UBE2T
ADAMTS4
AMD1

DOCK4
L1CAM
FRMD4A
STARD8
TRIM3
HGF
TRAF3
LHX6
PPFIA1
RNF31
FLI1
CTSF
CUX1
TCTP
PTPRM
SLA-DOA
SNAPIN
PDE2A
VLDLR
SOX13
LIMS2
UBXN1
DDIT3
FBXW4

Molecular chaperoning
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DMAP1
C1QTNF9
CCDC28A
HMCN2
MID2
KCNB1
PBLD

WGCNA demonstrates functional modules in early mammary gland development
Weighted Gene Co-Expression Network Analysis visualized the clustered
connectivity of the top 5000 genes, by variance, with a similar expression pattern, resulting in
functional modules which will be further explained in a pathway analysis (see Fig. 10). The
diagonal line represents the autocorrelation between the gene to itself, resulting in a
correlation value of 1 (perfect correlation). The distinct boxes that form around the diagonal
line represent the functional modules that contain highly interconnected genes, by
correlation, to other genes within the same module. Modules farther away from the diagonal
represent inter-module relationships (connected pathways, or one pathway regulating
another). Weighting has been used to adjust the correlation matrix such that only the
strongest of correlations are depicted. Systems biology approaches can be applied to the
RNA-seq data sets to identify groups of genes that are highly correlated (in this case, over
time) to form functional modules; WGCNA exists as a popular method to do so since its
introduction in 2005.The WGCNA method assumes that genes that are co-expressed with
similar variances over time are present in the same subsystem and is appropriate for use here
776–780

. The gene co-expression network (GCN) shown in Fig. 10 visually expresses these
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Figure 10: WGCNA demonstrates functional modules in early mammary gland
development. Heatmap plot of the top 5000 genes by variance; diagonal line
represents the autocorrelation between the gene to itself; distinct boxes around
diagonal line represent functional modules that contain highly interconnected
genes, by correlation, to other genes within the same module.

subsystems that were clustered based on co-variation within groups of genes (across
all 17 samples). GCN can be used to simulate functional significance for groups of genes;
tightly correlated gene groups can be thought of as one functional unit and related to
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phenotype 781. This pipeline has been used recently to: generate functional conclusions about
signaling pathways underlying familial breast cancer susceptibility 782, identify prognostic
biomarkers tumor state based on stromal gene expression 788, and identify modular
heterogeneity of breast cancer subtypes 789. Based on a review of literature wherein WGCNA
methods were applied to RNA-seq datasets, we concluded this method can be used in our
study to identify highly correlated groups of genes with functional roles in early
postnatal/prepubertal mammary gland development. Fig. 10 confirms the hypothesis that
there are genuine functional modules (shown in red/orange) present within the overall RNAseq dataset generated from samples collected during pre-pubertal mammary gland
development. These functional modules can be further dissected using the MCODE
algorithm and pathway analysis.

MCODE algorithm identifies highly correlated gene networks within RNA-seq dataset.

MCODE, shown in Fig. 11, shows functional modules that have been isolated from
WGCNA and filtered to exclude weak relationships. The ten highest weighted network
modules are shown in Fig. 12 and summarized in Table 10. These modules can be further
characterized using functional and pathway analysis to determine biological significance in
early postnatal mammary development.
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After suspected functional modules were identified in Fig. 10, the MCODE algorithm
was used as a Cytoscape 429,790 plug-in to find highly interconnected molecular clusters and
remove those with low connectivity from the original plot using the random matrix theory 791.
MCODE identifies densely connected nodes to graphically display both nodules and

Figure 11: MCODE algorithm identifies highly correlated gene networks within
mammary transcriptome dataset.
associated weights, which can be used to sort the relationships 792, and is commonly used in
cancer biology. The genes contributing to each functional module can be extracted as a base
for pathway analysis and biological interpretation. Although utilized frequently in the past
year to identify biomarkers in colorectal cancer 793 and head and neck squamous cell
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carcinoma 794, as well as attempt to isolate biomarkers and gene networks involved in breast
cancer 795–797, to our knowledge, MCODE has not yet been applied to developmental
mammary biology.

Functional annotation of MCODE clusters demonstrates biological significance
After MCODE identified densely connected nodes to graphically display both
nodules and associated weights (Fig. 11), which can be used to sort the relationships 792, the
genes contributing to each functional module were extracted for pathway analysis and
biological interpretation. The top ten network modules, sorted by weight, are shown below.

Table 10. Functional roles of top ten network modules

Cluster
1

Score
26.25

2

7.684

3

7.417

4

6

5

5.667

6

5.6

7

5.2

8

4.75

9

4.286

10

4

Function
1. Striated muscle contraction and actin cytoskeleton integrity. Focused
around the activity of titin (TTN). Most factors can be found in different
domains of muscle. Two oncogenes: TTN and EEFIA. Largest cluster. Can put
together good signaling pathway of interactions in muscle
development/contraction.
2. Oncogenic cluster. Adopogenesis, adipocyte metabolism, immune
function, and metabolic alterations in cancer. Involves
AKT/Laminin/FOXO/apoptosis. FAH has a functional link with BRCA. >50%
genes in network are oncogenes. Need to design own pathway of normal vs
oncogenic interactions. Tissue co-expression could be important in the story
here. Interesting interaction with the innate immune system (see Cluster 2 tab).
3. Lipid and protein metabolism + cell cycle control. Common protein
interaction: UBC. Definitely an oncogenic cluster.
4. Keratinocyte differentiation during development. Epithelial markers. Not
very oncogenic. Could play a role in melanoma and HPV.
5. Keratinization and differentiation; oncogenic cluster. Contains markers
for breast cancer among other types. Specifically contains markers for basal
breast cancer and EMT.
6. Muscle contraction. Low oncogenic potential, except a couple genes
interact with BRCA1/BRCA2.
7. Muscle contraction/actin binding + calcium signaling. Low oncogenic
potential.
8. Protein modification + cell-cell adhesion. Seems to have a neuronal
connection. Mixed bag of genes; >50% of them are oncogenes. Potential
oncogenic cluster with some laminin/integrin interactions.
9. Muscle contraction and actin binding. Low oncogenic potential; contains
several repeats from other clusters.
10. Metabolism. Genes do not interact clearly with eachother. Some immune
factors, muscle factors. Low oncogenic potential.
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Table 10 shows functional roles based on review of literature, Panther characterization, and
Reactome pathway analysis for the top ten modules. Functional annotation and visualization
of network interaction are shown in Fig. 12. Detailed functional analysis is shown in Tables
11-12. The overall network connectivity coefficient indicates the strength of interaction
between individual genes in each module, demonstrating novel interactions of genes
contributing to early postnatal mammary developmental trends.
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Figure 12. Functional annotation of MCODE clusters. The overall
network connectivity coefficient indicates the strength of interaction
between individual genes in each module, demonstrating novel
interactions of genes contributing to early postnatal mammary
developmental trends
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Table 11: Reactome pathway summary
Cluster
1

2

3

4

5

6
7

8

Weight Top Pathways
26.25
Muscle contraction
Striated Muscle Contraction
Metabolism
7.684
Metabolism
Immune System
Innate Immune System
Neutrophil degranulation
7.417
Metabolism
Post-translational protein
modification
Metabolism of proteins
Sphingolipid metabolism
Metabolism of lipids
Developmental Biology
Signal Transduction
6
Developmental Biology
Formation of the cornified
envelope
Keratinization
FGFR1 mutant receptor
activation
Signaling by FGFR1 in
disease
Signaling by FGFR in disease
5.667
Keratinization
Formation of the cornified
envelope
Developmental Biology
Type I hemidesmosome
assembly
Cell junction organization
Cell-Cell communication
5.6
Muscle contraction
Striated Muscle Contraction
5.2
Muscle contraction
Cardiac conduction
Metabolism
Striated Muscle Contraction
4.75
RHO GTPases Activate
ROCKs
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Function
Striated muscle contraction and
actin cytoskeleton integrity.
Adopogenesis, adipocyte
metabolism, immune function, and
metabolic alterations in cancer.
Lipid and protein metabolism +
cell cycle control.

Keratinocyte differentiation during
development.

Keratinization and differentiation

Muscle contraction
Muscle contraction/actin binding
+ calcium signaling

Protein modification + cell-cell
adhesion

9

4.286

10

4

Receptor protein tyrosine
phosphatases interactions
Sema4D induced cell
migration and growth-cone
collapse
Sema4D in semaphorin
signaling
SALM protein interactions at
the synapses
Muscle contraction
Ion homeostasis
Translocation of GLUT4 to
the plasma membrane
Cardiac conduction
Striated Muscle Contraction
Synthesis of pyrophosphates
in the cytosol
mRNA Editing: C to U
Conversion
Formation of the Editosome
mRNA Editing
HSF1 activation

Muscle contraction and actin
binding

Metabolism

Table 12: Gene families contained in each module (cluster)
Gene ID
ACTA1

Cluste
r
1

AMPD1

1

APOBEC2

1

ATP2A1

1

C14H10orf71

1

Gene Name, Gene Symbol,
Ortholog
Actin, α skeletal
muscle;ACTA1;ortholog
Adenosine monophosphate
deaminase 1 isoform
M;AMPD1;ortholog
Probable C-U-editing enzyme
APOBEC2;APOBEC2;ortholog;
Apolipoprotein B MRNA
Editing Enzyme Catalytic
Subunit 2
Calcium-transporting
ATPase;ATP2A1;ortholog
chromosome 14 open reading
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Family/Subfamily
ACTIN, Α SKELETAL
MUSCLE (PTHR11937:SF348)
AMP DEAMINASE 1
(PTHR11359:SF10)
C-U-EDITING ENZYME
APOBEC-2-RELATED
(PTHR13857:SF34)

SARCOPLASMIC/ENDOPLA
SMIC RETICULUM
CALCIUM ATPASE 1
(PTHR42861:SF17)

frame, human C10orf71
Calpain-3;CAPN3;ortholog

CAPN3

1

CARNS1

1

CASQ1

1

CKM

1

DHRS7C

1

EEF1A1

1

ENO3

1

LOC1005177
59

1

LOC1021641
59

1

Uncharacterized protein
(Fragment);LOC100517759;or
tholog; likely myomegalin
LOC102164159

MB

1

Myoglobin;MB;ortholog

MYBPC1

1

Uncharacterized
protein;MYBPC1;ortholog

MYBPC2

1

Uncharacterized
protein;MYBPC2;ortholog

MYH1

1

Myosin-1;MYH1;ortholog

MYOM2

1

MYOT

1

MYOZ1

1

Uncharacterized protein
(Fragment);MYOM2;ortholog
Uncharacterized
protein;MYOT;ortholog
Myozenin-1;MYOZ1;ortholog

NEB
NT5C1A

1
1

Nebulin;NEB;ortholog
Uncharacterized protein
(Fragment);NT5C1A;ortholog

PDE4DIP

1

Uncharacterized
protein;PDE4DIP;ortholog

Uncharacterized protein
(Fragment);CARNS1;ortholog
Calsequestrin;CASQ1;ortholog
Creatine kinase Mtype;CKM;ortholog
Uncharacterized
protein;DHRS7C;ortholog
Elongation factor 1α;LOC100514912;ortholog
Β-enolase;ENO3;ortholog
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CALPAIN-3
(PTHR10183:SF328)
CARNOSINE SYNTHASE 1
(PTHR10578:SF91)
CALSEQUESTRIN-1
(PTHR10033:SF20)
CREATINE KINASE M-TYPE
(PTHR11547:SF45)
DEHYDROGENASE/REDUC
TASE SDR FAMILY
MEMBER 7C
(PTHR43490:SF45)
SUBFAMILY NOT NAMED
(PTHR23115:SF198)
Β-ENOLASE
(PTHR11902:SF27)
SUBFAMILY NOT NAMED
(PTHR14199:SF24)
CALSARCIN (PF0556), FATZ
RELATED
PROTEINCALSARCINRELATED (PTHR15941);
myozenin-2 like
MYOGLOBIN
(PTHR11442:SF57)
MYOSIN-BINDING
PROTEIN C, SLOW-TYPE
(PTHR13817:SF24)
MYOSIN-BINDING
PROTEIN C, FAST-TYPE
(PTHR13817:SF16)
MYOSIN-1
(PTHR13140:SF649)
MYOMESIN-2
(PTHR13817:SF30)
MYOZENIN-1
(PTHR15941:SF18)
NEBULIN (PTHR11039:SF58)
CYTOSOLIC 5'NUCLEOTIDASE 1A
(PTHR31367:SF7)
MYOMEGALIN
(PTHR13140:SF634)

PYGM

1

Α-1,4 glucan
phosphorylase;PYGM;ortholo
g

TMOD4

1

TNNC1

1

Tropomodulin
4;TMOD4;ortholog
Troponin C, slow skeletal and
cardiac
muscles;TNNC1;ortholog

TNNT1

1

Troponin T, slow skeletal
muscle;TNNT1;ortholog

TNNT3

1

Troponin T, fast skeletal
muscle;TNNT3;ortholog

TTN
TXLNB

1
1

ABHD15

2

Titin;TTN;ortholog
Uncharacterized
protein;TXLNB;ortholog
Uncharacterized
protein;ABHD15;ortholog

ACAA1

2

Uncharacterized
protein;ACAA1;ortholog

ACO1

2

Aconitate
hydratase;ACO1;ortholog

ADORA1

2

AOC3

2

Adenosine receptor
A1;ADORA1;ortholog
Amine oxidase;AOC3;ortholog

AOC3

2

Amine oxidase;AOC3;ortholog

BCAM

2

Uncharacterized
protein;BCAM;ortholog

CAT

2

Catalase;CAT;ortholog

EPHX2

2

Bifunctional epoxide hydrolase
2;EPHX2;ortholog

FAH

2

GBE1

2

Uncharacterized
protein;FAH;ortholog
1,4-α-glucan-branching
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GLYCOGEN
PHOSPHORYLASE,
MUSCLE FORM
(PTHR11468:SF18)
TROPOMODULIN-4
(PTHR10901:SF21)
TROPONIN C, SLOW
SKELETAL AND CARDIAC
MUSCLES
(PTHR23064:SF13)
TROPONIN T, SLOW
SKELETAL MUSCLE
(PTHR11521:SF14)
TROPONIN T, FAST
SKELETAL MUSCLE
(PTHR11521:SF18)
TITIN (PTHR13817:SF35)
Β-TAXILIN
(PTHR16127:SF23)
ABHYDROLASE DOMAINCONTAINING PROTEIN 15
(PTHR10794:SF63)
3-KETOACYL-COA
THIOLASE, PEROXISOMAL
(PTHR43853:SF5)
CYTOPLASMIC
ACONITATE HYDRATASE
(PTHR11670:SF47)
ADENOSINE RECEPTOR A1
(PTHR24246:SF35)
MEMBRANE PRIMARY
AMINE OXIDASE
(PTHR10638:SF41)
MEMBRANE PRIMARY
AMINE OXIDASE
(PTHR10638:SF41)
BASAL CELL ADHESION
MOLECULE
(PTHR11973:SF23)
CATALASE
(PTHR11465:SF29)
BIFUNCTIONAL EPOXIDE
HYDROLASE 2
(PTHR43329:SF1)
FUMARYLACETOACETASE
(PTHR43069:SF2)
1,4-Α-GLUCAN-

enzyme;GBE1;ortholog
GBE1

2

LAYN

2

LIPE

2

ORM1

2

PLIN1

2

Uncharacterized
protein;LOC100157421;orthol
og
Uncharacterized
protein;LAYN;ortholog
Hormone-sensitive
lipase;LIPE;ortholog
ORM1-like protein
3;ORMDL3;ortholog
Perilipin-1;PLIN1;ortholog

PLIN1

2

Perilipin;PLIN1;ortholog

PPP1R1B

2

SGK2

2

Protein phosphatase 1
regulatory subunit 1B
(Fragment);PPP1R1B;ortholog
Uncharacterized
protein;SGK2;ortholog

SLC36A2

2

UNC93A

2

ACER3

3

ACKR4

3

ADIPOR2

3

Adiponectin receptor
2;ADIPOR2;ortholog

APOL6

3

AQP7

3

Uncharacterized protein
(Fragment);APOL6;ortholog
Aquaporin 7;AQP7;ortholog

ARL6IP1

3

ADP-ribosylation factor-like
protein 6-interacting protein
1;ARL6IP1;ortholog

ARSD

3

CEBPA

3

Uncharacterized protein
(Fragment);ARSD;ortholog
Uncharacterized
protein;CEBPA;ortholog

Proton-coupled amino acid
transporter
2;SLC36A2;ortholog
Protein unc-93 homolog
A;UNC93A;ortholog
Uncharacterized
protein;ACER3;ortholog
Atypical chemokine receptor
4;ACKR4;ortholog

130

BRANCHING ENZYME
(PTHR43651:SF1)
SUBFAMILY NOT NAMED
(PTHR10357:SF185)
LAYILIN (PTHR14789:SF5)
HORMONE-SENSITIVE
LIPASE (PTHR23025:SF6)
ORM1-LIKE PROTEIN 3
(PTHR12665:SF20)
PERILIPIN-1
(PTHR14024:SF37)
PERILIPIN-1
(PTHR14024:SF37)
PROTEIN PHOSPHATASE 1
REGULATORY SUBUNIT 1B
(PTHR15417:SF7)
SERINE/THREONINEPROTEIN KINASE SGK2
(PTHR24356:SF282)
PROTON-COUPLED AMINO
ACID TRANSPORTER 2
(PTHR22950:SF395)
PROTEIN UNC-93
HOMOLOG A
(PTHR19444:SF36)
ALKALINE CERAMIDASE 3
(PTHR12956:SF43)
ATYPICAL CHEMOKINE
RECEPTOR 4
(PTHR10489:SF754)
ADIPONECTIN RECEPTOR
PROTEIN 2
(PTHR20855:SF80)
APOLIPOPROTEIN L6
(PTHR14096:SF47)
AQUAPORIN-7
(PTHR43829:SF15)
ADP-RIBOSYLATION
FACTOR-LIKE PROTEIN 6INTERACTING PROTEIN 1
(PTHR20952:SF6)
ARYLSULFATASE D
(PTHR42693:SF3)
CCAAT/ENHANCERBINDING PROTEIN Α

CLSTN3

3

Uncharacterized
protein;CLSTN3;ortholog
Isocitrate dehydrogenase
[NADP] cytoplasmic
(Fragment);IDH1;ortholog
Uncharacterized
protein;MMD;ortholog

IDH1

3

MMD

3

PC

3

Pyruvate carboxylase,
mitochondrial;PC;ortholog

PDE8B

3

Uncharacterized
protein;PDE8B;ortholog

PEX3

3

Uncharacterized
protein;PEX3;ortholog

RBP4

3

RETSAT

3

Retinol-binding protein
4;RBP4;ortholog
All-trans-retinol 13,14reductase;RETSAT;ortholog

RGCC

3

Regulator of cell cycle
RGCC;RGCC;ortholog

SFRP5

3

Uncharacterized
protein;SFRP5;ortholog

SIK2

3

Uncharacterized
protein;SIK2;ortholog

TKT

3

Transketolase;tkt;ortholog

ASPRV1

4

Retroviral-like aspartic
protease 1;ASPRV1;ortholog

FLG

4

KRT1

4

Uncharacterized
protein;FLG;ortholog
Uncharacterized
protein;KRT1;ortholog

KRT77

4

Uncharacterized
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(PTHR23334:SF30)
CALSYNTENIN-3
(PTHR14139:SF9)

MONOCYTE TO
MACROPHAGE
DIFFERENTIATION
FACTOR (PTHR20855:SF59)
PYRUVATE
CARBOXYLASE,
MITOCHONDRIAL
(PTHR43778:SF4)
HIGH AFFINITY CAMPSPECIFIC AND IBMXINSENSITIVE 3',5'-CYCLIC
PHOSPHODIESTERASE 8B
(PTHR11347:SF152)
PEROXISOMAL
BIOGENESIS FACTOR 3
(PTHR28080:SF2)
RETINOL-BINDING
PROTEIN 4 (PTHR11873:SF4)
ALL-TRANS-RETINOL
13,14-REDUCTASE
(PTHR10668:SF96)
REGULATOR OF CELL
CYCLE RGCC
(PTHR32193:SF5)
SECRETED FRIZZLEDRELATED PROTEIN 5
(PTHR11309:SF110)
SERINE/THREONINEPROTEIN KINASE SIK2
(PTHR24343:SF247)
TRANSKETOLASE
(PTHR43195:SF3)
RETROVIRAL-LIKE
ASPARTIC PROTEASE 1
(PTHR37006:SF2)

KERATIN, TYPE II
CYTOSKELETAL 1
(PTHR23239:SF236)
KERATIN, TYPE II

protein;KRT77;ortholog
KRTDAP

4

Uncharacterized
protein;KRTDAP;ortholog

LOR
FXYD3

4
5

Loricrin;LOR;ortholog
FXYD domain-containing ion
transport regulator
3;FXYD3;ortholog

KRT15

5

Uncharacterized
protein;KRT15;ortholog

KRT5

5

Uncharacterized protein
(Fragment);KRT5;ortholog

RAB25

5

SPTLC3

5

Uncharacterized
protein;RAB25;ortholog
Uncharacterized
protein;SPTLC3;ortholog

TACSTD2

5

Uncharacterized
protein;TACSTD2;ortholog

TRIM29

5

Uncharacterized
protein;TRIM29;ortholog

CMYA5

6

Uncharacterized protein
(Fragment);CMYA5;ortholog

LOC1021609
16

6

PPP1R3A

6

Myosin light chain 1/3,
skeletal muscle
isoform;MYL1;ortholog
Uncharacterized
protein;PPP1R3A;ortholog

TRDN

6

TTN
YIPF7

6
6

ABLIM2

7

Uncharacterized
protein;ABLIM2;ortholog

ADSSL1

7

Adenylosuccinate synthetase

Uncharacterized protein
(Fragment);TRDN;ortholog
Titin;TTN;ortholog
Protein YIPF;YIPF7;ortholog
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CYTOSKELETAL 1B
(PTHR23239:SF322)
KERATINOCYTE
DIFFERENTIATIONASSOCIATED PROTEIN
(PTHR36463:SF2)
LORICRIN (PTHR39228:SF2)
FXYD DOMAINCONTAINING ION
TRANSPORT REGULATOR 3
(PTHR14132:SF19)
KERATIN, TYPE I
CYTOSKELETAL 15
(PTHR23239:SF239)
KERATIN, TYPE II
CYTOSKELETAL 5
(PTHR23239:SF279)
RAS-RELATED PROTEIN
RAB-25 (PTHR24073:SF815)
SERINE
PALMITOYLTRANSFERASE
3 (PTHR13693:SF74)
TUMOR-ASSOCIATED
CALCIUM SIGNAL
TRANSDUCER 2
(PTHR14168:SF8)
TRIPARTITE MOTIFCONTAINING PROTEIN 29
(PTHR24103:SF530)
CARDIOMYOPATHYASSOCIATED PROTEIN 5
(PTHR24099:SF12)
MYOSIN LIGHT CHAIN 1/3,
SKELETAL MUSCLE
ISOFORM (PTHR23048:SF21)
PROTEIN PHOSPHATASE 1
REGULATORY SUBUNIT 3A
(PTHR12307:SF26)
TRIADIN (PTHR14106:SF2)
TITIN (PTHR13817:SF35)
PROTEIN YIPF7
(PTHR21236:SF11)
ACTIN-BINDING LIM
PROTEIN 2
(PTHR24213:SF21)
ADENYLOSUCCINATE

isozyme 1;ADSSL1;ortholog
ANKRD23

7

Uncharacterized
protein;ANKRD23;ortholog

BIN1

7

Uncharacterized
protein;BIN1;ortholog

CACNG1

7

Voltage-dependent calcium
channel gamma-1
subunit;CACNG1;ortholog

CAMK2A

7

Uncharacterized
protein;CAMK2A;ortholog

GAPDH

7

MYH6

7

MYL2

7

Glyceraldehyde-3-phosphate
dehydrogenase;GAPDH;orthol
og
Uncharacterized protein
(Fragment);MYH6;ortholog
Myosin regulatory light chain
2, ventricular/cardiac muscle
isoform;MYL2;ortholog

MYO18B

7

Uncharacterized
protein;MYO18B;ortholog

MYOM1

7

OBSCN

7

Uncharacterized
protein;MYOM1;ortholog
Obscurin;OBSCN;ortholog

PGAM2

7

Phosphoglycerate mutase
2;PGAM2;ortholog

SMPX

7

SYPL2

7

Small muscular
protein;SMPX;ortholog
Uncharacterized
protein;SYPL2;ortholog

TRDN

7

XIRP2

7

CCDC120

8

Uncharacterized protein
(Fragment);TRDN;ortholog
Uncharacterized
protein;XIRP2;ortholog
Uncharacterized
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SYNTHETASE ISOZYME 1
(PTHR11846:SF5)
ANKYRIN REPEAT
DOMAIN-CONTAINING
PROTEIN 23
(PTHR24176:SF22)
MYC BOX-DEPENDENTINTERACTING PROTEIN 1
(PTHR10663:SF287)
VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-1 SUBUNIT
(PTHR15025:SF9)
CALCIUM/CALMODULINDEPENDENT PROTEIN
KINASE TYPE II SUBUNIT Α
(PTHR24347:SF318)
SUBFAMILY NOT NAMED
(PTHR10836:SF69)
MYOSIN-6-RELATED
(PTHR13140:SF522)
MYOSIN REGULATORY
LIGHT CHAIN 2,
VENTRICULAR/CARDIAC
MUSCLE ISOFORM
(PTHR23049:SF46)
UNCONVENTIONAL
MYOSIN-XVIIIB
(PTHR13140:SF576)
MYOMESIN-1
(PTHR13817:SF28)
OBSCURIN
(PTHR10489:SF903)
PHOSPHOGLYCERATE
MUTASE 2
(PTHR11931:SF24)
SMALL MUSCULAR
PROTEIN (PTHR17416:SF1)
SYNAPTOPHYSIN-LIKE
PROTEIN 2
(PTHR10306:SF22)
TRIADIN (PTHR14106:SF2)
SUBFAMILY NOT NAMED
(PTHR24206:SF39)
COILED-COIL DOMAIN-

protein;CCDC120;ortholog
CEP170B

8

Uncharacterized
protein;CEP170B;ortholog

GYLTL1B

8

Uncharacterized
protein;GYLTL1B;ortholog

LIMK2

8

Uncharacterized
protein;LIMK2;ortholog

MFSD6

8

Major facilitator superfamily
domain-containing protein
6;MFSD6;ortholog

PTPRF

8

Receptor-type tyrosine-protein
phosphatase F;PTPRF;ortholog

RAB11FIP1

8

ADCK3
(COQ8A)

9

Uncharacterized protein
(Fragment);RAB11FIP1;orthol
og
Uncharacterized
protein;ADCK3;ortholog

CORO6

9

Coronin;CORO6;ortholog

MYH1

9

Myosin-1;MYH1;ortholog

NRAP

9

Uncharacterized protein
(Fragment);NRAP;ortholog

TNNC2

9

TRDN

9

Troponin C, skeletal
muscle;TNNC2;ortholog
Uncharacterized protein
(Fragment);TRDN;ortholog
Probable C-U-editing enzyme
APOBEC2;APOBEC2;ortholog;
Apolipoprotein B MRNA
Editing Enzyme Catalytic
Subunit 2
Elongation factor 1α;LOC100514912;ortholog
Inositol hexakisphosphate
kinase 3;IP6K3;ortholog

APOBEC2

10

EEF1A1

10

IP6K3

10
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CONTAINING PROTEIN 120
(PTHR16093:SF7)
CENTROSOMAL PROTEIN
OF 170 KDA PROTEIN BRELATED (PTHR15715:SF34)
GLYCOSYLTRANSFERASELIKE PROTEIN LARGE2
(PTHR12270:SF40)
LIM DOMAIN KINASE 2RELATED
(PTHR23257:SF625)
MAJOR FACILITATOR
SUPERFAMILY DOMAINCONTAINING PROTEIN 6
(PTHR16172:SF35)
RECEPTOR-TYPE
TYROSINE-PROTEIN
PHOSPHATASE F
(PTHR19134:SF343)
RAB11 FAMILYINTERACTING PROTEIN 1
(PTHR15746:SF26)
ATYPICAL KINASE ADCK3,
MITOCHONDRIAL
(PTHR43851:SF1)
CORONIN-6
(PTHR10856:SF29)
MYOSIN-1
(PTHR13140:SF649)
NEBULIN-RELATEDANCHORING PROTEIN
(PTHR11039:SF55)
TROPONIN C, SKELETAL
MUSCLE (PTHR23064:SF14)
TRIADIN (PTHR14106:SF2)
C-U-EDITING ENZYME
APOBEC-2-RELATED
(PTHR13857:SF34)

SUBFAMILY NOT NAMED
(PTHR23115:SF198)
INOSITOL
HEXAKISPHOSPHATE
KINASE 3 (PTHR12400:SF57)

LOC1005111
57
LOC1065049
26
LOC1065092
60
MYOM2

10

ncRNA

10
10
10

Uncharacterized protein
(Fragment);MYOM2;ortholog

MYOMESIN-2
(PTHR13817:SF30)

After the hypothesis that there are genuine functional modules present within the
overall transcriptomic dataset generated from samples collected during pre-pubertal
mammary gland development was confirmed, the functional modules (‘clusters’) were
further dissected using the MCODE algorithm and Reactome pathway analysis/Panther
characterization and a review of the literature. Once MCODE identified densely connected
nodes to graphically display both nodules and associated weights, which were used to sort the
relationships from strongest to weakest 792, the genes contributing to each functional module
were extracted for detailed pathway analysis and biological interpretation based on functional
significance in mammary development and cancer if applicable. As shown in Table 10, ten
functional modules were extracted from the data, ranging in MCODE weights from 26.25
(greatest connectivity) to 4 (least connectivity). The overall network connectivity coefficient
for Cluster 1 indicates the highest strength of interaction between the individual genes in this
module, demonstrating a novel interactions of striated muscle contraction and actin
cytoskeleton integrity genes that significantly contribute to early postnatal mammary
developmental trends. In contrast, the overall network connectivity coefficient for Cluster 10
indicates the lowest strength of interaction between the individual genes in this module, and
pathway analysis suggests these genes have weak interaction with eachother; these could not
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be clearly grouped by their biological function in mammary development. Approximately
50% of the clusters contained genes with oncogenic potential, which will also be discussed.
Reactome pathway analysis confirms validity of the functional interactions (by
variance) using the MCODE algorithm, by clustering of distinct pathways utilized into
different modules. Cluster 1 genes utilized pathways of mainly striated muscle contraction
and actin cytoskeleton integrity, and much of the activity was centered around genes
encoding the proteins titin, troponin, actin, myomesin, myozenin, and troponin, with most
physically located in different domains of muscle 472. Cluster 2 genes utilized pathways of
adipogenesis, adipocyte metabolism, immune function, and metabolic alterations in cancer.
Importantly, there was interaction with the innate immune system and >50% of the genes
contained in this module were proto-oncogenes or oncogenes. Cluster 3 genes also were
largely proto-oncogenes or oncogenes and utilized lipid and protein metabolism pathways
and cell cycle control. Clusters 4 and 5 genes both utilized pathways of keratinocyte
differentiation and development, but Cluster 5 contained entirely proto-oncogenes and
oncogenes with significant integrin association. Clusters 6, 7, and 9 were weakly interacting
modules of genes mainly associated with muscle contraction, actin binding, and calcium
signaling. Interestingly, although weakly interacting, Cluster 8 contained genes involved in
protein modification and cellular adhesion with a majority acting as proto-oncogenes or
oncogenes. Lastly, the weakest interaction is represented by Cluster 10, which is a ‘mixed
bag’ of mainly metabolic genes. Clusters 6, 7, 9, and 10, in addition to being weakly
interacting modules, did not contain a majority of genes with interesting functional
significance to early pre-pubertal mammary development and will not be discussed at length
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here. Relevant clusters to the developmental model (Clusters 1, 2, 3, 4, 5, and 8), their
functional significance, and interacting gene members will be subsequently discussed.
Cluster 1, possessing the highest MCODE connectivity weight, contained genes
involved in actin cytoskeleton integrity and muscle contraction, which are both important
events during postnatal mammary development. This module included the most genes:
ACTA1, AMPD1, APOBEC2, ATP2A1, C14H10orf71, CAPN3, CARNS1, CASQ1, CKM,
DHRS7C, EEF1A1, ENO3, MB, MYBPC1, MYBPC2, MYH1, MYOM2, MYOT, MYOZ1,
NEB, NT5C1A, PDE4DIP, PYGM, TMOD4, TNNC1, TNNT1, TNNT3, TTN, TXLNB, and
two uncharacterized LOC IDs. MCODE modeling has been used to isolate biomarkers and
gene networks involved in breast cancer 795–797, but MCODE has not yet been applied to
developmental mammary biology. The applicability of this multivariate technique has been
confirmed for developmental biology through recognition of the known interactions of
Cluster 1 genes with each other in the literature, reports of Cluster 1 gene presence in
mammary epithelial cells, relationships between Cluster 1 genes and developmental DA/PRC
genes, and the widely accepted importance of the actin cytoskeleton in epithelial cell
adhesion and migration to promote mammary development 152,377,798–801. Striated muscle
involvement in the mammary gland was reported as early as 1988 by Griffiths et al 802; it is
not surprising that this pathway is utilized by strongly coordinating genes in this instance. As
reviewed in Chapter 1, mammary epithelial cells physically associate with each other through
adherens junctions; this association allows formation and mediation of stable
hemidesmosomes on the basal cell surface that link the cellular cytoskeleton with the BM 133.
The actin cytoskeleton is directly associated with this process through physical support of
hemidesmosomes, cell junctions, epithelial cell assembly, and cellular maintenance and

137

migration 803–806; the prominence of actin complexes within the highest weighted module
further suggests significant involvement of cytoskeletal dynamics in early pre-pubertal,
postnatal mammary gland development. Additionally, the actin cytoskeleton has been shown
to regulate EMT, an important process in early development, in normal and cancerous cells
807

. Pursuant to this research focus, integrin molecules promote assembly of the actin

cytoskeleton through recruitment of molecules to promote actin polymerization and
relocation of actin to cell adhesion sites 808 ; these adhesions are predominantly governed
through Rac signaling 269,809–811. ACTA1 (skeletal muscle actin α), presented in Cluster 1, is a
marker of basal epithelial cell differentiation 812,813, elucidating affiliation between actin
dynamics and mammary epithelial cell growth and maturation. ACTA1 is also a member of
the highly conserved family of actin isoforms that exhibit functional redundancy; this family
includes smooth muscle α-actin (ACTA2) that has recently been proven required specifically
for lactation in mammals 800. Additionally, it has been shown that during postnatal
development, mammary myoepithelial cells acquire a differentiated phenotype while gaining
expression of smooth muscle markers, associating muscular genes with epithelial cell
differentiation 801. It is hypothesized that a similar functional relationship is depicted with the
Cluster 1 module of genes. Discriminate analysis in Fig X. showed that during phase two of
development, Type VIII collagen was upregulated. Hou et al investigated smooth muscle cell
(SMC) migration via type VIII collagen and concluded its effects are mediated by α2β1 and
α1β1 integrin receptors as well as MMP-2 and MMP-9 expression 488, further suggesting
validity of the novel cluster results. A functional link between the network module in Cluster
1 and the positive PRC curve (consisting of genes supporting normal postnatal mammary
development) is demonstrated by the role of PINCH-2 in both the top 25 positive PRC genes
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and in the literature in actin dynamics; actin polymerization is stimulated at integrin
clustering sites through via recruitment of a complex of proteins, commonly ILK–PINCH-2
814

. This increases confidence and usability in the novel application of these multivariate

techniques, frequently only used in ecological studies, to mammary biology and
developmental biology. In adaptive immune system development, the actin cytoskeleton has
critical roles in T-cell activation, development, and motility, helping to form immunological
synapses 815. Furthermore, the Cluster 1 gene Elongation factor 1-α (EEF1A1) behaves as a T
helper 1 (Th1) cell-specific translation factor and is involved in Th1 cytokine production 816.
EEF1A is also commonly applied as an internal control gene when normalizing
transcriptional data of mammary epithelial cells, confirming its widespread presence in the
mammary gland 817. However, with roles in proliferation, invasion and migration of cancer
cells, its overexpression has been seen in cancers of the head and neck, breast, as well as
leukemia and hepatocarcinoma 818. Taken together, Cluster 1 module networks suggest that
the muscle-related genes are, in a coordinated fashion, supporting correct actin dynamics for
mammary epithelial cell migration, differentiation, and signaling; the links with published
literature and developmental genes discovered using other methods (DA/PRC) confirm
validity of the novel approach to characterize early pre-pubertal mammary development.
Cluster 2 is a highly interconnected module of genes utilizing metabolic and immune
system pathways to execute functional roles in adipogenesis, adipocyte metabolism, and
innate immune function; metabolic alterations present in cancers also appear in this module
430,431,472

. Greater than 50% of the genes in this module are proto-oncogenes or oncogenes,

leading to our characterization of this module as an ‘oncogenic cluster’. Genes included in
this module are: ABHD15, ACAA1, ACO1, ADORA1, AOC3, BCAM, CAT, EPHX2, FAH,
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LAYN, LIPE, ORM1, PLIN1, PPP1R1, SGK2, SLC36A2, and UNC93A; top Reactome
pathways utilized were metabolism, immune system, innate immune system, and neutrophil
degranulation. The significant involvement of adipogenesis in this postnatal mammary
development module can be explained by the concept that shortly after birth, adipocytes
densely packed in the fat pad begin to mature and become capable of supporting further
mammary epithelial cell morphogenesis 46,47. Adipocytes were formerly viewed as a storage
depot for energy; it is accepted currently that they also have endocrine functions and
metabolic roles in regulating whole body homeostasis, promoting inflammation, and
secretion of a range of factors 819. Cluster 2 suggests that as the mammary epithelial ducts
penetrate the surrounding mesenchyme during development, utilizing invasive cell signaling
detected with our PRC and DA analysis, surrounding fibroblasts and adipocytes play a large
role in the processes 9,10. It has been demonstrated that the absence of adipocytes in the
mammary gland results in disruption of ECM signaling events and normal mammary
development, suggesting these cells do regulate and sustain epithelial cell growth 820,821.
Furthermore, adipose-derived stem cells (ASCs) are capable of differentiating into both
adipocytes and epithelial cells in the mammary gland 822. Literature suggests that adipocytes
are critical for proper mammary gland development during puberty and for the maintenance
of the ductal architecture in the adult mammary gland 823; Cluster 2 supports this notion while
illustrating similar functions that could be essential for early postnatal mammary gland
development. Additionally, in tumors, there exists a complex metabolic collaboration
between TME adipocytes and cancer cells that promotes invasiveness and metastasis 824,
suggesting potential interaction between mammary epithelial cells and adipocytes during
normal mammary organogenesis. Knowledge of adipocyte metabolism and mammary
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development is simultaneously improving, but many factors (and genes generated by our
functional modules) remain to be studied and characterized. The Cluster 2 gene α/β-hydrolase
domain containing protein 15 (ABHD15) is a direct target gene of peroxisome proliferatoractivated receptor gamma (PPARγ), the master regulator of adipogenesis 825–827 and is
upregulated during adipocyte development. Knockdown of ABHD15 in vitro resulted in
apoptosis and a reduced proliferation capability of the cells 828. Prokesch et al in 2014
presented the idea of reciprocal transdifferentiation between mammary adipocytes and
epithelial cells; the researchers hypothesize it is one way in which the mammary gland
accomplishes cyclical remodeling throughout development, pregnancy, and lactation 829.
Importantly, they determined Perilipin1 (PLIN1; a Cluster 2 gene) is a critical regulator of
mammary transdifferentiation and detected cells with an intermediate phenotype – termed
‘adipoepithelial’ cells – in tissue during pregnancy that may be regulated by integrin
complexes 829. The presence of PLIN1 in a module aside adipogenesis genes suggests
possible transdifferentiation between adipocytes and mammary epithelial cells during
postnatal pre-pubertal mammary development.
Several Cluster 2 genes are overexpressed in breast cancers: adenosine A1 receptor
(ADORA1) and Protein Phosphatase 1 Regulatory Inhibitor Subunit 1B (PP1R1B; also
known as DARPP-32). ADORA1 is a member of the G protein-coupled receptor superfamily
that may regulate both normal and tumor cell development through promotion of survival and
inhibition of apoptosis. This gene acts as an E2/ERα target and a regulator of ERα
transcriptional activity, promoting breast cancer growth 830 and is overexpressed in breast
cancer cell lines 831, suggesting it is a mediator of estrogen activity in mammary epithelial
cell growth. PP1R1B/DARPP-32 is a signal transduction molecule, possibly linked to Wnt5a
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signaling 832, expressed in both normal and malignant breast tissue 833, with knockout in vivo
demonstrating decreased tumor growth 833. However, phosphorylation sites of DARPP-32
and their downstream effects indicate a complicated network of positive and negative
feedback/feedforward loops; several studies suggest its presence actually inhibits cell growth
833,834

, and thus its function in development remains largely unknown 835. Detection of

DARPP-32 in Cluster 2 suggests a relationship with genes regulating adipogenesis and
adipocyte metabolism. The Layilin (LAYN) gene encodes a cell surface glycoprotein thought
to function in cell migration by membrane anchorage and promotion of F-actin binding and
integrin/focal adhesion complexes 836; it is also a Treg cell-signature gene 837. LAYN is
present in Cluster 2, suggesting it may interact with adipocytes for cell migration during
postnatal mammary development and branching of the gland. Pursuant to our focus is the
activity of Basal Cell Adhesion Molecule (B-CAM; also known as Lutheran), a Cluster 2
gene proven to compete with integrin molecules for laminin α5 association in the BM in
order to maintain balance between static and migratory cell behaviors 838. Studies also
suggest BCAM may act as a suppressive oncogene 839 and/or join with AKT to form a
BCAM/AKT fusion kinase that is constitutively activated in ovarian carcinoma 840. Taken
together, the results of Cluster 2 module suggest a unique collaborative relationship between
adipocytes, the ECM, and mammary epithelial cells with some integrin involvement in
promotion of growth of the mammary gland.
Cluster 3 contains genes mainly involved in lipid metabolism, protein metabolism,
and cell cycle control. Reactome pathway analysis indicated the most common signaling
pathways utilized were: Metabolism, Post-translational protein modification, Metabolism of
proteins, Sphingolipid metabolism, Metabolism of lipids, Developmental Biology, and Signal
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Transduction. There are also several functional immune genes present in this cluster. Genes
included in this module were: ACER3, the uncharacterized LOCID LOC100739362,
ACKR4, ADIPOR2, APOL6, AQP7, ARL6IP1, ARSD, CEBPA, CLSTN3, PC, IDH1,
MMD, PC, PDE8B, PEX3, RBP4, RETSAT, RGCC, SFRP5, SIK2, and TKT. Immunerelated genes in Cluster 3 include ACKR4 (Atypical chemokine receptor 4), CEBPA
(CCAAT/enhancer binding protein A), and MMD (Monocyte-Macrophage Differentiation).
Not immediately obvious from pathway analysis results was the prevalence of several
important immune system relationships in this cluster, specifically those of CEBPA and
MMD, which will be discussed. ACKR4 is an atypical chemokine receptor that plays a role
in the migration of immune cells expressing chemokine receptors CCR7 and CCR9 by
reducing the availability of CCL19, CCL21, and CCL25 841–844 and in cancer cells, may
promote metastasis via an effect on EMT signaling 843. CEBPA, encoding the CCAAT
enhancer-binding protein-α (C/EBPα) is a member of a large family of C/EBP proteins that
regulate energy metabolism, immunity, inflammation, hematopoiesis, and adipogenesis 845–
849

. C/EBPα is expressed by early myeloid progenitors and may regulate monocyte and

macrophage development 850–852 and has a lesser understood, but important, impact on energy
metabolism of surrounding cells 853. Studies have shown that this gene regulates other nonimmune cell types and controls genes required for lipid accumulation and glycogen storage
854,855

, illustrating another potential association between immune development and

adipogenesis in the mammary gland. However, there is conflicting evidence for the presence
and role of C/EBPα in the mammary gland; some data suggest C/EBPα levels are low and
static throughout mouse mammary gland development 856,857 while others suggest dynamic
upregulation during different developmental phases 858. This data, indicating the presence of
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this gene in a highly interconnected cluster of other adipogenesis and mammary development
genes suggest that it is indeed active and sustains a functional role in development of the
gland. Interestingly, a separate Cluster 3 gene is also expressed by differentiated
macrophages; as its name indicates, MMD (monocyte to macrophage differentiation)
supports differentiation of monocytes to macrophages after they migrate through the
endothelial membrane 859. Differentiated macrophages can then subsequently secrete growth
factors, cytokines, and chemoattractants to recruit additional monocytes, support smooth
muscle cell development 860, and assist in lipoprotein binding through proteoglycan secretion
861

. A significant matrix effect, including integrin involvement, on monocyte to macrophage

differentiation has been recently demonstrated 862. In breast cancer models, initiation of
mammary tumors by tumor-associated macrophages results mainly from monocyte to
macrophage differentiation (reviewed by 863), further suggesting a role for MMD in the
growth of epithelial cells and ECM integrity and function.864 In Chapter 1, the contribution of
macrophages in mammary development was reviewed 91. Taken together with reports that in
the developing mammary gland, regulation of genes contributing to macrophage function
(immunity and defense, lipid, fatty acid and steroid metabolism, cell adhesion, carbohydrate
metabolism, amino acid metabolism, and endocytosis) are found 865, it is hypothesized that
MMD has a significant role within Cluster 3. The unique network of genes presented in the
Cluster 3 module further confirms the collaboration between immune cells, adipocytes, and
mammary epithelial cells during early mammary organogenesis.
Cluster 4 mainly contains genes utilizing pathways of keratinization during
development; these are predominantly epithelial cell markers that support keratinocyte
differentiation and structural integrity of epithelial cells 472,603 with low oncogenic potential.
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Interestingly, Cluster 5 utilizes the same pathways as Cluster 4, but is a small and highly
oncogenic cluster with multiple genetic markers of basal breast cancer and EMT. The
significance of the ECM, adherens junctions, and epithelial cell interactions in mammary
development has already been thoroughly covered in the discussion above; the same
significance applies here. The genes included in Cluster 5 are FXYD3, KRT15, KRT5,
RAB25, SPTLC3, TACSTD2, and TRIM29. Importantly, 100% of the genes in this cluster
have been reported to function as oncogenes or proto-oncogenes. FXYD3, also known as
mammary tumor protein 8, is an enzyme and chloride ion channel or chloride channel
regulator 866, but also a biomarker for breast 867,868, endometrial 869, colon and thyroid cancer
870

and is suspected to support extensive cellular proliferation. KRT15, keratin 15, has been

identified as a biomarker in TNBC and mammary stem cells 364. KRT5, keratin 5, is a marker
of basal epithelial differentiation that mediates cell-cell adhesion and hemidesmosome
formation in conjunction with integrin molecules 871. As a desmosome anchor for basal cells,
KRT5 has been implicated in the ECM-dependent transition of tumor cells in basal breast
cancer 872. RAB25, a member of the rat sarcoma (RAS) family of small GTPases, encodes a
protein whose functional role is recycling of cell surface receptors and signaling proteins and
regulation of cellular processes including proliferation, signal transduction, apoptosis,
microtubule organization, and integrin trafficking 873–881. Importantly, RAB-mediated
trafficking that contributes to invasion targets and upregulates integrin α6β4 while not
affecting levels of α3β1 integrin 873. This gene has also been reported to act as both a tumor
suppressor and tumor initiator, acting through multiple pathways to promote tumorigenesis in
TNBC 881, suggesting a functional relationship between RAB25 and α6β4 integrin could
influence TNBC development. SPTLC3 (Serine Palmitoyltransferase Long Chain Base
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Subunit 3), a sphingolipid biosynthesis gene, has been implicated in hepatocellular carcinoma
882

while TACSTD2 (Tumor-associated calcium signal transducer 2; also known as TROP2),

a calcium signal transducer with roles in maintenance of the epithelial barrier through
regulation of proper localization of tight junction proteins 883,884, has been seen overexpressed
in epithelial tumors 885 and TNBC 886,887 where it promotes stem cell renewal 885, EMT
signaling 888,889, PI3K activation 890, and β catenin signaling 885 – all processes leading to
cellular proliferation, migration, and metastasis. However, contradictory data by Wang et al
uncover a role for TACSTD2 loss in tumorigenesis in SCC. Despite its expression in a wide
range of cancers, little is known about normal TACSTD2 signaling or downstream targets
and its role in cell adhesion to the ECM is unclear 885. Interestingly, it was demonstrated
recently that TACSTD2 inhibits prostate cancer cell adhesion to fibronectin and promotes β1
integrin activation of the Src/FAK signaling pathway 891. Another related molecule also
found in Cluster 5 that has an important role in EMT and regulation of ECM components is
Tripartite motif–containing 29 (TRIM29) 892–897. It has been demonstrated that TRIM29
suppresses the activity of integrin β1and regulates the p63-mediated pathway in cervical
cancer p63 892, reduces PTEN expression and increases phosphorylated AKT levels which
induces proliferation through the PTEN/AKT/mTOR pathway in nasopharyngeal carcinoma
(NPC) 898, and directly binds p53 to increase proliferation by sequestering it outside the
nucleus 893. Clearly, the roles of TRIM29 across different cell types is still not completely
understood. Cluster 5 is an important functional module of genes present in our
transcriptomic data set – not only are all of the included genes oncogenes or protooncogenes, they all function mainly to maintain epithelial integrity, mediates cell-cell
adhesion, and have direct links with integrin molecules.
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Clusters 6-10 have weaker interactions; Clusters 6, 7, and 9 all contain genes mainly
related to muscle contraction while Cluster 10 does not have strong organization. Cluster 8 is
a group of genes that do have some function in cell adhesion, but the most significant
functional modules from our transcriptomic dataset were Clusters 1-3 and 5. Taken together,
application of the MCODE algorithm to transcriptomic data collected over time in early
postnatal mammary development generated distinct modules, or clusters, containing highly
interconnected genes. These clusters each had a unique biological function and strong
implications for the novel mammary development model.
A model has been provided to achieve what was previously lacking in mammary
biology: continuous developmental data collected from the same live animal over time. In
contrast with previous attempts using necropsy samples from different animals at different
ages 144, which does not completely control for variability between animals, mammary tissue
has been obtained from the same animal throughout a period of early postnatal development
without adverse effect to the animal or tissue. Anatomically and physiologically, the swine
model is more closely related to that of the human; this data supports this concept and the
swine model proved a good tool for histologic and transcriptomic evaluation of early
mammary development 150. Availability of the swine genome sequence that shows high
homology with humans 150 was especially helpful in interpretation of the data. Since the
immune system of humans varies considerably from that of the mouse, the previously
accepted model, this data suggests the use of swine to study immune system development in
mammals. Along with the assessment of key immune regulators and markers in swine, this
data supports use of the swine model to study human innate immunity and disease instead of
rodents 151. Additionally, multiple advanced multivariate techniques frequently applied to
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microbial ecology and less frequently, mammary biology, were utilized to generate several
models of postnatal, pre-pubertal mammary development. With the application of statistical
techniques to a new area of biology, there exists concerns of reproducibility; it is important to
note that these methods do not necessarily build on each other, meaning that the output of
one method does not always generate the input for the next method. The whole data set, or a
subset of variables sorted by variance, is used as the input for each method, so an incorrect
output of an earlier method (for example, DFA) would not lead to an inherent inaccuracy in a
latter method (for example, WGCNA).
As discussed, studying early mammary development is critical both due to the
suspected links between development and invasive cancer and the conflicting views of
researchers on the presence of developmental activity between birth and puberty. In contrast
with the popular perspective that postnatally, the mammary gland exists as a rudimentary
organ that remains quiescent and dormant until puberty 6–9, this data suggests that there is
significant growth occurring immediately after birth, including events previously suspected
such as epithelial cell proliferation, branching, and expansion11–14 as well as significant
immune system and ECM involvement. It is also accepted that in humans, the formation of
the breast in the embryo and early postnatal development contains some events akin to early
breast carcinogenesis16. This data supports this concept and the main signaling pathways
responsible for early postnatal mammary development and patterning over time have been
identified and characterized. Awareness of their downstream effects and targets has both
advanced the understanding of developmental biology and could provide future areas of
study for carcinogenesis and breast cancer treatment.
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Chapter two results and discussion
Given the disclosure of many proto-oncogenes or oncogenes involved in novel
interactions contributing to early postnatal mammary developmental trends in Chapter 1, the
hypothesis was strengthened that there are transcriptional similarities in early postnatal
mammary development and TNBC that can be modulated through the α6β4 integrin signaling
pathway. Therefore, it is expected that the MDA-MB-231 TNBC cell line should utilize
growth pathways similar to those uncovered in early postnatal mammary development which
are potentially affected by treatment with the recombinant rG3 protein. In this Chapter, the
effect of rG3 on viability is evaluated in multiple cell lines across species, while RNA
sequencing data reveal the prominent cell signaling pathways influenced by rG3 treatment,
suggesting this recombinant protein can be used as a novel tool to study apoptosis signaling
in TNBC.
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Production of purest form of rG3
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Figure 13. a) rG3 Western Blot using anti-polyhistidine monoclonal antibody
after in-house production. Lane 1: Marker. Lane 2: First isolation elution.
Lane 3: Second isolation elution. Lane 4: Third isolation elution. Lane 5:
Fourth isolation elution. kDa size marker shown on left. b) rG3 Western Blot
using anti-polyhistidine monoclonal antibody after Vanderbilt production and
purification. Purest fractions were chosen for further analysis.
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Fig 13. shows the purity of rG3 after production in-house or after further purification by
MSRC Proteomics Laboratory at Vanderbilt University School of Medicine. In the Qiagen
Fast Start Ni-NTA Kit used for in-house production, rG3 elution is repeated four times to
maximize protein yield. In the first elution, the majority of rG3 is captured, and the highest
concentration of protein is present at the ~27 kDa (rG3) band. The newest purified rG3
produced using Vanderbilt’s technique can be seen in the Western Immunoblot in Figure
13B. Lanes 4-15 contain the fractions from purification. The cleanest fractions were chosen
to be used in subsequent assays and can be seen in Lanes 8, 9, and 12. For the final
experiments, production and isolation of rG3 were modified to obtain the purest form of rG3
since purification of rG3 in-house using the Ni-NTA Fast Start purification yielded a protein
with two main components (as seen in Figure 13B at approximately 27 kDa and
approximately 57 kDa). Since the active portion of rG3 is at approximately 27 kDa, any nonspecific proteins are a concern.
rG3 isolation was confirmed by both gel electrophoresis and Western Blotting using
an anti-polyhistidine monoclonal antibody (As previously demonstrated by Turner in 2005,
the molecular weight of rG3 including the histidine tag is ~27 kDa). Figure X confirms the
presence of rG3 with the histidine tag, but the inclusion of larger MW bands contain the
histidine tag suggest the presence of larger protein fragments (~70 kDa, band 2) that are an
rG3 protein complex. As shown in Figure XB, Vanderbilt’s purification procedure did yield
cleaner fractions. The cleanest fractions, in Lanes 8, 9, and 12, were chosen for subsequent
assays. Mass spectrometry results confirmed that the upper MW band contains the chaperone
heat shock Protein 60 complexed with the rG3 protein (by sequence) and the majority of the
lower band is the rG3 protein sequence. Mass spectrometry, also performed at Vanderbilt,
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confirmed that the upper MW band is the chaperone heat shock Protein 60 (accession number
CH60_ECOLI).

Evaluation of hsp-60 effect on viability
MTT viability assay results using representative concentrations of pure heat shock
protein 60 on the MDA-MB-231 cancer cells can be seen in Fig. 14.

Figure 14. MTT results for MDA-M-231 cell line after 24 hr treatment in vitro
with 0 – 10µg/mL pure hsp-60.

The MTT results suggest that pure hsp-60, up to 10µg/mL, does not have a
significant effect on MDA-MB-231 cell viability. Therefore, it is likely that the biological
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effect of rG3 is specifically due to the recombinant portion of Laminin-5 G3 domain and not
the inclusion of a hsp-60/rG3 protein complex.

*
*

Figure 15. MTT results for MDA-M-231, MCF-10A, and primary swine fibrolast
cell line after 24 hr treatment in vitro with 0 – 30µg/mL rG3.

Evaluation of rG3 effect on TNBC viability in vitro
MTT viability assays were performed with 0, 20, 30, 40, and 50 µg/ml concentrations
of rG3. As shown in Fig. 15., all concentrations of rG3 induced % SI values that were
significantly different from each other. At 20 µg/mL, the 231s have the most significant
reduction in viability (% SI) compared to 0 µg/mL. At 20 µg/mL, primary swine fibroblasts
do not show a significant reduction in viability compared to 0 µg/mL and have a significantly

153

higher viability in comparison with the 231s (p ≤ 0.0001). Although the remaining cell line
(MCF-10A) has a higher viability than the 231s at 20 µg/mL, their SI values are not
significantly greater than the 231 cells at this concentration.
At 20 µg /mL, the lowest concentration where significant reduction in proliferation
was seen (Fig 15), MDA-MB 231 exhibit the highest inhibition of proliferation. MCF10A
cells, the “normal” mammary epithelial cell line, exhibit a significant decrease in viability at
20 µg/mL, which raises questions regarding the suitability of these cells as a control as
previously discussed 146,899. Any response of MCF10A cells to rG3 treatment may be due to
the level of integrin ß4 expression on these cells (Fig. 17) being comparable to the level of
integrin ß4 expression in MDA-MB-231 cancer cells.

*

Figure 16. Western Blotting for p53 after treatment with 20ug/mL rG3 in vitro using MCF10A, MDA-MB-231, and primary swine fibroblast lysate.
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Figure 17. Western Blotting for integrin ß4 in vitro using MCF-10A, MDA-MB-231, and
primary swine fibroblast lysate. MCF10 and MDA-MB-231 lysate showed significantly
higher integrin ß4 expression in comparison with the primary swine fibroblasts (p =
0.0016)

Analysis of integrin ß4 and p53 protein expression after rG3 treatment in multiple cell lines
To understand at what level integrin ß4, the indirect target of rG3, is expressed in the
cell lines used for in vitro assays, Western Immunoblotting was performed using an antiintegrin ß4 antibody on cell lysates collected from MDA-MB-231 cells, MCF-10A cells, and
primary swine Fibroblasts. All images were analyzed at n=3 and integrin ß4 expression was
normalized to β actin expression in respective samples. ANOVA indicated significant
differences in means among the three different cell types, so Tukey HSD analysis was chosen
to determine if tumorigenic cell types (MDA-MB-231) express significantly more integrin
ß4. To understand how rG3 treatment is affecting downstream protein expression of a
common apoptosis marker, p53, Western Immunoblotting was performed on cell lysates
collected from MDA-MB-231 cells, MCF-10A cells, and primary swine Fibroblasts with and
without 24 hr of treatment with 20 µg/mL rG3. All images were analyzed at n=3 and integrin
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ß4 expression was normalized to β actin expression in respective samples. ANOVA indicated
differences in means among the three cell types and between treatments, so Tukey HSD
analysis was chosen to determine if MDA-MB-231 cells expressed significantly more p53
after treatment than the other three non-tumorigenic cell types. In Figure 16, these differences
are shown between cell lines and with or without rG3 treatment.
In Figure 17, integrin ß4 protein expression is significantly higher (p = 0.0016) in the
MDA-MB-231 and MCF-10A cell lines in comparison to the primary swine fibroblasts,
which have low integrin ß4 protein expression. MDA-MB-231 cells are the only cell line that
has a significant increase in p53 expression (p ≤ 0.001) after 24 hours of 20 µg/mL rG3
treatment. MCF-10A cells do not indicate a significant difference in p53 protein expression
after 24 hours of 20 µg/mL rG3 treatment. Additionally, p53 expression after rG3 treatment
in the MCF-10A cells is significantly lower than MDA-MB-231 cells after rG3 treatment (p
≤ 0.001). Primary swine fibroblasts do not show significantly different p53 expression levels
with or without 24 hours of 20 µg/mL rG3 treatment. Cell death due to p53-dependent
apoptosis typically follows the mitochondrial pathway, however p53 can also modulate cell
death through death receptors 900; it is suspected that one or both of these p53 associated
pathways are utilized upon binding of rG3 to the integrin ß4 ligand. As shown in Figure 16,
significantly increased p53 expression after rG3 treatment was only detected in the MDAMB-231 cell line and not MCF10A or fibroblast cells, indicating induction of the p53specific apoptotic pathway in MDA-MB-231 cells only. It is important to note that although
MCF10A cells show expression of integrin ß4 (Fig 17) and a decrease in viability after rG3
treatment (Fig 15), a significant increase of apoptotic protein p53 is not seen after treatment.
This could indicate that although rG3 affects viability of these cells, it is not through a p53-
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dependent manner and therefore they are not an appropriate control or tool to study p53mediated apoptosis induction and were not included in subsequent assays.

RNA sequencing confirms primary swine fibroblasts utilized generic growth pathways and
are appropriate control
RNA sequencing provided data for approximately 25,000 gene transcripts for the
primary swine fibroblast line. After 24 hours of growth in vitro, the most commonly utilized
Reactome pathways by fibroblasts were metabolism of proteins, immune system, signal
transduction, metabolism, Post-translational protein modification, Gene expression
(Transcription), Innate Immune System, RNA Polymerase II Transcription, Metabolism of
RNA, Cytokine Signaling in Immune system, Generic Transcription Pathway,
Developmental Biology, and Adaptive Immune System.
As mentioned and seen in MTT results (Fig. 15), MCF-10A cells can exhibit stem
cell-like features and possess a variable phenotype dependent on culture conditions146. Due to
the discrepancy in results using MCF10As, and the anatomical and physiological
resemblance to human tissue 147,150, swine mammary tissue was collected in vivo and a
primary cell line was established in vitro. Fibroblasts are the most common cells of
connective tissue in mammals 901; these cells can direct cell-cell interactions, release various
factors, and modulate ECM interactions 902. These properties led to the choice of primary
swine fibroblasts as a control cell line for rG3 studies because of their close association with
mammary tissue and low β4 integrin expression, which is the indirect target of rG3 (see Fig.
17). Additionally, a primary cell line serves as a better control for in vitro assays than an
immortalized cell line due to the loss of the p53 tumor suppressor pathway function in many

157

immortalized lines 903–905 which is a major pathway focus of this dissertation. Interestingly,
Reactome analysis of transcripts after RNA sequencing indicates pathways utilized by
primary swine fibroblasts are very similar to those identified by K-means clustering in early
mammary development, including immune system, metabolism, signal transduction, cell
cycle regulation, gene transcription, and protein translation, as shown in Table 3.
Importantly, TP53 and CASP genes, critical inducers of apoptosis 906, are not found
expressed in the top 5% of genes expressed while integrin β4, integrin β1, and integrin α6 are
among the top 5% genes expressed (see Appendix C). As seen in Fig. 17, integrin ß4 protein
expression is significantly higher (p = 0.0016) in the MDA-MB-231 and MCF-10A cell lines
in comparison to the primary swine fibroblasts, but RNA sequencing results confirm that
integrin ß4 is still expressed to some level in this line. Panther analysis for biological process
of the top 5% of expressed transcripts indicates generic cellular and metabolic processes are
being executed for growth, suggesting this line is a good choice for comparison against the
MDA-MB-231 cell line (Fig. 18).

Table 13: Reactome analysis of top 15 pathways utilized by fibroblasts in vitro after 24 hr growth
Pathway
identifier
R-HSA-168256

Pathway name

#Entities found

Immune System

187

#Entities
total
2765

R-HSA-1430728

Metabolism

172

3461

R-HSA-162582

Signal Transduction

169

3002

R-HSA-392499

Metabolism of proteins

119

2373

R-HSA-1266738

Developmental Biology

104

1175

R-HSA-1280215

Cytokine Signaling in Immune system

103

1222

R-HSA-74160

Gene expression (Transcription)

97

1619

R-HSA-168249

Innate Immune System

92

1632

R-HSA-73857

RNA Polymerase II Transcription

90

1440
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R-HSA-597592

Post-translational protein modification

88

1530

R-HSA-556833

Metabolism of lipids

87

1316

R-HSA-449147

Signaling by Interleukins

85

910

R-HSA-212436

Generic Transcription Pathway

84

1300

R-HSA-372790

Signaling by GPCR

65

1509

R-HSA-1280218

Adaptive Immune System

57

1189

immune system
process
metabolic process

cellular component
organization or
biogenesis

biological adhesion
cellular process
multicellular
organismal process

developmental
process

response to stimulus
biological regulation

reproduction

localization

Figure 18. Panther biological Process analysis; primary fibroblasts after 24 hr growth in vitro
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Swine fibroblasts are unaffected by rG3 treatment at 20ug/mL
Differential gene expression analysis performed on primary swine fibroblasts treated
with 20ug/mL rG3 or with media further confirms the usage of this cell line as an in vitro
control for rG3 studies. After normalization, the maximum shift change between treated and
untreated fibroblasts was <31 with only 0.33% of the whole transcriptome resulting in a shift
change >5 with rG3 treatment. For the differentially expressed genes that increased with
treatment by a shift change of ³5, Reactome analysis indicated the pathways differentially
utilized were: Immune System, Signal Transduction, Metabolism, Cytokine Signaling in
Immune system, Metabolism of proteins, Innate Immune System, Gene expression
(Transcription), RNA Polymerase II Transcription, Generic Transcription Pathway, Signaling
by Interleukins, Post-translational protein modification, and Developmental Biology. A
summary of rG3 effect on primary swine fibroblasts can be seen in Table 14. Taken together
with the MTT results (Fig. 15), this transcriptome data indicates the primary swine
fibroblasts are largely unaffected by rG3 treatment, although they express the receptor for
rG3. This confirms their suitability as a control for subsequent in vitro assays.

Table 14. Top 75 Reactome pathways utilized by differentially expressed genes – rG3 treated
fibroblasts
Pathway
identifier

Pathway name

#Entities
found

R-HSA-168256

Immune System

187

2765

R-HSA-1430728

Metabolism

172

3461

R-HSA-162582

Signal Transduction

169

3002

R-HSA-392499

Metabolism of proteins

119

2373

R-HSA-1266738

Developmental Biology

104

1175

R-HSA-1280215

Cytokine Signaling in Immune system

103

1222

160

#Entities
total

R-HSA-74160

Gene expression (Transcription)

97

1619

R-HSA-168249

Innate Immune System

92

1632

R-HSA-73857

RNA Polymerase II Transcription

90

1440

R-HSA-597592

Post-translational protein modification

88

1530

R-HSA-556833

Metabolism of lipids

87

1316

R-HSA-449147

Signaling by Interleukins

85

910

R-HSA-212436

Generic Transcription Pathway

84

1300

R-HSA-372790

Signaling by GPCR

65

1509

R-HSA-1280218

Adaptive Immune System

57

1189

R-HSA-382551

Transport of small molecules

56

987

R-HSA-109582

Hemostasis

56

798

R-HSA-1643685

Disease

55

1496

R-HSA-422475

Axon guidance

51

611

R-HSA-166520

Signalling by NGF

45

615

R-HSA-5653656

Vesicle-mediated transport

43

828

R-HSA-199991

Membrane Trafficking

40

667

R-HSA-388396

GPCR downstream signaling

38

1140

R-HSA-6785807

Interleukin-4 and 13 signaling

37

212

R-HSA-1474244

Extracellular matrix organization

36

329

R-HSA-1433557

Signaling by SCF-KIT

34

468

R-HSA-186797

Signaling by PDGF

33

520

R-HSA-187037

33

527

R-HSA-194315

NGF signalling via TRKA from the
plasma membrane
Signaling by Rho GTPases

32

445

R-HSA-186763

Downstream signal transduction

31

489

R-HSA-2454202

Fc epsilon receptor (FCERI) signaling

31

594

R-HSA-177929

Signaling by EGFR

31

502

R-HSA-2424491

DAP12 signaling

30

492

R-HSA-2172127

DAP12 interactions

30

509

R-HSA-112316

Neuronal System

29

425

R-HSA-6809371

Formation of the cornified envelope

28

137

R-HSA-6805567

Keratinization

28

225

R-HSA-881907

28

504

R-HSA-194138

Gastrin-CREB signalling pathway via
PKC and MAPK
Signaling by VEGF

28

381

R-HSA-1989781

PPARA activates gene expression

27

177

R-HSA-400206

Regulation of lipid metabolism by
Peroxisome proliferator-activated

27

180

161

receptor α (PPARα)
R-HSA-6798695

Neutrophil degranulation

27

480

R-HSA-4420097

VEGFA-VEGFR2 Pathway

27

372

R-HSA-1852241

Organelle biogenesis and maintenance

26

334

R-HSA-8957322

Metabolism of steroids

25

316

R-HSA-983169

25

464

R-HSA-5683057

Class I MHC mediated antigen processing
& presentation
MAPK family signaling cascades

25

324

R-HSA-8953897

Cellular responses to external stimuli

25

598

R-HSA-375165

NCAM signaling for neurite out-growth

24

306

R-HSA-74752

Signaling by Insulin receptor

24

349

R-HSA-76002

24

305

R-HSA-5663202

Platelet activation, signaling and
aggregation
Diseases of signal transduction

24

463

R-HSA-451927

Interleukin-2 family signaling

23

288

R-HSA-512988

Interleukin-3, 5 and GM-CSF signaling

23

293

R-HSA-448424

Interleukin-17 signaling

23

332

R-HSA-5688426

Deubiquitination

23

289

R-HSA-2262752

Cellular responses to stress

23

511

R-HSA-194840

Rho GTPase cycle

22

144

R-HSA-912526

Interleukin receptor SHC signaling

22

277

R-HSA-8853659

RET signaling

22

292

R-HSA-2428928

IRS-related events triggered by IGF1R

22

325

R-HSA-2428924

IGF1R signaling cascade

22

326

R-HSA-2404192

22

327

R-HSA-74751

Signaling by Type 1 Insulin-like Growth
Factor 1 Receptor (IGF1R)
Insulin receptor signalling cascade

22

324

R-HSA-425407

SLC-mediated transmembrane transport

22

413

R-HSA-500792

GPCR ligand binding

22

592

R-HSA-112315

Transmission across Chemical Synapses

22

278

R-HSA-2871796

FCERI mediated MAPK activation

21

377

R-HSA-112399

IRS-mediated signalling

21

321

R-HSA-913531

Interferon Signaling

21

292

R-HSA-3700989

Transcriptional Regulation by TP53

21

485

R-HSA-5673001

RAF/MAP kinase cascade

20

267

R-HSA-112412

SOS-mediated signalling

20

267

R-HSA-187706

Signalling to p38 via RIT and RIN

20

272

R-HSA-167044

Signalling to RAS

20

278
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Table 15. Shift change values for rG3 treated fibroblasts
Condition
rG3 treated
fibroblasts at 24
hours. Formula =
(Fibro treated 24
hr - Fibro control
24 hr)/(Fibro
control 24 hr)

Shift
change
31.00

GeneID

Gene Name

RND1

13.33

EGR3

13.25
13.00
13.00

CHI3L2
KLHL9
RORC

12.00

ALOX5AP

10.00
10.00

RASIP1
MLXIPL

9.14
9.00

TRIB1
NR4A3

8.33

SLC16A1

8.00

WDFY4

8.00

TTC21A

8.00

GATM

8.00
8.00

SOST
NLRP3

8.00

SRCIN1

8.00

IQSEC3

7.32

DUSP5

7.00

TCF7L1

7.00

RASGEF1A

7.00
6.95
6.60
6.10

LTB
HES1
OLFM1
HCLS1

Rho-related GTP-binding protein
Rho6;RND1;ortholog
Early growth response protein
3;EGR3;ortholog
Chitinase-3-like protein 2;CHI3L2;ortholog
Kelch-like protein 9;KLHL9;ortholog
Nuclear receptor RORgamma;RORC;ortholog
Arachidonate 5-lipoxygenase-activating
protein;ALOX5AP;ortholog
Ras-interacting protein 1;RASIP1;ortholog
Carbohydrate-responsive element-binding
protein;MLXIPL;ortholog
Tribbles homolog 1;TRIB1;ortholog
Nuclear receptor subfamily 4 group A
member 3;NR4A3;ortholog
Monocarboxylate transporter
1;SLC16A1;ortholog
WD repeat- and FYVE domain-containing
protein 4;WDFY4;ortholog
Tetratricopeptide repeat protein
21A;TTC21A;ortholog
Glycine amidinotransferase,
mitochondrial;GATM;ortholog
Sclerostin;SOST;ortholog
NACHT, LRR and PYD domainscontaining protein 3;NLRP3;ortholog
SRC kinase signaling inhibitor
1;SRCIN1;ortholog
IQ motif and SEC7 domain-containing
protein 3;IQSEC3;ortholog
Dual specificity protein phosphatase
5;DUSP5;ortholog
Transcription factor 7-like
1;TCF7L1;ortholog
Ras-GEF domain-containing family
member 1A;RASGEF1A;ortholog
Lymphotoxin-β;LTB;ortholog
Transcription factor HES-1;HES1;ortholog
Noelin;OLFM1;ortholog
Hematopoietic lineage cell-specific
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6.00

PIANP

6.00

TMC4

6.00

TMEM198

6.00
6.00
5.64

FAM189A2
MYH7B
EGR2

5.50

USP2

5.50

LRRK2

5.33

SLC7A8

5.25
5.25
5.17

ZNF404
ZNF704
DOCK8

5.00

NRARP

5.00

ARHGAP30

5.00

KCNK1

5.00

RAB37

5.00

RGL3

5.00

TTC22

5.00
5.00

NCF4
AGER

protein;HCLS1;ortholog
PILR α-associated neural
protein;PIANP;ortholog
Transmembrane channel-like protein
4;TMC4;ortholog
Transmembrane protein
198;TMEM198;ortholog
Protein FAM189A2;FAM189A2;ortholog
Myosin-7B;MYH7B;ortholog
E3 SUMO-protein ligase
EGR2;EGR2;ortholog
Ubiquitin carboxyl-terminal hydrolase
2;USP2;ortholog
Leucine-rich repeat serine/threonine-protein
kinase 2;LRRK2;ortholog
Large neutral amino acids transporter small
subunit 2;SLC7A8;ortholog
Zinc finger protein 404;ZNF404;ortholog
Zinc finger protein 704;ZNF704;ortholog
Dedicator of cytokinesis protein
8;DOCK8;ortholog
Notch-regulated ankyrin repeat-containing
protein;NRARP;ortholog
Rho GTPase-activating protein
30;ARHGAP30;ortholog
Potassium channel subfamily K member
1;KCNK1;ortholog
Ras-related protein Rab37;RAB37;ortholog
Ral guanine nucleotide dissociation
stimulator-like 3;RGL3;ortholog
Tetratricopeptide repeat protein
22;TTC22;ortholog
Neutrophil cytosol factor 4;NCF4;ortholog
Advanced glycosylation end productspecific receptor;AGER;ortholog

MDA-MB-231 TNBC transcriptome from in vitro growth suggests signaling similarities with
early postnatal mammary development in vivo
RNA sequencing provided data for approximately 58,000 gene transcripts for the
MDA-MB-231 TNBC cell line, 30,000 of which were actively expressed (raw transcript
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count ³ 1). As seen in Table 16, after 24 hours of growth in vitro, the most frequently utilized
Reactome pathways by the TNBC cells were: Metabolism of proteins, Immune System,
Signal Transduction, Metabolism, Post-translational protein modification, Innate Immune
System, Disease, Gene expression (Transcription), Metabolism of RNA, Cytokine Signaling
in Immune system, Developmental Biology, RNA Polymerase II Transcription, Adaptive
Immune System, Signaling by Interleukins, and Generic Transcription Pathway. Importantly,
the top pathways utilized by the MDA-MB-231 during normal growth and proliferation
cycles are almost identical to the signaling pathways identified by K-means clustering in
early mammary development AND the pathways utilized by primary swine fibroblasts during
growth.
The MDA-MB-231 line is an invasive breast cancer cell line that lacks expression of
estrogen (ER) α, progesterone (PR) and human epidermal growth factor receptor 2 (HER2),
and is classified as a TNBC line 378. As previously discussed, MDA-MB-231 cells express
some level of integrin α6 and integrin ß4 284,312,373–377, and the α6ß4 complex is necessary for
the tumorigenic properties of these cells 303. In addition to the Western Blotting results in Fig.
17, the expression of these integrin molecules is confirmed through RNA sequencing.
Importantly, TP53 and CASP genes, critical inducers of apoptosis 906, are not found
expressed in the top 5% of active genes (see Appendix C) expressed in untreated, normally
proliferating MDA-MB-231 cells in vitro. Panther analysis for biological process indicates
common cellular and metabolic processes are being executed for growth of this TNBC cell
line in vitro (Fig. 19).
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Table 16: Reactome pathways utilized by MDA-MB-231 cells after 24 hrs growth in vitro
Pathway
identifier
R-HSA-392499

Pathway name
Metabolism of proteins

511

#Entities
total
2373

R-HSA-168256

Immune System

464

2765

R-HSA-162582

Signal Transduction

427

3002

R-HSA-1430728

Metabolism

344

3461

R-HSA-597592

Post-translational protein modification

289

1530

R-HSA-168249

Innate Immune System

279

1632

R-HSA-1643685

Disease

271

1496

R-HSA-74160

Gene expression (Transcription)

255

1619

R-HSA-8953854

Metabolism of RNA

249

782

R-HSA-1280215

Cytokine Signaling in Immune system

245

1222

R-HSA-1266738

Developmental Biology

229

1175

R-HSA-73857

RNA Polymerase II Transcription

225

1440

R-HSA-1280218

Adaptive Immune System

223

1189

R-HSA-449147

Signaling by Interleukins

215

910

R-HSA-212436

Generic Transcription Pathway

193

1300

R-HSA-5653656

Vesicle-mediated transport

184

828

R-HSA-422475

Axon guidance

172

611

R-HSA-199991

Membrane Trafficking

171

667

R-HSA-5663205

Infectious disease

163

531

R-HSA-1640170

Cell Cycle

154

680

R-HSA-166520

Signalling by NGF

150

615

R-HSA-8953897

Cellular responses to external stimuli

141

598

R-HSA-69278

Cell Cycle, Mitotic

140

566

R-HSA-186797

Signaling by PDGF

135

520

R-HSA-71291

Metabolism of amino acids and
derivatives
Cellular responses to stress

133

656

133

511

133

527

R-HSA-382551

NGF signalling via TRKA from the
plasma membrane
Transport of small molecules

133

987

R-HSA-72766

Translation

131

381

R-HSA-2262752
R-HSA-187037

#Entities found
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immune system
process
cellular component
organization or
biogenesis

growth

metabolic process

cellular process

biological
adhesion
locomotion
multicellular
organismal process

developmental
process
localization
response to stimulus

reproduction
biological regulation

Figure 19. Panther Biological Processes utilized by MDA-MB-231 transcriptome
after 24 hrs growth in vitro
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Differential expression analysis of MDA-MB-231 cells with and without 20ug/mL rG3
treatment for 24 hours indicates widespread apoptotic induction and downregulation of
extracellular matrix organization
In contrast with the primary swine fibroblasts (Table 14), when MDA-MB-231 cells
were treated with rG3, 18% of the active transcriptome showed an upregulation in gene
expression (shift change >5; maximum 14,000) and 5.8% of the active transcriptome was
downregulated (shift change < -5). In contrast with fibroblast controls and untreated 231s,
Reactome analysis indicates the top 75 pathways utilized by upregulated genes are indicative
of apoptosis and cellular damage, as shown in Table 17. Seventy-five was chosen as a cutoff
due to the decrease in functional significance of pathways below this. The top 75 pathways
utilized by upregulated genes with a significant z-score (> 2), shown in Table 18, are
similarly indicative of apoptosis and IFN (link to TRAIL and p53) signaling. The top 75
pathways utilized by downregulated genes with significant z-score (Table 19) are:
Extracellular matrix organization, ECM proteoglycans, Integrin cell surface interactions,
Degradation of the extracellular matrix, Immune System, Signal Transduction, Non-integrin
membrane-ECM interactions, Cytokine Signaling in Immune system, Collagen chain
trimerization, Assembly of collagen fibrils and other multimeric structures, Collagen
degradation, Collagen biosynthesis and modifying enzymes, Collagen formation, MET
activates PTK2 signaling, MET promotes cell motility, and Signaling by MET. Importantly,
Transcriptional regulation by TP53 is not present in this Reactome list and apoptosis and
programmed cell death are not present in the top 100 pathways generated.
This indicates a much greater effect of rG3 on the transcriptome of MDA-MB-231
cells than primary swine fibroblast control cells. A literature review indicates that 56% of the
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genes in the top 0.15% of differentially expressed genes after rG3 treatment (normalized by
control) are positive regulators of apoptosis (with 10% both positive and negative), 14% are
negative, and 18% are unknown or unconfirmed. When z-scores are applied, 40% of
upregulated genes with a z-score >2 could function as positive apoptosis regulators.
Interestingly, genes downregulated with rG3 treatment (Table 19) predominantly fall
into ECM organization and stability categories and are similar to those genes that contribute
positively to early postnatal mammary gland development (as seen in Fig. 9). Since direct
attachment of mammary epithelial cells to the ECM can occur through focal adhesions (FAs)
and HDs, which are two adhesion complexes that form mechanical links between the ECM
and the actomyosin cytoskeleton 140, linking the ECM and the cytoskeleton is critical in
regulation of a variety of processes, including proliferation and differentiation. Additionally,
apoptosis is frequently characterized largely by a large loss of cellular contact with the matrix
907

, so the downregulation of ECM genes after rG3 treatment of TNBC cells in vitro suggest

that rG3 leads to decreased stability and integrity of the ECM and cell cytoskeleton,
supporting apoptosis. Taken together, functional analysis of differentially expressed genes
after rG3 treatment indicates widespread apoptotic induction in MDA-MB-231 cells in
comparison to treated fibroblasts and suggests TP53- dependent signaling is partially
responsible.

Table 17. Top 75 Reactome pathways utilized by differentially expressed genes in rG3
treated MDA-MB-231s
Pathway identifier

Pathway name

R-HSA-168256

Immune System

#Entities found
364

169

#Entities
total
2765

R-HSA-1430728

Metabolism

335

3461

R-HSA-392499

Metabolism of proteins

217

2373

R-HSA-1280215

Cytokine Signaling in Immune system

208

1222

R-HSA-162582

Signal Transduction

189

3002

R-HSA-168249

Innate Immune System

177

1632

R-HSA-74160

Gene expression (Transcription)

169

1619

R-HSA-1280218

Adaptive Immune System

156

1189

R-HSA-73857

RNA Polymerase II Transcription

153

1440

R-HSA-212436

Generic Transcription Pathway

147

1300

R-HSA-597592

Post-translational protein modification

135

1530

R-HSA-556833

Metabolism of lipids

132

1316

R-HSA-913531

Interferon Signaling

117

292

R-HSA-983169

109

464

R-HSA-1643685

Class I MHC mediated antigen
processing & presentation
Disease

98

1496

R-HSA-877300

Interferon gamma signaling

97

176

R-HSA-6798695

Neutrophil degranulation

95

480

R-HSA-449147

Signaling by Interleukins

90

910

R-HSA-909733

Interferon α/β signaling

90

141

R-HSA-198933

87

316

R-HSA-1266738

Immunoregulatory interactions between
a Lymphoid and a non-Lymphoid cell
Developmental Biology

85

1175

R-HSA-1236975

Antigen processing-Cross presentation

83

186

R-HSA-1236974

ER-Phagosome pathway

80

164

R-HSA-8953897

Cellular responses to external stimuli

79

598

R-HSA-382551
R-HSA-2262752

Transport of small molecules
Cellular responses to stress

78
76

987
511

R-HSA-983170

76

102

R-HSA-1236977

Antigen Presentation: Folding,
assembly and peptide loading of class
I MHC
Endosomal/Vacuolar pathway

74

82

R-HSA-1640170

Cell Cycle

71

680

R-HSA-109582

Hemostasis

68

798

R-HSA-3700989

Transcriptional Regulation by TP53

67

485

R-HSA-8953854

Metabolism of RNA

60

782

R-HSA-69278

Cell Cycle, Mitotic

57

566

R-HSA-372790

Signaling by GPCR

56

1509

R-HSA-5653656

Vesicle-mediated transport

55

828

170

R-HSA-199991

Membrane Trafficking

52

667

R-HSA-422475

Axon guidance

44

611

R-HSA-1428517

44

219

R-HSA-72766

The citric acid (TCA) cycle and
respiratory electron transport
Translation

43

381

R-HSA-166520

Signalling by NGF

42

615

R-HSA-8957322

Metabolism of steroids

42

316

R-HSA-425407

SLC-mediated transmembrane transport

39

413

R-HSA-1852241

Organelle biogenesis and maintenance

39

334

R-HSA-68886

M Phase

39

390

R-HSA-163200

Respiratory electron transport, ATP
synthesis by chemiosmotic coupling, and
heat production by uncoupling proteins.
DNA Repair

39

146

38

348

37

656

R-HSA-2172127

Metabolism of amino acids and
derivatives
DAP12 interactions

37

509

R-HSA-71387

Metabolism of carbohydrates

36

414

R-HSA-211859

Biological oxidations

36

548

R-HSA-196854

Metabolism of vitamins and cofactors

36

356

R-HSA-187037

35

527

R-HSA-1474244

NGF signalling via TRKA from the
plasma membrane
Extracellular matrix organization

34

329

R-HSA-186797

Signaling by PDGF

34

520

R-HSA-2424491

DAP12 signaling

34

492

R-HSA-194315

Signaling by Rho GTPases

34

445

R-HSA-388396

GPCR downstream signaling

34

1140

R-HSA-611105

Respiratory electron transport

34

115

R-HSA-177929

Signaling by EGFR

33

502

R-HSA-6785807

Interleukin-4 and 13 signaling

33

212

R-HSA-2454202

Fc epsilon receptor (FCERI) signaling

32

594

R-HSA-186763

Downstream signal transduction

32

489

R-HSA-72312

rRNA processing

32

239

R-HSA-1433557

Signaling by SCF-KIT

31

468

R-HSA-8978868

Fatty acid metabolism

30

435

R-HSA-69620

Cell Cycle Checkpoints

30

279

R-HSA-72306

tRNA processing

30

205

R-HSA-5663205

Infectious disease

29

531

R-HSA-3371556

Cellular response to heat stress

29

133

R-HSA-73894
R-HSA-71291

171

R-HSA-5368287

Mitochondrial translation

29

143

R-HSA-1483257

Phospholipid metabolism

28

315

R-HSA-446203

Asparagine N-linked glycosylation

28

420

R-HSA-5357801

Programmed Cell Death

28

187

R-HSA-109581

Apoptosis

28

179

R-HSA-76002

Platelet activation, signaling and
aggregation

28

305

Table 18: Top 75 pathways utilized by upregulated genes in MDA-MB-231 cells after rG3
treatment (with significant z-score)
Pathway identifier

Pathway name

R-HSA-168256

Immune System

R-HSA-1280215

107

#Entities
total
2765

Cytokine Signaling in Immune system

91

1222

R-HSA-1280218

Adaptive Immune System

69

1189

R-HSA-983169

Class I MHC mediated antigen
processing & presentation
Interferon Signaling

63

464

63

292

Antigen Presentation: Folding,
assembly and peptide loading of class
I MHC
ER-Phagosome pathway

61

102

61

164

Antigen processing-Cross
presentation
Interferon gamma signaling

61

186

60

176

59

316

R-HSA-1236977

Immunoregulatory interactions
between a Lymphoid and a nonLymphoid cell
Endosomal/Vacuolar pathway

58

82

R-HSA-909733

Interferon α/β signaling

57

141

R-HSA-1430728

Metabolism

50

3461

R-HSA-392499

Metabolism of proteins

39

2373

R-HSA-168249

Innate Immune System

32

1632

R-HSA-449147

Signaling by Interleukins

31

910

R-HSA-1643685

Disease

30

1496

R-HSA-8953854

Metabolism of RNA

28

782

R-HSA-162582

Signal Transduction

26

3002

R-HSA-109582

Hemostasis

25

798

R-HSA-913531
R-HSA-983170
R-HSA-1236974
R-HSA-1236975
R-HSA-877300
R-HSA-198933

#Entities found

172

R-HSA-6798695

Neutrophil degranulation

20

480

R-HSA-5663205

Infectious disease

19

531

R-HSA-72312

rRNA processing

18

239

R-HSA-597592

Post-translational protein modification

18

1530

R-HSA-382551

Transport of small molecules

16

987

R-HSA-5653656

Vesicle-mediated transport

16

828

R-HSA-71387

Metabolism of carbohydrates

15

414

R-HSA-2262752

Cellular responses to stress

15

511

R-HSA-8953897

Cellular responses to external stimuli

15

598

R-HSA-1428517

14

219

14

305

R-HSA-199991

The citric acid (TCA) cycle and
respiratory electron transport
Platelet activation, signaling and
aggregation
Membrane Trafficking

14

667

R-HSA-74160

Gene expression (Transcription)

14

1619

R-HSA-114608

Platelet degranulation

13

137

R-HSA-76005

13

144

R-HSA-1266738

Response to elevated platelet cytosolic
Ca2+
Developmental Biology

13

1175

R-HSA-447115

Interleukin-12 family signaling

12

95

R-HSA-422475

Axon guidance

12

611

R-HSA-212436

Generic Transcription Pathway

12

1300

R-HSA-73857

RNA Polymerase II Transcription

12

1440

R-HSA-6785470

tRNA processing in the mitochondrion

11

47

R-HSA-8868766

rRNA processing in the mitochondrion

11

41

R-HSA-72306

tRNA processing

11

205

R-HSA-1474244

Extracellular matrix organization

11

329

R-HSA-168255

Influenza Life Cycle

10

183

R-HSA-8950505

10

74

R-HSA-168254

Gene and protein expression by JAKSTAT signaling after Interleukin-12
stimulation
Influenza Infection

10

194

R-HSA-72766

Translation

10

381

R-HSA-3700989

Transcriptional Regulation by TP53

10

485

R-HSA-1640170

Cell Cycle

10

680

R-HSA-556833

Metabolism of lipids

10

1316

R-HSA-163200

Respiratory electron transport, ATP
synthesis by chemiosmotic coupling,
and heat production by uncoupling

9

146

R-HSA-76002

173

proteins.
R-HSA-2172127

DAP12 interactions

9

509

R-HSA-372790

Signaling by GPCR

9

1509

R-HSA-156902

Peptide chain elongation

8

99

R-HSA-70171

Glycolysis

8

108

R-HSA-156842

Eukaryotic Translation Elongation

8

104

R-HSA-611105

Respiratory electron transport

8

115

R-HSA-70326

Glucose metabolism

8

139

R-HSA-2408522

Selenoamino acid metabolism

8

189

R-HSA-168273

8

171

R-HSA-917937

Influenza Viral RNA Transcription and
Replication
Iron uptake and transport

8

83

R-HSA-6785807

Interleukin-4 and 13 signaling

8

212

R-HSA-69275

G2/M Transition

8

210

R-HSA-453274

Mitotic G2-G2/M phases

8

212

R-HSA-381119

Unfolded Protein Response (UPR)

8

160

R-HSA-71291

8

656

R-HSA-69278

Metabolism of amino acids and
derivatives
Cell Cycle, Mitotic

8

566

R-HSA-2424491

DAP12 signaling

8

492

R-HSA-72689

Formation of a pool of free 40S subunits

7

106

R-HSA-72764

Eukaryotic Translation Termination

7

108

R-HSA-975956

Nonsense Mediated Decay (NMD)
independent of the Exon Junction
Complex (EJC)
L13a-mediated translational silencing of
Ceruloplasmin expression
SRP-dependent cotranslational protein
targeting to membrane

7

102

7

118

7

120

R-HSA-156827
R-HSA-1799339

Table 19: Top 75 pathways utilized by downregulated genes with significant z-score
Pathway
identifier
R-HSA1474244
R-HSA3000178
R-HSA-216083

Pathway name

#Entities found

Extracellular matrix organization

14

#Entities
total
329

ECM proteoglycans

12

78

Integrin cell surface interactions

10

87

R-HSA-

Degradation of the extracellular matrix

9

148

174

1474228
R-HSA-168256

Immune System

9

2765

R-HSA-162582

Signal Transduction

9

3002

R-HSA3000170
R-HSA3000171
R-HSA1280215
R-HSA8948216
R-HSA2022090
R-HSA1442490
R-HSA1650814
R-HSA1474290
R-HSA6785807
R-HSA-186797

Syndecan interactions

7

29

Non-integrin membrane-ECM
interactions
Cytokine Signaling in Immune system

7

61

7

1222

Collagen chain trimerization

6

44

Assembly of collagen fibrils and other
multimeric structures
Collagen degradation

6

67

6

69

Collagen biosynthesis and modifying
enzymes
Collagen formation

6

76

6

104

Interleukin-4 and 13 signaling

6

212

Signaling by PDGF

6

520

R-HSA-449147

Signaling by Interleukins

6

910

R-HSA8874081
R-HSA8875878
R-HSA6806834
R-HSA2173782
R-HSA-397014

MET activates PTK2 signaling

5

32

MET promotes cell motility

5

45

Signaling by MET

5

87

Binding and Uptake of Ligands by
Scavenger Receptors
Muscle contraction

5

169

5

216

R-HSA-76002

5

305

R-HSA-375165

Platelet activation, signaling and
aggregation
NCAM signaling for neurite out-growth

5

306

R-HSA-422475

Axon guidance

5

611

R-HSA-109582

Hemostasis

5

798

R-HSA5653656
R-HSA1266738
R-HSA1643685
R-HSA-390522

Vesicle-mediated transport

5

828

Developmental Biology

5

1175

Disease

5

1496

Striated Muscle Contraction

4

40

175

R-HSA-419037

NCAM1 interactions

4

44

R-HSA3781865
R-HSA-597592

Diseases of glycosylation

4

190

Post-translational protein modification

4

1530

R-HSA-392499

Metabolism of proteins

4

2373

R-HSA1430728
R-HSA-445355

Metabolism

4

3461

Smooth Muscle Contraction

3

39

R-HSA3560782
R-HSA3000480
R-HSA-76009

Diseases associated with
glycosaminoglycan metabolism
Scavenging by Class A Receptors

3

49

3

50

Platelet Aggregation (Plug Formation)

3

52

R-HSA8957275
R-HSA-381426

Post-translational protein phosphorylation

3

109

Regulation of Insulin-like Growth Factor
(IGF) transport and uptake by Insulin-like
Growth Factor Binding Proteins (IGFBPs)
Platelet degranulation

3

127

3

137

Response to elevated platelet cytosolic
Ca2+
Glycosaminoglycan metabolism

3

144

3

183

Cell surface interactions at the vascular
wall
Immunoregulatory interactions between a
Lymphoid and a non-Lymphoid cell
Metabolism of carbohydrates

3

256

3

316

3

414

R-HSA1280218
R-HSA3595174
R-HSA3595172
R-HSA3595177
R-HSA-430116

Adaptive Immune System

3

1189

Defective CHST14 causes EDS,
musculocontractural type
Defective CHST3 causes SEDCJD

2

9

2

9

Defective CHSY1 causes TPBS

2

10

GP1b-IX-V activation signalling

2

12

R-HSA2022923
R-HSA2214320
R-HSA-75892

Dermatan sulfate biosynthesis

2

13

Anchoring fibril formation

2

15

Platelet Adhesion to exposed collagen

2

16

R-HSA3560801

Defective B3GAT3 causes JDSSDHD

2

21

R-HSA-114608
R-HSA-76005
R-HSA1630316
R-HSA-202733
R-HSA-198933
R-HSA-71387
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R-HSA4420332
R-HSA3560783
R-HSA2243919
R-HSA2022870
R-HSA2024101
R-HSA1971475
R-HSA2129379
R-HSA1566948
R-HSA-114604

Defective B3GALT6 causes EDSP2 and
SEMDJL1
Defective B4GALT7 causes EDS,
progeroid type
Crosslinking of collagen fibrils

2

21

2

21

2

24

Chondroitin sulfate biosynthesis

2

25

CS/DS degradation

2

29

A tetrasaccharide linker sequence is
required for GAG synthesis
Molecules associated with elastic fibres

2

31

2

38

Elastic fibre formation

2

46

GPVI-mediated activation cascade

2

64

R-HSA1793185
R-HSA8936459

Chondroitin sulfate/dermatan sulfate
metabolism
RUNX1 regulates genes involved in
megakaryocyte differentiation and platelet
function
Heparan sulfate/heparin (HS-GAG)
metabolism
Transcriptional regulation by RUNX1

2

73

2

78

2

88

2

260

Generic Transcription Pathway

2

1300

R-HSA-73857

RNA Polymerase II Transcription

2

1440

R-HSA-74160

Gene expression (Transcription)

2

1619

R-HSA1566977
R-HSA3656244
R-HSA3656225

Fibronectin matrix formation

1

7

Defective B4GALT1 causes B4GALT1CDG (CDG-2d)
Defective CHST6 causes MCDC1

1

9

1

9

R-HSA1638091
R-HSA8878171
R-HSA-212436
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cellular component
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biogenesis

immune system
process

cellular process

multicellular
organismal process
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biological regulation
response to stimulus

biological adhesion

developmental
process

Figure 20. Panther Biological Process utilized by top genes expressed with negative zscore (downregulated) in MDA-MB-231 cells in vitro
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T cell activation

FAS
Plasminogen
FGF
ATP Apoptosis Interleukin
signaling
activating
cascade
signaling
synthesis signaling signaling
pathway
pathway pathway
pathway

Angiogenesis

Alzheimer diseasepresenilin pathway

Glycolysis
Wnt signaling
pathway
Pyruvate
metabolism

Integrin signalling
pathway

p53 pathway

Alzheimer
disease-amyloid
secretase
pathway

Huntington disease

Inflammation
mediated by
chemokine and
cytokine signaling
pathway
Parkinson disease

Fructose galactose
metabolism

EGF receptor
signaling pathway

CCKR signaling map

Gonadotropinreleasing hormone
receptor pathway

Blood coagulation
Cadherin
signaling
pathway

Nicotinic
acetylcholine receptor
signaling pathway

Oxidative
stress response

Cytoskeletal
regulation by Rho
GTPase

PI3 kinase pathway

Figure 21. Panther Pathway utilized by top genes expressed with positive z-score
(upregulated) in MDA-MB-231 cells in vitro
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POS Z SCORE BP- rG3 treated MDA-MB-231
immune system
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growth
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biogenesis
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reproduction

response to stimulus

biological regulation

Figure 22. Panther Biological Process utilized by top genes expressed with positive zscore (upregulated) in MDA-MB-231 cells in vitro
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rG3 binds to integrin α-6 β-4 to modulate downstream signaling
Integrin transcript expression, shown in Figure 23, indicates that rG3 highly
upregulates the expression of ITGA2, ITGA3, ITGA6, ITGB1, ITGB4, and ITGB5 on the
MDA-MB-231 cell surface after 24 hours of in vitro treatment. Additionally, the α6β4
signaling pathway specific to rG3 originally proposed is shown in Fig. 24 with RNA
sequencing results applied. Taken together with the heat map in Figure 24, these results show

Integrin transcript counts in MDA-MB-231 cells
60000
50000
40000
30000
20000
10000
0

JC0

J T 24

J C 24

JT0

Figure 23. Integrin transcript expression in MDA-MB-231 cells at 0 and
after 24 hours of in vitro treatment. JC = control; JT = rG3 treated.

modulation of the PI3K/AKT pathway through integrin expression by rG3 treatment.
As previously discussed, any normal cellular signaling and ECM pathways
containing integrin receptors are deregulated in cancer to allow cellular migration, as
evidenced by differential integrin expression among normal breast, simple hyperplasia,
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atypical hyperplasia, ductal carcinoma in situ (DCIS) and invasive tumors 307. α6β4 integrin
is thought to remodel the ECM through interaction with the PI3K and RhoA cell signaling
pathways 308,309, supporting PI3K activation through different receptor tyrosine kinases
(RTKs) 312. targeted therapies 137. Notably, α6β4 integrin may modulate oncogenic signaling
through association with Laminin molecules in the ECM. Modulation of integrin transcript
expression after rG3 treatment indicates that this recombinant form of Laminin-5 is binding
to or influencing integrin expression in MDA-MB-231 cells.
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Figure 24: α6β4 integrin modulation and signaling in MDA-MB-231 cells with and without
rG3 treatment. Left half of node represents untreated cells; right half of node represents
treated cells. Blue represents expression levels of 0-1. Shades of red represent high
expression levels.
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Modulation of the α6β4 integrin signaling pathway through rG3
RNA seq transcript count values between rG3 treated and untreated MDA-MB-231
cells were used to curate pathways using PathVisio and WikiPathways 435–438; raw counts for
rG3 treated and untreated MDA-MB-231 cells and primary swine fibroblasts were
normalized and prepared into heat maps with Genesis 428. Blue = downregulation/low
expression; red = upregulation /high expression; Pathvisio gray = no change; heatmap gray =
gene not found. For comparison of human and swine genes, swine gene orthologs were
included if possible using OrthoDB 439. After rG3 treatment, upregulation of multiple
members of the PI3K/AKT pathway is shown in Fig 24. Upregulated gene transcripts include
ITGA6 and ITGB4; especially important for apoptosis are the upregulated gene transcripts of
BIM, BCL2, BAX, P53, BAD, and CASP9.
Upon binding to its ligand, ITGA6 and ITGB4 are likely upregulated due to “insideout” signaling characteristic of integrin molecules 908 that allow intracellular signals to
increase the affinity of integrin molecules to their extracellular ligands. Downstream, our data
suggests slight upregulation in PTEN, a multifunctional tumor suppressor previously
discussed 337,909–911. However, pro-survival signaling molecules such as Paxillin and AKT1
are not downregulated, but pro-apoptosis molecules downstream of AKT1 including BIM,
BLC2, BAX, P53, BAD, and CASP9 are upregulated with rG3 treatment. This suggests that
the signaling mechanisms between ITGA6 and ITGB4 induction and apoptosis induction are
more complicated than the original hypothesis, and will be elucidated using a more
comprehensive apoptosis modulation pathway.
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Differential expression analysis of MDA-MB-231 cells with and without 20ug/mL rG3
treatment for 24 hours indicates widespread apoptotic signaling and modulation of cell death
pathways
RNA seq transcript count values between rG3 treated and untreated MDA-MB-231
cells were used to curate pathways using PathVisio and WikiPathways 435–438; raw counts for
rG3 treated and untreated MDA-MB-231 cells and primary swine fibroblasts were
normalized and prepared into heat maps in Genesis 428. Blue = downregulation/low
expression; red = upregulation /high expression; Pathvisio gray = no change; heatmap gray =
gene not found. For comparison of human and swine genes, swine gene orthologs were
included if possible using OrthoDB 439. Pathway analysis demonstrates the widespread
apoptotic signaling that occurs with rG3 treatment after 24 hours (Figure 25).
A better understanding of the diverse modes of cell death in TNBC cells could
provide a molecular basis for new strategies targeting apoptotic molecules and programmed
cell death pathways. Our results elucidate further the cell signaling pathways and factors that
may modulate apoptosis; widespread apoptotic signaling is seen after rG3 treatment in MDAMB-231 cells, confirming the results of rG3 effect on cell viability in Fig 25. Apoptosis, or
programmed cell death, is tightly regulated process possessing a critical role in cellular
functions such as cell turnover, homeostasis, growth regulation, early development, immune
system function, and disease 906,912–916. This defensive mechanism acts to remove infected,
mutated, or damaged cells in response to a variety of internal and external stimuli, and is
characterized primarily by a large loss of cellular contact with the matrix 907. Apoptosis can
occur extrinsically, through activation of death receptors, or intrinsically, through the
mitochondria 913,914,917; evidence supports that in some cases these two pathways may be

185

converging rather than distinct entities 907. As shown in Fig 25 and 26, rG3 treatment of
TNBC cells in vitro leads to upregulation of multiple apoptotic molecules and modulation of
both intrinsic and extrinsic apoptosis, suggesting crosstalk between the two cell signaling
pathways is induced by rG3 treatment. A series of steps in either the extrinsic or intrinsic
pathway leads to activation of effector cysteine protease molecules known as caspases. In a
cascade of apoptotic activity, caspase molecules cleave both each other and nuclear and
cytoplasmic substrates responsible for the maintenance of nuclear integrity, cell cycle
progression, and DNA repair 918. Although less frequently, apoptosis can occur independently
of caspase molecules 919.
Caspases can be initiated extrinsically in several different ways, including ligation of
transmembrane members of the TNF receptor superfamily, specifically CD95/Fas or TNFrelated apoptosis-inducing ligand (TRAIL) 920–922. Upregulated apoptotic molecules after rG3
treatment include the transmembrane members of the TNF receptor superfamily capable of
downstream apoptosis induction (TRAIL, TRAIL-R4, TRAIL-R1, TRAIL-R2, TNFR-1,
TNFR-2) and FAS. These data suggest that rG3 treatment is initiating caspases extrinsically,
which leads to downstream apoptotic signaling modulation. Extrinsic initiation results in
activation of the initiator caspase-8, which cleaves downstream effector caspases including
caspase-3 920. Results show that after rG3 treatment, through activation of the TRAIL
receptors, FADD, CASP8, and CASP10 are upregulated in comparison to untreated TNBC
cells.
A wide range of signals in the extrinsic apoptosis pathway are stimulated by p53, the
most extensively studied and tightly regulated tumor suppressor that can be activated by
DNA damage, hypoxia, or oncogene expression 923. Our results also show an upregulation of
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TP53 and TP53 targets (Fig. 26), after rG3 treatment, indicating this tumor suppressor is
highly involved in apoptosis induced by rG3. When triggered by stress, p53 selectively
regulates cell cycle arrest, DNA repair, and apoptosis to protect genomic stability and prevent
tumor formation 264; p53 is often mutated in metastatic tumors; somatic p53 mutations occur
in greater than 50% of tumors and almost every cancer type 235,265,266. p53 is important in
therapeutic development as p53-dependent apoptosis contributes to cell death induced by
chemotherapy 924 and loss of p53 function has been associated with chemoresistance in
certain tumor types 925,926. Research suggests that p53-mediated apoptosis proceeds primarily
through the intrinsic apoptotic pathway 927, but the extrinsic pathway is also regulated by p53
though poorly understood 923. A greater understanding of the p53 modulated apoptosis
pathways and their crosstalk in response to rG3 treatment suggests rG3 is a valuable tool for
understanding the molecular mechanisms of cancer development, diagnosis, and therapy.
The most significant link between p53 activation and apoptosis comes from its ability
to control pro-apoptotic members of the Bcl-2 family, including Bax, Noxa, Puma, and Bid
928–932

. The intrinsic apoptosis pathway relies upon the the Bcl-2 protein family for release of

cytochrome c from the mitochondria 933–935, further linking p53 activation to intrinsic
apoptosis. Much remains to be uncovered regarding the mechanism of apoptotic control by
p53 targets, but it is accepted that the net effect is increase of the ratio of pro- to antiapoptotic proteins, shifting the balance to favor caspase activation and cell death 923. Baxinduced release of cytochrome c from the mitochondria subsequently activates caspase-9
929,936

. Interestingly, Bax has been recently shown to participate in apoptosis as an indirect

p53 target with the primary target being PUMA/BBC3 937. Noxa is thought to be involved in
p53 mediated apoptosis in a similar fashion to PUMA/BBC3 and Bax 938. The pro-apoptotic
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protein Bid has a unique role in uniting the extrinsic death pathway to the intrinsic pathway
through activation of mitochondrial disruption 929; impact of both pathways may be enhanced
when these converge through Bid 929. After rG3 treatment of MDA-MB-231 cells in vitro,
intrinsic apoptotic factors are highly upregulated, including BID, BAK1, BOK, BNIP3,
NOXA, PUMA, CYTOC, and CASP9 (seen in Fig 25 and 26 in red). Interestingly, although
anti-apoptotic BCL-XL 939 is upregulated after rG3 treatment, expression of BAK and BOK
is not inhibited. Modulation of apoptosis through cell cycle regulation is an important cell
signaling event, and the cell cycle regulator p16(INK4A) (p16) has been reported to be
upregulated in cervical cancer tissues where it promotes cell survival 940. After rG3 treatment,
expression of p16 is highly downregulated, suggesting it no longer can positively regulate
growth. Importantly, we do not see the same upregulation of pro-apoptotic factors in rG3
treated fibroblasts, although these genes are present; they remain mostly unchanged, as seen
in Fig. 25.
Extrinsically, p53 can induce mRNA expression of Fas receptor (CD95/Apo-1), a
member of the TNF-R family of receptors and a key component of the extrinsic death
pathway that is activated by binding of its ligand expressed predominantly on T-cells,
FasL/TNFSF6 941–943. When overexpressed, p53 can also stimulate Fas levels on the cell
surface, rapidly sensitizing cells to Fas-induced apoptosis before transcription-dependent
effects are seen 944. In human tumors, there is often a decrease in or disappearance of the
expression of Fas receptor (Apo-1; CD95) on the cell surface, inhibiting or decreasing Fasmediated death signaling that normally would recruit FADD and caspase-8 to the Fas
receptor to form the death-inducing signaling complex 945,946. In some cases, loss of Fas
expression can be a result of silencing by STAT-3 and CJUN, which is regulated by PI3K
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signaling 947,948. FAP-1 has been shown to suppress Fas-mediated apoptosis, but the specific
mechanisms of inhibition remain unknown 949. FAP-1, in association with either DPP4,
PLAUR or integrin molecules, is a negative regulator of apoptosis that is involved in
proteolysis of the extracellular matrix to promote cell adhesion, migration, and invasion; it
can also enhance tumor growth progression and reducing antitumor response of the immune
system. During autophagy, FAP-1 protein is degraded, promoting apoptosis 950. Our results
show that FAP-1 is highly downregulated during rG3 induced apoptosis where it is not able
to efficiently inhibit FADD/CASP8 signaling. PRKD1, another molecule capable of
inhibiting FADD/CASP8 signaling, is linked to increased proliferation and survival when
activated or expressed in various cell lines 951–957. After rG3 treatment in vitro, PRKD1
expression is highly downregulated, indicating its contribution to the decrease in cell
survival.
p53 can also induce TRAIL-R2, as confirmed by our results, which is the deathdomain-containing receptor for TNF-related apoptosis-inducing ligand (TRAIL) 958. PERP,
p53 apoptosis effector related to PMP-22, is another gene that is a direct p53 transcriptional
target and novel effector of apoptosis 959, but it remains to be defined how specifically this
gene contributes to p53-mediated apoptosis 960. However, it is known that PERP is induced
during apoptosis only and not during cell cycle arrest 961. After rG3 treatment in vitro, the
PERP gene is highly upregulated (see Appendix C). Elevation of the PERP protein
positively influences p53 through enhancement of nuclear localization and stabilization,
revealing a potential target for exploitation in enhancing p53 activity 961. Normally, caspase-8
and -10 respond to external death ligands while caspase-2 and -9 sense changes in
mitochondrial potential from the intrinsic pathway 929. After treatment, upregulation of
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CASP8, CASP10, CASP2, and CASP9 is seen, in addition to upregulation of CASP7,
CASP3, CASP4, CASP6, and DFFA indicating rG3 activates both the extrinsic and intrinsic
apoptotic pathway and modulates caspase signaling (Fig. 25/26).
P53, in addition to its ability to activate genes directly supporting apoptosis, can also
regulate genes that elude typical anti-apoptotic pathways. Pursuant to our focus, p53 has the
ability to regulate PTEN, the negative regulator of the PI3K/AKT pathway 962 Normally, the
PI3K pathway phosphorylates the major inhibitor of p53, Mdm2, in order to promote cell
survival under normal conditions 929. During stress-induced activation of p53, however,
caspase-mediated cleavage and degradation of the AKT protein 929,963 and expression of the
PTEN tumor suppressor gene (which dephosphorylates PI3K), are induced, impairing
PI3K/AKT signaling function 964. Our data show upregulation of PTEN and modulation of
the PI3K cell signaling pathway after rG3 treatment (Fig. 24). Taken together, this indicates
that p53-dependent apoptosis induced by rG3 treatment allows cells to counteract survival
signals - although still present - possibly reducing the threshold required for pro-apoptotic
factors to activate apoptotic signaling and again shifting the balance from survival to
apoptosis. This data, demonstrating widespread apoptotic signaling, suggests that by
simultaneously targeting multiple pathways of the apoptotic process, p53 increases the
probability of successful programmed cell death. The ability of rG3 to induce such a
widespread p53-dependednt effect makes it an incredibly valuable research tool.
Additionally, since different cell types have different induction programs after p53 activation
923

, rG3 could be used as a targeted tool to study apoptosis across multiple tissue types and

species.
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Interestingly, some upregulation of pro-survival factors can be seen with rG3
treatment, though the effect is not extreme in comparison to the upregulation of pro-apoptotic
factors (Fig. 24), suggesting that apoptosis is about shifting a balance between two programs,
rather than specifically silencing all growth signals. An important PI3K/AKT factor that is
downregulated with rG3 treatment is PIK3R2, which normally promotes cell growth and
survival 965. Interestingly, GSK3 is also downregulated with rG3 treatment. GSK3
hyperactivation has been implicated in inflammation, neurological disorders, and
tumorigenesis 966. It is also implicated in the Wnt-β-catenin signaling pathway with a
positive role in Wnt signal transduction by phosphorylating the Wnt receptors low density
lipoprotein receptor-related protein (LRP5/6) 966. As seen in Fig. 24/25, MDM2 is slightly
regulated with treatment, but possibly cannot inhibit p53 efficiently due to highly upregulated
p53 activator molecules such as BAX.
Taken together, the modulation of the apoptotic pathway seen with rG3 treatment,
especially the induction of p53-depending signaling, suggests this recombinant protein has
significant potential for use as a research tool to further study the complicated interaction of
apoptotic signaling pathways.
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Figure 25: Apoptosis modulation and signaling in MDA-MB-231 cells with and without rG3 treatment. Left half of node represents
untreated cells; right half of node represents treated cells. Blue represents expression levels of 0-1. Shades of red represent high
expression levels.
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Figure 26: TP53 signaling modulation and signaling in MDA-MB-231 cells with and without
rG3 treatment. Left half of node represents untreated cells; right half of node represents treated
cells. Blue represents expression levels of 0-1. Shades of red represent high expression levels.
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CHAPTER FIVE: SUMMARY AND CONCLUSIONS
Using a global transcriptomic approach, biomarkers, signaling events, and novel
pathways of early postnatal mammary gland development were elucidated. Multivariate
techniques that are not frequently applied to developmental biology were used to analyze the
developing mammary transcriptome with success. PCA confirmed the hypothesis that there
are unique signaling events occurring over time and confirmed our transcriptomic data set
allows for evaluation of mammary development throughout time without interference from
variability between animals used. RDA confirmed that although variability in animals
sampled does exist, it does not interfere with the variable of interest: that of over time (age).
CLA confirmed trends are present in the transcriptomic data set correlating to time; K-means
clustering of our RNA-seq data set in Genesis generated unique gene sets demonstrating
similar gene expression over time which were further elucidated using discriminant function
analysis. Discriminate analysis of gene expression during the two phases chosen from
histological analysis revealed temporal regulation of important signaling events and
importantly, confirmed significant involvement of the immune system in early mammary
development, specifically during the first two months after birth. Pathway analysis on the
differentially expressed genes during early mammary development also indicated that the
adaptive immune system is highly utilized beginning in the period of 18-25 days after birth
and remains active until at least 39 days after birth, during which it contributes to
developmental trends. PRC analysis further confirmed these results, indicating that these
same immune pathways are utilized by genes with positive PRC values (increasing in
abundance with the curve). Uniquely, PRC allowed identification of specific genes
contributing functionally, and possibly interacting with each other, toward development over
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time. We hypothesized that the genes decreasing in abundance with the PRC curve are very
early genes contributing to the phenotype at birth or prior; these could also be similar to
phase one genes (upregulated during 4-18 DOA) discussed in the discriminant analysis
section, which was successfully confirmed. Conversely, we hypothesized that the positive
PRC genes, those that increase in abundance with the PRC curve, are developmental genes,
possibly similar to phase two DA genes discussed previously. Our data suggest that these
positive PRC genes function synergistically to significantly contribute to early postnatal
mammary development over time. WGCNA was used to confirm the hypothesis that there
are genuine functional modules present within the overall RNA-seq dataset generated from
samples collected during pre-pubertal mammary gland development, which were dissected
using the MCODE algorithm and pathway analysis. Several clusters were significant to our
research, especially those demonstrating a collaborative relationship between adipocytes,
immune cells, the ECM, and mammary epithelial cells with some integrin involvement in
promotion of growth of the mammary gland.
To our knowledge, swine models have not been used to investigate functions of any
of these genes in early postnatal development, adding further novelty to our approach. Taken
together, our data and the assessment of key immune regulators and markers in swine by
other researchers suggests this is a much better model of human innate immunity and disease
than rodents. Accordingly, understanding the function of immune molecules in normal
development and their concert with other signaling mechanisms can provide insight into
these roles during cancer development. In Chapter 1, we have provided a model to achieve
what was previously lacking in mammary biology: continuous developmental data collected
from the same live animal over time.
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Our data suggested that there is significant growth occurring immediately after birth,
including events previously suspected such as epithelial cell proliferation, branching, and
expansion, as well as significant immune system interaction. The presence of oncogenes and
proto-oncogenes in our model suggest that a better understanding of developmental
mammary biology and could provide future areas of study for carcinogenesis and breast
cancer treatment, leading us to investigate cellular signaling at the same global transcriptomic
level in a TNBC model in vitro.
In Chapter 2, a recombinant laminin protein (rG3) with significant potential to be
used as a research tool was evaluated to study apoptosis in both normal and tumorigenic
models. By using primary swine fibroblasts as a control in comparison to the frequently
debated MCF-10A line, we were able to confirm that signaling pathways utilized by this
normal cell line were very similar to those identified by K-means clustering in early
mammary development, including immune system, metabolism, signal transduction, cell
cycle regulation, gene transcription, and protein translation. The fibroblasts lacked TP53 and
CASP in the top 5% of genes expressed while integrin β4, integrin β1, and integrin α6 were
still present. Combined with the absence of an rG3 effect at 20ug/mL, these cells
demonstrated appropriateness as a control. Interestingly, the top pathways utilized by the
MDA-MB-231 cells during normal growth and proliferation cycles were almost identical to
the signaling pathways identified by K-means clustering in early mammary development and
the pathways utilized by primary swine fibroblasts during growth.
Possibly the most significant finding in Chapter 2 is the widespread apoptotic
induction and downregulation of extracellular matrix organization that occurs when rG3 is
applied in vitro. Further functional analysis of differentially expressed genes after rG3
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treatment indicated TP53- dependent signaling is partially responsible, and suggest crosstalk
between intrinsic and extrinsic apoptotic pathways. A greater understanding of a range of
apoptosis pathways and their crosstalk can be gained by using rG3 as a tool.
The original hypothesis of this dissertation has been confirmed; there are specific
transcriptional differences and a unique interaction of a gene set over time that contributes to
postnatal mammary gland development, and this model clearly shares similarities and
signaling pathways with oncogenic development. Now that we have a better understanding of
normal development using high throughput analysis and a clinically relevant animal model, it
is obvious which pathways should be studied in depth to better understand oncogenic
development- those of the adaptive and innate immune system, ECM remodeling and integrin
interactions, and extrinsic and intrinsic TP53-mediated apoptosis, which could lead to early
detection of potential tumorigenic growth and identification of potential treatment avenues.
Presented is a novel, comprehensive, transcriptomic model of early mammary development
along with several panels of biomarkers that possess a role in normal mammary development,
are involved in aggressive cancers, and are affected by apoptosis induced by rG3 treatment.
These biomarkers and the cell signaling modules discussed in this dissertation are highly
clinically relevant and should be further dissected using more targeted and specific
techniques.
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APPENDICES

APPENDIX A. PRC Top 50 positive weighted genes
PRC
Weight

Gene ID

Gene ID

Mapped
ID2

Gene Name, Gene
Symbol, Ortholog

0.75531
2569

CENPU

HUMAN|HGNC=21348|UniProtKB
=Q71F23

CENPU

Centromere protein
U;CENPU;ortholog

0.68776
4094

TIMM8A

PIG|Ensembl=ENSSSCG00000012
494|UniProtKB=K7GKR4

TIMM8A

0.67843
9898

CCNE2

PIG|Ensembl=ENSSSCG00000006
095|UniProtKB=F1RY56

CCNE2

Uncharacterized
protein;TIMM8A;ortholo
g
Uncharacterized
protein;CCNE2;ortholog

0.65031
4355

NPM3

PIG|Ensembl=ENSSSCG00000010
568|UniProtKB=F1S8T7

NPM3

Uncharacterized
protein;NPM3;ortholog

0.64622
6192

MYBL2

PIG|Ensembl=ENSSSCG00000007
366|UniProtKB=F1SDT3

MYBL2

Uncharacterized
protein;MYBL2;ortholog

0.64293
2862

RNFT1

HUMAN|HGNC=30206|UniProtKB
=Q5M7Z0

RNFT1

0.63091
2134

TTC27

HUMAN|HGNC=25986|UniProtKB
=Q6P3X3

TTC27

0.62959
3806

GAR1

HUMAN|HGNC=14264|UniProtKB
=Q9NY12

GAR1

0.62876
6562

DONSON

PIG|Ensembl=ENSSSCG00000027
089|UniProtKB=I3LJ77

DONSON

0.62646
9029

RFC4

PIG|Ensembl=ENSSSCG00000011
804|UniProtKB=F1SFI3

RFC4

RING finger and
transmembrane domaincontaining protein
1;RNFT1;ortholog
Tetratricopeptide repeat
protein
27;TTC27;ortholog
H/ACA ribonucleoprotein
complex subunit
1;GAR1;ortholog
Uncharacterized
protein;DONSON;ortholo
g
Uncharacterized
protein;RFC4;ortholog

0.61727
193

CCNE1

PIG|Ensembl=ENSSSCG00000002
855|UniProtKB=F1RNY7

CCNE1

Uncharacterized
protein;CCNE1;ortholog

0.61290
4564

NEDD1

PIG|Ensembl=ENSSSCG00000000
890|UniProtKB=F1SQR9

NEDD1

Uncharacterized
protein;NEDD1;ortholog

0.60991
4388

CIT

PIG|Ensembl=ENSSSCG00000009
839|UniProtKB=F1RL46

CIT

Uncharacterized protein
(Fragment);CIT;ortholog

0.60833
1544

WDR12

PIG|Ensembl=ENSSSCG00000016
116|UniProtKB=F1SHE8

WDR12

0.60654
5954

DESI1

PIG|Ensembl=ENSSSCG00000000
060|UniProtKB=F1SRD9

DESI1

Ribosome biogenesis
protein
WDR12;WDR12;ortholog
Uncharacterized
protein;DESI1;ortholog
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0.60117
7154

NUDCD2

PIG|Ensembl=ENSSSCG00000027
931|UniProtKB=F1RR73

NUDCD2

0.59887
7627

FAM64A

PIG|Ensembl=ENSSSCG00000017
893|UniProtKB=F1RGM1

FAM64A

0.59580
5113

GALE

PIG|Ensembl=ENSSSCG00000027
827|UniProtKB=I3LL84

GALE

0.59342
0751

ABT1

HUMAN|HGNC=17369|UniProtKB
=Q9ULW3

ABT1

0.59256
649

KCNE5

PIG|Ensembl=ENSSSCG00000012
582|UniProtKB=F1RWU6

KCNE5

0.59230
4891

CDKN2C

PIG|Ensembl=ENSSSCG00000003
876|UniProtKB=F1S6F7

CDKN2C

Uncharacterized
protein;CDKN2C;ortholo
g

0.58622
6873

LOC10216
7061

Truly uncharacterized

0.58396
9995

PRELID3
B

HUMAN|HGNC=15892|UniProtKB
=Q9Y3B1

PRELID3
B

Protein slowmo homolog
2;SLMO2;ortholog

0.58142
9846

CTPS1

PIG|Ensembl=ENSSSCG00000003
973|UniProtKB=F1SF78

CTPS1

CTP
synthase;CTPS1;ortholog

0.57811
8522

DOHH

PIG|Ensembl=ENSSSCG00000013
478|UniProtKB=F1S8E6

DOHH

0.57678
3145

ERCC6L

PIG|Ensembl=ENSSSCG00000021
834|UniProtKB=I3LFY4

ERCC6L

0.57219
8441

CENPK

PIG|Ensembl=ENSSSCG00000016
946|UniProtKB=F1SKT7

CENPK

Deoxyhypusine
hydroxylase;DOHH;ortho
log
Uncharacterized protein
(Fragment);ERCC6L;orth
olog
Uncharacterized
protein;CENPK;ortholog

0.57135
0974

DUSP11

PIG|Ensembl=ENSSSCG00000008
298|UniProtKB=F1SLG2

DUSP11

Uncharacterized
protein;DUSP11;ortholog

0.56764
138

ALG8

PIG|Ensembl=ENSSSCG00000014
887|UniProtKB=F1STY3

ALG8

Uncharacterized
protein;ALG8;ortholog

0.56630
587

MTHFD2

PIG|Ensembl=ENSSSCG00000023
444|UniProtKB=F1SLH1

MTHFD2

0.56510
6896

WDR74

PIG|Ensembl=ENSSSCG00000028
025|UniProtKB=I3LD53

WDR74

Uncharacterized protein
(Fragment);MTHFD2;ort
holog
Uncharacterized
protein;WDR74;ortholog

0.56237
2872

RABGGT
B

PIG|Ensembl=ENSSSCG00000003
775|UniProtKB=F1S9R0

RABGGT
B

0.56035
3639

MPHOSP
H6

PIG|Ensembl=ENSSSCG00000010
818|UniProtKB=F1S9K8

MPHOSP
H6

0.55925
4552

RNFT1

PIG|Ensembl=ENSSSCG00000017
671|UniProtKB=F1S223

RNFT1
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Uncharacterized
protein;NUDCD2;ortholo
g
Uncharacterized
protein;FAM64A;ortholo
g
Uncharacterized
protein;GALE;ortholog
Activator of basal
transcription
1;ABT1;ortholog
Uncharacterized
protein;KCNE5;ortholog

Uncharacterized
protein;RABGGTB;orthol
og
Uncharacterized protein
(Fragment);MPHOSPH6;
ortholog
Uncharacterized protein
(Fragment);RNFT1;orthol

og
0.55794
8831

RRP8

PIG|Ensembl=ENSSSCG00000023
880|UniProtKB=I3LPL4

RRP8

Uncharacterized
protein;RRP8;ortholog

0.55186
6159

PRELID3
B

PIG|Ensembl=ENSSSCG00000007
525|UniProtKB=A5GFX0

PRELID3
B

Protein slowmo homolog
2;SLMO2;ortholog

0.54940
4483

BUB1

PIG|Ensembl=ENSSSCG00000030
469|UniProtKB=I3LRF1

BUB1

Uncharacterized
protein;BUB1;ortholog

0.54854
7924

CYP26B1

PIG|Ensembl=ENSSSCG00000008
311|UniProtKB=F1SLE8

CYP26B1

0.54699
3466

BCHE

PIG|Gene=BCHE|UniProtKB=P327
52

BCHE

0.54588
4312

MPLKIP

PIG|Ensembl=ENSSSCG00000016
768|UniProtKB=F1SSC4

MPLKIP

Uncharacterized
protein;CYP26B1;ortholo
g
Cholinesterase
(Fragment);BCHE;ortholo
g
Uncharacterized
protein;MPLKIP;ortholog

0.54578
3381

LOC10650
9864

truly uncharacterized

0.54554
8898

INCENP

PIG|Ensembl=ENSSSCG00000013
066|UniProtKB=F1RPW7

INCENP

Uncharacterized
protein;INCENP;ortholog

0.54113
617

MINPP1

PIG|Ensembl=ENSSSCG00000010
435|UniProtKB=F1SCZ6

MINPP1

0.54062
8807

NQO1

PIG|Ensembl=ENSSSCG00000002
754|UniProtKB=F1S395

NQO1

Uncharacterized protein
(Fragment);MINPP1;orth
olog
Uncharacterized
protein;NQO1;ortholog

0.53748
8756

CSRNP1

PIG|Ensembl=ENSSSCG00000011
264|UniProtKB=F1SJR3

CSRNP1

Uncharacterized
protein;CSRNP1;ortholog

0.53668
2609

ANP32A

PIG|Ensembl=ENSSSCG00000004
963|UniProtKB=F1SIU2

ANP32A

0.53619
4601

UBE2T

PIG|Ensembl=ENSSSCG00000010
924|UniProtKB=F1S5B2

UBE2T

Uncharacterized protein
(Fragment);ANP32A;orth
olog
Uncharacterized
protein;UBE2T;ortholog

0.53501
2107

ADAMTS
4

PIG|Ensembl=ENSSSCG00000006
359|UniProtKB=F1S1A7

ADAMTS
4

0.53339
6073

AMD1

PIG|Ensembl=ENSSSCG00000004
392|UniProtKB=F1RT08

AMD1

0.53129
9615

C2H11orf
31

truly uncharacterized

0.53078
8325

CDCA4

PIG|Ensembl=ENSSSCG00000002
559|UniProtKB=F1S970
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CDCA4

Uncharacterized
protein;ADAMTS4;orthol
og
S-adenosylmethionine
decarboxylase
proenzyme;AMD1;orthol
og

Uncharacterized
protein;CDCA4;ortholog

APPENDIX B. PRC Top 50 negative genes
PRC
Weight
0.51559
019

Gene ID

Gene ID2

SLADOA

HUMAN|HGNC=4936|UniProtKB=
P06340

0.51544
9036
0.49519
9325
0.48963
1223
0.46195
3857
0.45410
8222
0.44311
5828

PINK1

PIG|Ensembl=ENSSSCG000000035
06|UniProtKB=F1SU10

PINK1

EFCC1

PIG|Ensembl=ENSSSCG000000240
00|UniProtKB=I3L9P1

EFCC1

SNAPIN

PIG|Ensembl=ENSSSCG000000270
49|UniProtKB=F1SFV0

SNAPIN

DOCK4

HUMAN|HGNC=19192|UniProtKB
=Q8N1I0

DOCK4

ZNF613

HUMAN|HGNC=25827|UniProtKB
=Q6PF04

ZNF613

GALNT1
5

HUMAN|HGNC=21531|UniProtKB
=Q8N3T1

GALNT
15

0.42230
6462
0.41645
8647
0.41216
7164
0.41086
8587
0.40414
9309
0.39396
0511
0.39107
6702
0.38199
6691

L1CAM

PIG|Ensembl=ENSSSCG000000127
87|UniProtKB=F1S293

L1CAM

FRMD4A

PIG|Ensembl=ENSSSCG000000110
56|UniProtKB=F1RTX2

FRMD4
A

STARD8

PIG|Ensembl=ENSSSCG000000128
28|UniProtKB=F1RZ20

STARD8

ZNF174

PIG|Ensembl=ENSSSCG000000079
58|UniProtKB=F1RK39

ZNF174

PDE2A

PIG|Ensembl=ENSSSCG000000293
88|UniProtKB=I3LNQ5

PDE2A

VLDLR

PIG|Ensembl=ENSSSCG000000052
29|UniProtKB=E7CXS1

VLDLR

MPND

PIG|Ensembl=ENSSSCG000000135
07|UniProtKB=F1S7L9

MPND

Uncharacterized
protein;MPND;ortholog

SOX13

PIG|Ensembl=ENSSSCG000000152
77|UniProtKB=F1S3U8

SOX13

Uncharacterized protein
(Fragment);SOX13;ortho
log
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Mapped
ID2
HLADOA

Gene Name, Gene
Symbol, Ortholog
HLA class II
histocompatibility
antigen, DO alpha
chain;HLADOA;ortholog
Uncharacterized protein
(Fragment);PINK1;ortho
log
Uncharacterized
protein;EFCC1;ortholog
Uncharacterized
protein;SNAPIN;ortholo
g
Dedicator of cytokinesis
protein
4;DOCK4;ortholog
Zinc finger protein
613;ZNF613;ortholog
Polypeptide Nacetylgalactosaminyltran
sferase
15;GALNT15;ortholog
Uncharacterized
protein;L1CAM;ortholog
Uncharacterized
protein;FRMD4A;orthol
og
Uncharacterized protein
(Fragment);STARD8;ort
holog
Uncharacterized
protein;ZNF174;ortholog
Uncharacterized protein
(Fragment);PDE2A;orth
olog
Uncharacterized
protein;Vldlr;ortholog

0.38191
2433
0.38103
8717
0.38096
0327
0.38048
8353
0.37922
2784
0.37907
4354
0.37889
2532
0.37795
0717
0.36765
6669
0.36313
8248
0.35687
3254
0.35652
6442
0.35623
7482
0.35416
4393

LIMS2

PIG|Ensembl=ENSSSCG000000158
62|UniProtKB=F1RQH7

LIMS2

UBXN1

PIG|Ensembl=ENSSSCG000000231
10|UniProtKB=I3LUD5

UBXN1

DDIT3

PIG|Ensembl=ENSSSCG000000224
82|UniProtKB=B8Q504

DDIT3

TRIM3

PIG|Ensembl=ENSSSCG000000146
25|UniProtKB=F1RMN8

TRIM3

FBXW4

PIG|Ensembl=ENSSSCG000000105
66|UniProtKB=F1S8T9

FBXW4

Uncharacterized
protein;FBXW4;ortholog

HGF

PIG|Ensembl=ENSSSCG000000154
03|UniProtKB=F1SB93

HGF

DMAP1

PIG|Ensembl=ENSSSCG000000283
12|UniProtKB=I3LNQ2

DMAP1

Uncharacterized protein
(Fragment);HGF;ortholo
g
Uncharacterized
protein;DMAP1;ortholog

TRAF3

PIG|Ensembl=ENSSSCG000000025
25|UniProtKB=F1SA11

TRAF3

Uncharacterized
protein;TRAF3;ortholog

LOC1065
06316

truly uncharacterized

LHX6

PIG|Ensembl=ENSSSCG000000055
30|UniProtKB=F1SLQ9

LHX6

Uncharacterized
protein;LHX6;ortholog

RGS18

PIG|Ensembl=ENSSSCG000000108
08|UniProtKB=F1SA94

RGS18

Uncharacterized
protein;RGS18;ortholog

CTIF

PIG|Ensembl=ENSSSCG000000045
06|UniProtKB=F1RPR2

CTIF

Uncharacterized
protein;CTIF;ortholog

LOC1007
39121

truly uncharacterized

C1QTNF9

HUMAN|HGNC=28732|UniProtKB
=P0C862

C1QTNF
9

0.35272
9291
0.35260
0564
0.35003
8204

GNLY

PIG|Ensembl=ENSSSCG000000082
28|UniProtKB=F1SVC1

GNLY

Complement C1q and
tumor necrosis factorrelated protein
9A;C1QTNF9;ortholog
Uncharacterized
protein;GNLY;ortholog

PPFIA1

HUMAN|HGNC=9245|UniProtKB=
Q13136

PPFIA1

Liprin-alpha1;PPFIA1;ortholog

RNF31

PIG|Ensembl=ENSSSCG000000020
03|UniProtKB=F1SGN1

RNF31

Uncharacterized
protein;RNF31;ortholog
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Uncharacterized protein
(Fragment);LIMS2;ortho
log
Uncharacterized
protein;UBXN1;ortholog
DNA-damage-inducible
transcript
3;Ddit3;ortholog
Uncharacterized
protein;TRIM3;ortholog

0.34965
5753
0.34929
7781
0.34768
7199
0.34709
9383

FLI1

PIG|Ensembl=ENSSSCG000000152
37|UniProtKB=F1S6G7

FLI1

Uncharacterized
protein;FLI1;ortholog

A4GALT

PIG|Ensembl=ENSSSCG000000269
62|UniProtKB=I3L755

A4GAL
T

CCDC28
A

PIG|Ensembl=ENSSSCG000000041
48|UniProtKB=F1S6Y0

CCDC28
A

GPANK1

HUMAN|HGNC=13920|UniProtKB
=O95872

GPANK
1

0.34649
8169
0.34162
4683
0.34161
9986
0.34156
9075
0.33794
3464
0.33792
9917
0.33640
5962
0.33411
1451
0.33388
2104
0.33320
9584

CCDC130

PIG|Ensembl=ENSSSCG000000137
55|UniProtKB=F1SD79

CCDC13
0

CEP95

PIG|Ensembl=ENSSSCG000000289
25|UniProtKB=I3LTR6

CEP95

Uncharacterized
protein;A4GALT;ortholo
g
Uncharacterized
protein;CCDC28A;ortho
log
G patch domain and
ankyrin repeatcontaining protein
1;GPANK1;ortholog
Uncharacterized
protein;CCDC130;orthol
og
Uncharacterized
protein;CEP95;ortholog

CTSF

PIG|Ensembl=ENSSSCG000000273
68|UniProtKB=F1RU48

CTSF

Uncharacterized
protein;CTSF;ortholog

LOC1065
05043

truly uncharacterized

HMCN2

PIG|Ensembl=ENSSSCG000000056
99|UniProtKB=F1S0Y1

HMCN2

MID2

PIG|Ensembl=ENSSSCG000000125
64|UniProtKB=F1RXJ0

MID2

Uncharacterized protein
(Fragment);HMCN2;orth
olog
Uncharacterized
protein;MID2;ortholog

ABLIM3

PIG|Ensembl=ENSSSCG000000144
30|UniProtKB=F1RLA7

ABLIM3

CUX1

PIG|Ensembl=ENSSSCG000000076
81|UniProtKB=F1RKF9

CUX1

TCTP

PIG|Ensembl=ENSSSCG000000006
22|UniProtKB=F1SQ68

TCTP

Uncharacterized
protein;TCTP;ortholog

KCNB1

PIG|Gene=KCNB1|UniProtKB=O18
868

KCNB1

0.33230
6307
0.33126
8784
0.33121

PTPRM

PIG|Ensembl=ENSSSCG000000288
05|UniProtKB=I3LC13

PTPRM

CUX1

PIG|Ensembl=ENSSSCG000000076
81|UniProtKB=F1RKF9

CUX1

Potassium voltage-gated
channel subfamily B
member
1;KCNB1;ortholog
Uncharacterized protein
(Fragment);PTPRM;orth
olog
Uncharacterized
protein;CUX1;ortholog

ANKRD2
4

PIG|Ensembl=ENSSSCG000000134
97|UniProtKB=F1S7P0

ANKRD
24

203

Uncharacterized
protein;ABLIM3;ortholo
g
Uncharacterized
protein;CUX1;ortholog

Uncharacterized
protein;ANKRD24;ortho

179
0.32972
1287

log
PBLD

PIG|Ensembl=ENSSSCG000000258
76|UniProtKB=I3LTZ8

PBLD

Uncharacterized
protein;PBLD;ortholog

APPENDIX C. rG3 treated MDA-MB-231 transcriptome shift changes

ENSID
ENSG00000169429
ENSG00000175061
ENSG00000151651
ENSG00000090339
ENSG00000162645
ENSG00000198840
ENSG00000183696
ENSG00000186480
ENSG00000214049
ENSG00000196352
ENSG00000073008
ENSG00000021355
ENSG00000117335
ENSG00000197249
ENSG00000160932
ENSG00000049245
ENSG00000204592
ENSG00000128340
ENSG00000162433
ENSG00000163739
ENSG00000138771
ENSG00000107959
ENSG00000126860
ENSG00000141682
ENSG00000197971
ENSG00000275216
ENSG00000198695

GENEID
CXCL8
LRRC75A-AS1
ADAM8
ICAM1
GBP2
MT-ND3
UPP1
INSIG1
UCA1
CD55
PVR
SERPINB1
CD46
SERPINA1
LY6E
VAMP3
HLA-E
RAC2
AK4
CXCL1
SHROOM3
PITRM1
EVI2A
PMAIP1
MBP
RP11-54H7.4
MT-ND6
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Shift
change
14400
7937
7685
6827
6697
6521
6440
5968
5799.5
5793.5
5616
5519
5257
4855
4722
4634
4584
4534
4517
4480
4386
3633
3608
3559
3464
3463.8
3459

ENSG00000204388
ENSG00000135373
ENSG00000137210
ENSG00000091317
ENSG00000019582
ENSG00000176171
ENSG00000162892
ENSG00000166710
ENSG00000177410
ENSG00000160213
ENSG00000173432
ENSG00000189143
ENSG00000234741
ENSG00000183255
ENSG00000119917
ENSG00000130303
ENSG00000110218
ENSG00000182952
ENSG00000158825
ENSG00000011422
ENSG00000099204
ENSG00000204520
ENSG00000172137
ENSG00000121797
ENSG00000087074
ENSG00000138772
ENSG00000133142
ENSG00000002586
ENSG00000204381
ENSG00000108679
ENSG00000160326
ENSG00000134802
ENSG00000211459
ENSG00000085063
ENSG00000204387
ENSG00000111846
ENSG00000146678
ENSG00000101846

HSPA1B
EHF
TMEM14B
CMTM6
CD74
BNIP3
IL24
B2M
ZFAS1
CSTB
SAA1
CLDN4
GAS5
PTTG1IP
IFIT3
BST2
PANX1
HMGN4
CDA
PLAUR
ABLIM1
MICA
CALB2
CCRL2
PPP1R15A
ANXA3
TCEAL4
CD99
LAYN
LGALS3BP
SLC2A6
SLC43A3
MT-RNR1
CD59
C6orf48
GCNT2
IGFBP1
STS

3355
3347
3235
3184
3025
3020.25
2958
2946.5
2908
2890
2858
2856
2849
2828
2816
2773
2739
2721
2669
2652
2644.5
2630
2571
2544
2418.8
2369.666667
2345
2335.5
2291
2201.111111
2177
2133.142857
2116.8
2105.333333
2085.5
2064
2050
2048
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ENSG00000212907
ENSG00000186866
ENSG00000184584
ENSG00000185499
ENSG00000165949
ENSG00000112379
ENSG00000107984
ENSG00000166920
ENSG00000198712
ENSG00000132334
ENSG00000163235
ENSG00000137275
ENSG00000132561
ENSG00000130513
ENSG00000163694
ENSG00000101439
ENSG00000148346
ENSG00000166145
ENSG00000108064
ENSG00000222041
ENSG00000198886
ENSG00000128487
ENSG00000198804
ENSG00000132821
ENSG00000198113
ENSG00000198899
ENSG00000164818
ENSG00000136205
ENSG00000185567
ENSG00000117151
ENSG00000198768
ENSG00000177106
ENSG00000169129
ENSG00000125538

MT-ND4L
POFUT2
TMEM173
MUC1
IFI27
ARFGEF3
DKK1
C15orf48
MT-CO2
PTPRE
TGFA
RIPK1
MATN2
GDF15
RBM47
CST3
LCN2
SPINT1
TFAM
LINC00152
MT-ND4
SPECC1
MT-CO1
VSTM2L
TOR4A
MT-ATP6
DNAAF5
TNS3
AHNAK2
CTBS
APCDD1L
EPS8L2
AFAP1L2
IL1B

2032.5
2030
1995
1977
1933
1912
1910.166667
1884
1867.666667
1853
1843
1816
1788.5
1745.5
1735
1675.2
1675
1661
1660
1652
1644.311475
1640
1630.527027
1629
1627
1623.428571
1616
1612.2
1604.25
1594
1591
1579
1575
1569

ENSG00000248527
ENSG00000003436
ENSG00000149564

MTATP6P1
TFPI
ESAM

1560.666667
1559.666667
1554
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ENSG00000136244
ENSG00000127399
ENSG00000198938
ENSG00000133321
ENSG00000013588
ENSG00000198888
ENSG00000069122
ENSG00000140950
ENSG00000228253
ENSG00000167642
ENSG00000171606
ENSG00000027697
ENSG00000150403
ENSG00000164251
ENSG00000146833
ENSG00000116701
ENSG00000198763
ENSG00000162511
ENSG00000104611
ENSG00000163814
ENSG00000128567
ENSG00000141524
ENSG00000122862
ENSG00000050344
ENSG00000206053
ENSG00000142166
ENSG00000112096
ENSG00000181381
ENSG00000099940
ENSG00000065923
ENSG00000214113
ENSG00000089327
ENSG00000099998
ENSG00000137699
ENSG00000169174
ENSG00000138134
ENSG00000204604
ENSG00000105612

IL6
LRRC61
MT-CO3
RARRES3
GPRC5A
MT-ND1
ADGRF5
TLDC1
MT-ATP8
SPINT2
ZNF274
IFNGR1
TMCO3
F2RL1
TRIM4
NCF2
MT-ND2
LAPTM5
SH2D4A
CDCP1
PODXL
TMC6
SRGN
NFE2L3
HN1L
IFNAR1
SOD2
DDX60L
SNAP29
SLC9A7
LYRM4
FXYD5
GGT5
TRIM29
PCSK9
STAMBPL1
ZNF468
DNASE2

1548.4
1532.666667
1529.179487
1519
1481.818182
1479.6
1462.4
1454
1439.5
1410
1401
1388
1388
1383
1381
1373
1364.615385
1351
1340
1329.08
1321.25
1321
1311
1307
1302
1286.5
1286.018868
1267
1260
1248
1238
1227.333333
1223
1213.666667
1195
1187
1185
1158
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ENSG00000132182
ENSG00000101191
ENSG00000109519
ENSG00000112763
ENSG00000198142
ENSG00000160285
ENSG00000196743
ENSG00000117984
ENSG00000115648
ENSG00000188112
ENSG00000104368
ENSG00000120889
ENSG00000163565
ENSG00000172270
ENSG00000164096
ENSG00000188707
ENSG00000111057
ENSG00000130707
ENSG00000171067
ENSG00000116815
ENSG00000214944
ENSG00000130312
ENSG00000133216
ENSG00000228300
ENSG00000125657
ENSG00000240694
ENSG00000198727
ENSG00000059804
ENSG00000148300
ENSG00000170949
ENSG00000163597
ENSG00000106305
ENSG00000203875
ENSG00000135114
ENSG00000219481
ENSG00000181104
ENSG00000123843
ENSG00000170542

NUP210
DIDO1
GRPEL1
BTN2A1
SOWAHC
LSS
GM2A
CTSD
MLPH
C6orf132
PLAT
TNFRSF10B
IFI16
BSG
C4orf3
ZBED6CL
KRT18
ASS1
C11orf24
CD58
ARHGEF28
MRPL34
EPHB2
C19orf24
TNFSF9
PNMA2
MT-CYB
SLC2A3
REXO4
ZNF160
SNHG16
AIMP2
SNHG5
OASL
NBPF1
F2R
C4BPB
SERPINB9

1153
1122
1119
1111
1075
1072.888889
1056.5
1056.333333
1053
1046.2
1046
1043.75
1037.333333
1035.136364
1031.75
1026.5
1026.5
1022
1011
1001
996.5
991
991
987
970
946
945.8636364
942.25
939
937
895.5
889
886.5
875
874
866
862
859.5
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ENSG00000197077
ENSG00000181634
ENSG00000181885
ENSG00000231925
ENSG00000008394
ENSG00000210082
ENSG00000227507
ENSG00000176974
ENSG00000182307
ENSG00000174652
ENSG00000176340
ENSG00000130023
ENSG00000107738
ENSG00000041353
ENSG00000196878
ENSG00000198910
ENSG00000146670
ENSG00000198585
ENSG00000151388
ENSG00000132846
ENSG00000184292
ENSG00000184281
ENSG00000189223
ENSG00000026751
ENSG00000145623
ENSG00000127666
ENSG00000075218
ENSG00000185803
ENSG00000141504
ENSG00000221963
ENSG00000134955
ENSG00000105355
ENSG00000172927
ENSG00000214026
ENSG00000181192
ENSG00000166801
ENSG00000169689
ENSG00000204525

KIAA1671
TNFSF15
CLDN7
TAPBP
MGST1
MT-RNR2
LTB
SHMT1
C8orf33
ZNF266
COX8A
ERMARD
C10orf54
RAB27B
LAMB3
L1CAM
CDCA5
NUDT16
ADAMTS12
ZBED3
TACSTD2
TSSC4
PAX8-AS1
SLAMF7
OSMR
TICAM1
GTSE1
SLC52A2
SAT2
APOL6
SLC37A2
PLIN3
MYEOV
MRPL23
DHTKD1
FAM111A
STRA13
HLA-C

859
858.3333333
855
853.8823529
853.2
852.990099
836
834
824
822
819.6
818
813
803
802.7083333
802.3
801.5
789
788.75
785
778.5
773
772.6666667
772.5
767.4761905
765
762
758.6666667
755.5
754.5
747.7692308
747
743
737
733
732
730
727.95
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ENSG00000165512
ENSG00000198546
ENSG00000063241
ENSG00000197608
ENSG00000242485
ENSG00000145365
ENSG00000166012
ENSG00000065809
ENSG00000117602
ENSG00000148677
ENSG00000137274
ENSG00000163257
ENSG00000181061
ENSG00000146859
ENSG00000204054
ENSG00000247271
ENSG00000159212
ENSG00000198931
ENSG00000135929
ENSG00000121858
ENSG00000232774
ENSG00000204941
ENSG00000006453
ENSG00000186283
ENSG00000119673
ENSG00000198959
ENSG00000163191
ENSG00000108342
ENSG00000119922
ENSG00000167034
ENSG00000163975
ENSG00000127870
ENSG00000065518
ENSG00000159128
ENSG00000142252
ENSG00000111335
ENSG00000136193
ENSG00000091592

ZNF22
ZNF511
ISOC2
ZNF841
MRPL20
TIFA
TAF1D
FAM107B
RCAN3
ANKRD1
BPHL
DCAF16
HIGD1A
TMEM140
LINC00963
ZBED5-AS1
CLIC6
APRT
CYP27A1
TNFSF10
FLJ22447
PSG5
BAIAP2L1
TOR3A
ACOT2
TGM2
S100A11
CSF3
IFIT2
NKX3-1
MELTF
RNF6
NDUFB4
IFNGR2
GEMIN7
OAS2
SCRN1
NLRP1

724
719
717
712
711
704
703.6
702.4285714
701
698.2666667
683
680
678.5
672
671
669
662
661.5
659
657
654
648
647.5
644
642
641.893617
639.7916667
639
636.6666667
634
628.8333333
624.6666667
624.5
623
622
613
612.8571429
612
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ENSG00000173272
ENSG00000059378
ENSG00000103888
ENSG00000148773
ENSG00000046604
ENSG00000174718
ENSG00000130304
ENSG00000103381
ENSG00000163013
ENSG00000134070
ENSG00000130193
ENSG00000213654
ENSG00000060558
ENSG00000272398
ENSG00000160336
ENSG00000101187
ENSG00000109452
ENSG00000119888
ENSG00000132256
ENSG00000067066
ENSG00000248092
ENSG00000162777
ENSG00000106538
ENSG00000166900
ENSG00000006744
ENSG00000197586
ENSG00000185862
ENSG00000163435
ENSG00000196422
ENSG00000175567
ENSG00000147689
ENSG00000123609
ENSG00000164744
ENSG00000171425
ENSG00000104689
ENSG00000147676
ENSG00000128335
ENSG00000029534

MZT2A
PARP12
CEMIP
MKI67
DSG2
KIAA1551
SLC27A1
CPPED1
FBXO41
IRAK2
THEM6
GPSM3
GNA15
CD24
ZNF761
SLCO4A1
INPP4B
EPCAM
TRIM5
SP100
NNT-AS1
DENND2D
RARRES2
STX3
ELAC2
ENTPD6
EVI2B
ELF3
PPP1R26
UCP2
FAM83A
NMI
SUN3
ZNF581
TNFRSF10A
MAL2
APOL2
ANK1

603
595
592.5151515
586.2
581
580
580
580
579
578.8
578
576
575
575
574
574
570.75
564
558
558
557
553
553
552.5714286
552.5
547.3333333
545
542
542
541.25
540
533
532
532
531.5
531
527
525
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ENSG00000151690
ENSG00000090661
ENSG00000130775
ENSG00000125798
ENSG00000134905
ENSG00000122644
ENSG00000128510
ENSG00000186814
ENSG00000189339
ENSG00000100426
ENSG00000157870
ENSG00000171051
ENSG00000148426
ENSG00000085662
ENSG00000074416
ENSG00000156711
ENSG00000069998
ENSG00000244045
ENSG00000197467
ENSG00000170421
ENSG00000227036
ENSG00000160953
ENSG00000109390
ENSG00000168393
ENSG00000260032
ENSG00000185608
ENSG00000198169
ENSG00000149792
ENSG00000183828

MFSD6
CERS4
THEMIS2
FOXA2
CARS2
ARL4A
CPA4
ZSCAN30
SLC35E2B
ZBED4
FAM213B
FPR1
PROSER2
AKR1B1
MGLL
MAPK13
CECR5
TMEM199
COL13A1
KRT8
LINC00511
MUM1
NDUFC1
DTYMK
NORAD
MRPL40
ZNF251
MRPL49
NUDT14

524.75
522
521
521
519.5
518
515
510
510
506.5
505.5
500
499
497.5935484
496.7142857
496.6666667
495
489
488.5
485.8461538
483
482
480
479.5
478.9545455
477
475
474
473

ENSG00000250462
ENSG00000172031
ENSG00000167767
ENSG00000142794
ENSG00000168653
ENSG00000168528

LRRC37BP1
EPHX4
KRT80
NBPF3
NDUFS5
SERINC2

472
470
469.5714286
465
465
463.0625

ENSG00000106610

STAG3L4

462
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ENSG00000106853
ENSG00000183421
ENSG00000164509
ENSG00000163956
ENSG00000122952
ENSG00000046651
ENSG00000226137
ENSG00000146674
ENSG00000251003
ENSG00000115041
ENSG00000186281
ENSG00000198756
ENSG00000223547
ENSG00000117525
ENSG00000048052
ENSG00000149798
ENSG00000001460
ENSG00000103018
ENSG00000186918
ENSG00000152078
ENSG00000167595
ENSG00000154319
ENSG00000090263
ENSG00000008283
ENSG00000156411
ENSG00000112186
ENSG00000100422
ENSG00000204370
ENSG00000166452
ENSG00000113070
ENSG00000153558
ENSG00000167378
ENSG00000162976
ENSG00000141179
ENSG00000134463
ENSG00000223891
ENSG00000203805
ENSG00000155850

PTGR1
RIPK4
IL31RA
LRPAP1
ZWINT
OFD1
BAIAP2-AS1
IGFBP3
ZFPM2-AS1
KCNIP3
GPAT2
COLGALT2
ZNF844
F3
HDAC9
CDC42EP2
STPG1
CYB5B
ZNF395
TMEM56
PROSER3
FAM167A
MRPS33
CYB561
C14orf2
CAP2
CERK
SDHD
AKIP1
HBEGF
FBXL2
IRGQ
PQLC3
PCTP
ECHDC3
OSER1-AS1
PLPP4
SLC26A2

460.6666667
460
459
456.1666667
455.5
454
454
452.125
452
452
451
445
444
443.5
441.7777778
441
440.5
438
437.3333333
437
435
433
432
430.1666667
429.3333333
429
425.5
424
421
420.6
419
418
417
416
415.5
415
415
414

213

ENSG00000182325
ENSG00000105053
ENSG00000186532
ENSG00000164171
ENSG00000198743
ENSG00000100814
ENSG00000169252
ENSG00000173193
ENSG00000197620
ENSG00000145536
ENSG00000137965
ENSG00000122711
ENSG00000170647
ENSG00000150433
ENSG00000181924
ENSG00000166689
ENSG00000196139
ENSG00000231074
ENSG00000169093
ENSG00000130589
ENSG00000081692
ENSG00000106078
ENSG00000125148
ENSG00000168116
ENSG00000173818
ENSG00000156675
ENSG00000188015
ENSG00000131115
ENSG00000183291
ENSG00000184985
ENSG00000167700
ENSG00000204287
ENSG00000110628
ENSG00000185917
ENSG00000255737
ENSG00000176396
ENSG00000124275
ENSG00000242125

FBXL6
VRK3
SMYD4
ITGA2
SLC5A3
CCNB1IP1
ADRB2
PARP14
CXorf40A
ADAMTS16
IFI44
SPINK4
TMEM133
TMEM218
COA4
PLEKHA7
AKR1C3
HCG18
ASMTL
HELZ2
JMJD4
COBL
MT2A
KIAA1586
ENDOV
RAB11FIP1
S100A3
ZNF227
42993
SORCS2
MFSD3
HLA-DRA
SLC22A18
SETD4
AGAP2-AS1
EID2
MTRR
SNHG3

412
411.6666667
408
405.5
403.3214286
403.25
401
400
399
395
393
393
391
390
387.5
386.25
384.1111111
383.2
383
382.6666667
382
382
381.4545455
381
379
378.4
377.2
377
375.8
375.75
373
370.5
370
369
369
369
367.5
362.5
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ENSG00000137331
ENSG00000158828
ENSG00000189067
ENSG00000163283
ENSG00000167173
ENSG00000131943
ENSG00000187609
ENSG00000204267
ENSG00000198624
ENSG00000081041
ENSG00000174749
ENSG00000173530
ENSG00000133317
ENSG00000112679
ENSG00000180921
ENSG00000189114
ENSG00000121966
ENSG00000105928
ENSG00000140545
ENSG00000138166
ENSG00000219200
ENSG00000148399
ENSG00000100014
ENSG00000106479
ENSG00000119986
ENSG00000062582
ENSG00000188321
ENSG00000105048
ENSG00000215012
ENSG00000179958
ENSG00000072135
ENSG00000227706
ENSG00000164054
ENSG00000112977
ENSG00000180448
ENSG00000196917
ENSG00000110031
ENSG00000180573

IER3
PINK1
LITAF
ALPP
C15orf39
C19orf12
EXD3
TAP2
CCDC69
CXCL2
C4orf32
TNFRSF10D
LGALS12
DUSP22
FAM83H
BLOC1S3
CXCR4
DFNA5
MFGE8
DUSP5
RNASEK
DPH7
SPECC1L
ZNF862
AVPI1
MRPS24
ZNF559
TNNT1
C22orf29
DCTPP1
PTPN18
RP11-301G19.1
SHISA5
DAP
ARHGAP45
HCAR1
LPXN
HIST1H2AC
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360.8582677
360.3333333
358.6666667
356.6666667
355.8333333
354.5
347
347
346.8571429
346.5833333
346
346
346
344
344
342.5
341
340.6666667
338.8
338.6428571
338
338
337.5
337
336.8
335
332
331.1666667
331
331
330
327
326.1428571
325.3714286
324.2222222
324
323.5
323

ENSG00000151503
ENSG00000103160
ENSG00000164379
ENSG00000119900
ENSG00000272391
ENSG00000217555
ENSG00000143845
ENSG00000232119
ENSG00000189180
ENSG00000023191
ENSG00000206503
ENSG00000135925
ENSG00000198168
ENSG00000144645
ENSG00000078237

NCAPD3
HSDL1
FOXQ1
OGFRL1
POM121C
CKLF
ETNK2
MCTS1
ZNF33A
RNH1
HLA-A
WNT10A
SVIP
OSBPL10
TIGAR

ENSG00000270231

NBPF8

ENSG00000100058
ENSG00000242259
ENSG00000130202
ENSG00000105877
ENSG00000110013
ENSG00000146066
ENSG00000155275
ENSG00000112877
ENSG00000067064
ENSG00000104979
ENSG00000253161
ENSG00000186951
ENSG00000102699
ENSG00000096696
ENSG00000114544
ENSG00000171943
ENSG00000255248
ENSG00000111348
ENSG00000168394
ENSG00000253910

CRYBB2P1
C22orf39
NECTIN2
DNAH11
SIAE
HIGD2A
TRMT44
CEP72
IDI1
C19orf53
LINC01605
PPARA
PARP4
DSP
SLC41A3
SRGAP2C
MIR100HG
ARHGDIB
TAP1
PCDHGB2

322.5
320.3333333
316
315.4358974
315
315
311.5
310.2
309.75
308.4736842
306.7357143
305
305
304.8
304
303.5
303
301
299.8947368
299
297.3333333
297.2
297
297
296.875
295.1666667
295
294.8333333
293.625
292.5384615
291.6666667
290
288.75
288
286.7692308
283
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ENSG00000133101
ENSG00000112343
ENSG00000188827
ENSG00000173898
ENSG00000166592
ENSG00000198786
ENSG00000131941
ENSG00000093010
ENSG00000141562
ENSG00000099194
ENSG00000142920
ENSG00000156510
ENSG00000164535
ENSG00000163945
ENSG00000239887
ENSG00000171490
ENSG00000141030
ENSG00000179532
ENSG00000196843
ENSG00000253729
ENSG00000234608
ENSG00000132740
ENSG00000088888
ENSG00000122778
ENSG00000168884
ENSG00000176485
ENSG00000091622
ENSG00000229833
ENSG00000111843

CCNA1
TRIM38
SLX4
SPTBN2
RRAD
MT-ND5
RHPN2
COMT
NARF
SCD
AZIN2
HKDC1
DAGLB
UVSSA
C1orf226
RSL1D1
COPS3
DNHD1
ARID5A
PRKDC
MAPKAPK5-AS1
IGHMBP2
MAVS
KIAA1549
TNIP2
PLA2G16
PITPNM3
PET100
TMEM14C

283
282.2
281
281
280.5
279.7851852
278.6666667
278
278
277.3877551
277
276.8461538
276.2
275
274
273.4375
272.625
272
270
269.48
269
268.6666667
268.5
268.2
268
266.4210526
265.5
265
263.4375

ENSG00000225630
ENSG00000161277
ENSG00000108021
ENSG00000065609
ENSG00000164919
ENSG00000137337
ENSG00000100034
ENSG00000108179

MTND2P28
THAP8
FAM208B
SNAP91
COX6C
MDC1
PPM1F
PPIF

263.3333333
263
261.7272727
260
258
256.9
256.25
256.2083333
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ENSG00000167705
ENSG00000153363
ENSG00000131591
ENSG00000187266
ENSG00000085117
ENSG00000183161
ENSG00000103152
ENSG00000067182
ENSG00000132109
ENSG00000130270
ENSG00000128578
ENSG00000179526
ENSG00000152443
ENSG00000167397
ENSG00000173821
ENSG00000247516
ENSG00000028277
ENSG00000058335
ENSG00000124588
ENSG00000118197
ENSG00000120256
ENSG00000242498
ENSG00000106789
ENSG00000141556
ENSG00000170006
ENSG00000139410
ENSG00000003402
ENSG00000196449
ENSG00000056558

RILP
LINC00467
C1orf159
EPOR
CD82
FANCF
MPG
TNFRSF1A
TRIM21
ATP8B3
STRIP2
SHARPIN
ZNF776
VKORC1
RNF213
MIR4458HG
POU2F2
RASGRF1
NQO2
DDX59
LRP11
ARPIN
CORO2A
TBCD
TMEM154
SDSL
CFLAR
YRDC
TRAF1

255.5
255
255
252.5
250.8125
248
248
245.8571429
245.5
245
244.5
244
243.5
242.5
242.3913043
242
241.75
241
240.875
240
239.8
238.5
238.25
237.4285714
237
237
236.9230769
236.75
236.2222222

ENSG00000205763
ENSG00000170791
ENSG00000135953
ENSG00000160072
ENSG00000275342
ENSG00000246273
ENSG00000130489
ENSG00000137936

RP9P
CHCHD7
MFSD9
ATAD3B
SGK223
SBF2-AS1
SCO2
BCAR3

236
236
235
234
233.3333333
233
233
232.7272727
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ENSG00000197208
ENSG00000138744
ENSG00000139178
ENSG00000116285
ENSG00000119655
ENSG00000204922
ENSG00000120875
ENSG00000214194
ENSG00000188938
ENSG00000113845
ENSG00000127124
ENSG00000149948
ENSG00000142556
ENSG00000275993
ENSG00000116260
ENSG00000165609
ENSG00000104823
ENSG00000122687
ENSG00000088876
ENSG00000163624
ENSG00000002587
ENSG00000181274
ENSG00000159733
ENSG00000129355
ENSG00000183087
ENSG00000141526
ENSG00000180190
ENSG00000103253
ENSG00000076351
ENSG00000154328
ENSG00000154134
ENSG00000109084
ENSG00000111321
ENSG00000182362
ENSG00000224531
ENSG00000129422
ENSG00000100099
ENSG00000188785

SLC22A4
NAAA
C1RL
ERRFI1
NPC2
UQCC3
DUSP4
LINC00998
FAM120AOS
TIMMDC1
HIVEP3
HMGA2
ZNF614
CH507-42P11.8
QSOX1
NUDT5
ECH1
MRM2
ZNF343
CDS1
HS3ST1
FRAT2
ZFYVE28
CDKN2D
GAS6
SLC16A3
TDRP
HAGHL
SLC46A1
NEIL2
ROBO3
TMEM97
LTBR
YBEY
SMIM13
MTUS1
HPS4
ZNF548

219

232
232
231
230.3252033
229.3030303
229
228.9607843
228.6666667
227
227
226.75
226.4285714
226
225.3333333
225.3088235
224.3
221.6666667
221.25
221
220
220
219
218.5
218.3333333
217.8695652
217.6190476
217.5
217
217
217
216.5
216.4285714
216.1666667
216
215.3333333
215.3
213.5
213

ENSG00000185442
ENSG00000160062
ENSG00000104679
ENSG00000123146
ENSG00000212916
ENSG00000154710
ENSG00000196976
ENSG00000008513
ENSG00000181458
ENSG00000188157
ENSG00000124614
ENSG00000138759
ENSG00000196372
ENSG00000039068
ENSG00000143740
ENSG00000177685
ENSG00000109062
ENSG00000078401
ENSG00000146410
ENSG00000115107
ENSG00000146232
ENSG00000167536
ENSG00000113645
ENSG00000205476
ENSG00000179271
ENSG00000133678
ENSG00000013810
ENSG00000078804
ENSG00000170271
ENSG00000165684
ENSG00000099330
ENSG00000198286
ENSG00000165480
ENSG00000105341
ENSG00000253352
ENSG00000143786
ENSG00000010219
ENSG00000028137

FAM174B
ZBTB8A
R3HCC1
ADGRE5
MAP10
RABGEF1
LAGE3
ST3GAL1
TMEM45A
AGRN
RPS10
FRAS1
ASB13
CDH1
SNAP47
CRACR2B
SLC9A3R1
EDN1
MTFR2
STEAP3
NFKBIE
DHRS13
WWC1
CCDC85C
GADD45GIP1
TMEM254
TACC3
TP53INP2
FAXDC2
SNAPC4
OCEL1
CARD11
SKA3
ATP5SL
TUG1
CNIH3
DYRK4
TNFRSF1B

220

212.5
212
212
211.7777778
211
211
211
210.1111111
209.5
209.3829787
208.4814815
208
207.5
207.3333333
206.8
206
206
206
205.5
204.8421053
204.5
203
202.2083333
201.75
200.7142857
200
200
199.6666667
199
199
198.6666667
198.6666667
198.3333333
198.25
197.8235294
197.75
197.5
196.25

ENSG00000185022
ENSG00000075643
ENSG00000168765
ENSG00000182957
ENSG00000172888
ENSG00000147804
ENSG00000122376
ENSG00000198721
ENSG00000026103
ENSG00000157510
ENSG00000185298
ENSG00000152558
ENSG00000120217
ENSG00000160961
ENSG00000185127
ENSG00000168672
ENSG00000173706
ENSG00000157601
ENSG00000163131
ENSG00000171813
ENSG00000070814
ENSG00000256683
ENSG00000173210
ENSG00000137185
ENSG00000054277
ENSG00000157895
ENSG00000137198
ENSG00000164142
ENSG00000182858
ENSG00000165689
ENSG00000167969
ENSG00000231365
ENSG00000184371
ENSG00000219665

MAFF
MOCOS
GSTM4
SPATA13
ZNF621
SLC39A4
FAM35A
ECI2
FAS
AFAP1L1
CCDC137
TMEM123
CD274
ZNF333
C6orf120
FAM84B
HEG1
MX1
CTSS
PWWP2B
TCOF1
ZNF350
ABLIM3
ZSCAN9
OPN3
C12orf43
GMPR
FAM160A1
ALG12
SDCCAG3
ECI1
RP11-418J17.1
CSF1
CTD-2006C1.2

195.9285714
194.7
193.8571429
193
192.8333333
192.5
192.3333333
191.2666667
191
190.3333333
189.3333333
189.2631579
189
188
187.125
186
185.3739837
185.25
185.0833333
184.3333333
182.5833333
182
181
181
180
180
179.5714286
178.5
178.5
178.3333333
177.5
177
176.4083333
176

ENSG00000237550
ENSG00000128833
ENSG00000259974

RPL9P9
MYO5C
LINC00261

175.8571429
175
174

221

ENSG00000137642
ENSG00000179242
ENSG00000117877
ENSG00000100104
ENSG00000131697

SORL1
CDH4
CD3EAP
SRRD
NPHP4

174
173.5
173
172.6666667
172.5

ENSG00000188002
ENSG00000165832
ENSG00000112584
ENSG00000214087
ENSG00000272888
ENSG00000078114
ENSG00000166278
ENSG00000067606
ENSG00000160299
ENSG00000167840
ENSG00000101017
ENSG00000065054
ENSG00000171224
ENSG00000213366
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CD40
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GALNT3
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AP5B1
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SH3RF1
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MAP3K9
LLGL2
ZSCAN25
XKR9
RP11-295G20.2
HIST1H4I
EGFR
CD99L2
VWA1
FAM57A
OSBP2
EVPL
RP11-24F11.2
PTER
PEX10
TBC1D2
CDK5R2
FGFR1OP
ZNF543
RGS20
SUN1
PER2
CBWD5
DHRSX
FRMD4B
NEU1
UBE2L6
ZNF324
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ITGAE
CRCP
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EPS8L1
RHBDD3
SPATA2L
AFAP1-AS1
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159.6
157.6666667
157.3333333
156.5
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154.8288288
154.5714286
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154.4545455
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153.6666667
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153.3333333
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153.1666667
153
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148
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ENSG00000174607
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DNAH2
RNF187
RHNO1
ABCG1
ABALON
HIST1H2BK
GRPEL2
CNDP2
RBM43
ZNF17
PML
EMP2
APOBEC3C
LINC00909
E2F7
RNF144B
HCFC1R1
SVIL
GNB1L
CGNL1
NDUFB6
KLC3
IQCD
ARL4D
GPANK1
PCNX2
PLPP2
SLC24A1
PSORS1C1
NAT14
AURKAIP1
PKIG
FANCC
TTF1
CD9
QSOX2
UGT8

147
146.7142857
146.4074074
146.2857143
146
146
145.8
144.75
144.21875
144
144
143.5
143.3333333
143.1666667
143
142.55
142
141.3571429
141
141
141
140.8571429
140
139
139
138.8333333
138.5
138
138
138
137.75
137.7
137.25
136.8
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ENSG00000187957
ENSG00000170017
ENSG00000153395
ENSG00000182118
ENSG00000177427
ENSG00000087269
ENSG00000139209
ENSG00000149218
ENSG00000101160
ENSG00000174059
ENSG00000243667
ENSG00000005884
ENSG00000064199
ENSG00000169241
ENSG00000136866
ENSG00000101400
ENSG00000152464
ENSG00000165102
ENSG00000143842
ENSG00000214013
ENSG00000110921

ZNF317
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SLC38A4
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CD34
WDR92
ITGA3
SPA17
SLC50A1
ZFP37
SNTA1
RPP38
HGSNAT
SOX13
GANC
MVK

135.1818182
135
135
134.4
133.7272727
133.6666667
133.6470588
133.25
133
133
133
132.25
132.1666667
132.1
132
132
131.7424658
131.5
131
130
129.3
129.25
129.2307692
129.1
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128.25

ENSG00000215548
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ENSG00000058085
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MRPL30
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GPX3

128
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ENSG00000139725
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KIF14
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MRPL11
FBXO2
RNF182
NOG
MLYCD
SYT17
DBF4B
HS3ST3B1
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SEMA4B
BET1L
CLDN3
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XKR8
TXNRD3
TOP1MT
MYH15
AC018738.2
BDH1
FAM217B
SLBP
FABP5
NFATC2IP
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125
124.6973684
124.5
124.3636364
124
124
124
123.96
123.6666667
123.6
123.2285714
122.6
122.5555556
122.4444444
122.4285714
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121.7058824
121.5
121
120.8
120.75
120.6666667
120.3478261
120.2777778
120
120
119.625
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118
118

226

ENSG00000158062
ENSG00000116213
ENSG00000164751
ENSG00000228672
ENSG00000260822
ENSG00000130921
ENSG00000106868
ENSG00000138821
ENSG00000076944
ENSG00000114626
ENSG00000082458
ENSG00000119705
ENSG00000171729
ENSG00000172889
ENSG00000163701
ENSG00000234745
ENSG00000169908
ENSG00000176720
ENSG00000119632
ENSG00000267673
ENSG00000228594
ENSG00000146109
ENSG00000123240
ENSG00000273604
ENSG00000049089
ENSG00000125898
ENSG00000007520
ENSG00000213694
ENSG00000004961
ENSG00000144026
ENSG00000167685
ENSG00000188636
ENSG00000112208
ENSG00000077157
ENSG00000132591
ENSG00000156313
ENSG00000050730
ENSG00000231721

UBXN11
WRAP73
PEX2
PROB1
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ABTB1
DLG3
SLIRP
TMEM51
EGFL7
IL17RE
HLA-B
TM4SF1
BOK
IFI27L2
FDX2
FNDC10
ABT1
OPTN
C17orf96
COL9A2
FAM110A
TSR3
S1PR3
HCCS
ZNF514
ZNF444
LDOC1L
BAG2
PPP1R12B
ERAL1
RPGR
TNIP3
LINC-PINT

117.5
117.3333333
117.25
117
116.5
116.125
116
115.8888889
115.75
115.4285714
115.3333333
115.1666667
115.1428571
115
115
114.7589577
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114.4
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114
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112.5
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SHC3
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FAM210A
CYB5D2
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LDLR
OSBPL3
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TAF1C
SEMA6B
APBA3
SDR42E1
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DSCR3
GPR157
ZBTB21
ANKRD18EP
ZNF215
CCDC190
PEMT
ZNF37A
TOMM34
SPR
SEMA5A
ARHGAP26
LRRC75B
ZNF470
STK32C
C12orf49
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112
111.5
111.4444444
111
110.75
110.3571429
110.3333333
110
110
109.9375
109.75
109.4
109.2515723
109.1896552
109
109
109
108.7142857
108.5
108.5
108.48
108.3333333
108.2307692
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107.6153846
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107.1666667
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SLC17A5
UNC13D
PDXK
ENO2
RPP40
SYNM
SLC16A13
BCL2L1
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SNTB1
USB1
LPIN1
FZD5
METTL26
SPIDR
SLC25A23
TOM1L1
SDK1
PEX26
DAPK1
ZNF616
MBD3
DPP7
CYP51A1
RP5-862P8.2
FAM127C
CTC1
ZNF670
C21orf58
AP5Z1
PHPT1
P3H2
CASP7
NUPR1
MYL5
FAM72A
ATP5D
CDYL

106.1886792
105.8787879
105.6333333
105.5576923
105.5
105.5
105.4615385
105.3555556
105.3018868
105.25
104.862069
104.7222222
104.6666667
104.3333333
104.3
104.2
104.1
104
103.9
103.6666667
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103.4230769
103.3157895
103.2857143
103.2
103.2
103.1666667
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102.5454545
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102.2727273
102.125
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101.8181818
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ENSG00000168994
ENSG00000257093
ENSG00000148296
ENSG00000143774
ENSG00000112378
ENSG00000086232
ENSG00000100302
ENSG00000072042
ENSG00000116883
ENSG00000125731

CYSTM1
PXDC1
KIAA1147
SURF6
GUK1
PERP
EIF2AK1
RASD2
RDH11
RP11-268J15.5
SH2D3A
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101.2
101.1428571
100.8333333
100.7777778
100.7241379
100.6363636
100.4444444
100.25
100.1578947
100
100
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